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Abstract 
 
Background: People with gestational diabetes mellitus (GDM) and impaired glucose 
regulation (IGR) are at increased risk of developing type 2 diabetes but lifestyle change 
can help to delay or prevent type 2 diabetes in these groups.  
Aims: This thesis comprises five publications which inform the development of lifestyle 
interventions for people with IGR and GDM by describing the epidemiology, progression 
to type 2 diabetes, and patient views and perceptions associated with these conditions.  
Methods: Publications one and two used systematic review and meta-analysis methods 
to describe the prevalence of IGR and GDM in Europe. A retrospective cohort design 
utilising routinely collected health care data from one region in Scotland was used in 
publications three and four to describe the incidence of IGR, and the progression from 
GDM and IGR to type 2 diabetes. Publication five explored women’s perceptions and 
experiences of GDM using semi-structured interviews informed by behaviour change 
theory. 
Results: Mean prevalence of IGR and GDM in developed Europe was 22.3% and 5.4% 
respectively. Rates of progression to type 2 diabetes were 9% in a mean time of 34 months 
for IGR and 25% in a mean time of eight years for GDM. Older people with IGR living 
in deprived areas and women with GDM who were overweight and with higher fasting 
plasma glucose levels were at most risk of developing type 2 diabetes. Publication five 
highlighted how perceptions about the consequences of GDM and timeline and 
consequences of type 2 diabetes may be linked to the lifestyle change women make after 
diagnosis of GDM and their lack of success in maintaining these changes postnatally.  
Conclusions: This thesis provides a clear understanding of the prevalence of IGR and 
GDM, rates of progression to type 2 diabetes, and patient views and perceptions on which 
to base intervention planning and health care delivery.  
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Preface 
This PhD submission includes five papers published in peer reviewed journals that report 
on a series of related empirical studies (see Table 1 for references).  These studies focus 
on two groups who are at high risk of developing type 2 diabetes; specifically, people 
with impaired glucose regulation and women who have had gestational diabetes mellitus. 
Together the publications inform the development of interventions to prevent type 2 
diabetes in these two groups.  Publications one to four describe the epidemiology of 
impaired glucose regulation and the rate of progression from impaired glucose regulation 
and gestational diabetes mellitus to type 2 diabetes. Publications five explored knowledge 
and perceptions held by people with gestational diabetes mellitus about their condition.  
The studies reported in these publications were conducted over a seven-year period 
during the period of PhD registration. I was first author on all five publications in this 
thesis, but each publication had at least two authors in addition to myself as the first 
author. As the first author on these publications I took the lead in designing the research, 
day to day running of projects, conducting fieldwork, carrying out analyses and writing 
publications. However, I was assisted by my co-authors in various aspects of these 
projects. Appendix 1 outlines author contributions for each publication. 
Chapter one sets the context for the thesis by providing an overview of type 2 diabetes, 
IGR, and GDM, and discusses the evidence for interventions to prevent progression to 
type 2 diabetes in high risk individuals. The first chapter concludes by outlining the gaps 
in the literature that will be addressed by the publications in this thesis. Chapter two 
provides general background to the methods used in this thesis. The publications are 
included in the thesis in chapters three (publication one), four (publication two), five 
(publication three), six (publication four) and seven (publication five).  These 
publications are presented verbatim except for changes to abbreviations, table and figure 
numbering, and referencing format which were made to ensure consistency with the rest 
of the thesis. Each of these publication chapters is concluded by a critique of the research 
and methods in the publication and discussion of ethical considerations where relevant. 
Chapter eight presents a comparison of the publications to other literature, discussion of 
their contribution to the field, and implications for development of interventions to 
prevent type 2 diabetes. 
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Chapter one: Background 
1.1 Type 2 diabetes  
Diabetes mellitus is a group of metabolic disorders characterised by blood glucose levels 
that are persistently raised above the normal range. There are four types of diabetes, each 
with different aetiologies: type 1 diabetes, type 2 diabetes, specific types of diabetes due 
to other causes (e.g. genetic defects) and gestational diabetes mellitus (GDM; WHO 
2016).  Type 2 diabetes is the most common, accounting for around 88% of diabetes 
diagnoses in Scotland (Scottish Diabetes Survey Monitoring Group 2017). In type 2 
diabetes elevated blood glucose levels occur because of impairment in the cells that 
produce insulin, a hormone that controls blood glucose levels, and a cellular resistance to 
the action of insulin (Kahn et al. 2014). 
The metabolic changes seen in type 2 diabetes are associated with a number of serious 
health complications including cardiovascular and cerebrovascular disease, renal failure, 
neuropathy, peripheral vascular disease and visual problems. As a result, people with type 
2 diabetes in England and Wales have a 28.4% additional risk of death and died on 
average 6 years earlier compared to people without diabetes (Healthcare Quality 
Improvement Partnership 2017; Emerging Risk Factors Collaboration 2011). Compared 
to people without diabetes, people with type 2 diabetes are 20 times more likely to be 
blind, 40 times more likely to have an amputation, twice as likely to suffer a myocardial 
infarction and twice as likely to have a stroke (Donnelly et al. 2000; Emerging Risk 
Factors Collaboration 2010).  The psychological impact of type 2 diabetes is also 
considerable; people with diabetes are two to three times more likely to suffer depression, 
have higher anxiety rates and lower quality of life than people without diabetes (Colagiuri 
et al. 2006). In addition to reducing the length and quality of life, diabetes places a 
considerable burden on the National Health Service (NHS) in the UK. Treating diabetes 
and its complications uses around 10% of the total NHS budget amounting to around £8.8 
billion pounds a year (Hex et al. 2012).  
Type 2 diabetes is believed to be caused by a complex interaction between genetic and 
environmental factors and consequently risk factors can be categorised as those that are 
modifiable, and offer opportunity for preventative intervention, and those that are not 
modifiable (Nolan et al. 2011). Non-modifiable risk factors for type 2 diabetes include 
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genetic susceptibility, age, family history and ethnic origin. Although research has 
identified several genes linked with type 2 diabetes, the potential for genetic risk scores 
to predict subsequent diabetes is limited (Khan et al. 2014). Furthermore, increasing rates 
of type 2 diabetes in populations with relatively stable gene pools point to the importance 
of other factors in the development of type 2 diabetes (Wild et al. 2004). It is suggested 
that increasing prevalence is driven partly by ageing populations but also by global 
increases in the rates of overweight and obesity (Wild et al. 2004; Danaei et al. 2011). 
Obesity and physical activity are the two main modifiable risk factors for type 2 diabetes. 
The relationship between obesity and type 2 diabetes is well established in both cross 
sectional and prospective studies (Wild and Byrne 2006; Prospective Studies 
Collaboration 2009). In Scotland, around 87% of people with type 2 diabetes have a Body 
Mass Index (BMI; weight in kilograms divided by the square of height in metres) of over 
25 meaning they are classed as overweight or obese (Scottish Diabetes Survey 
Monitoring Group 2017). Although physical inactivity is associated with obesity, the 
relationship between physical activity and type 2 diabetes is only partially mediated by 
obesity (Aune et al. 2015; Smith et al. 2016). Evidence suggests that the increased insulin 
sensitivity brought about by physical activity may also partly explain the relationship 
between physical activity and type 2 diabetes (Schulze and Hu 2005). 
The association between obesity and type 2 diabetes has meant that the global rise in 
obesity rates has been mirrored with a similar increase in rates of type 2 diabetes, with 
the result that type 2 diabetes is now considered a global epidemic (Wild et al. 2004). The 
International Diabetes Federation (Cho et al. 2018) estimates that there are 451 million 
adults worldwide with type 2 diabetes compared to an estimate of 171 million in 2000 
(Wild et al. 2004). The IDF predicts that this figure will rise to 642 million by 2040 and 
it is thought that type 2 diabetes will increasingly affect people under the age of 65 (King 
et al. 1998; Global Burden of Disease Study 2013 Collaborators 2015). This increase 
among those of working age will further increase the financial burden of type 2 diabetes 
through the indirect costs to the economy associated with decreased productivity (Breton 
et al. 2013). 
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1.2 Prevention of type 2 diabetes 
Evidence regarding the increasing rates of type 2 diabetes and the associated personal 
and financial burden provides a clear rationale for preventative efforts. The NHS in 
England has recognised this and highlighted diabetes prevention as one of four priority 
areas (NHS 2014). There are two general strategies for the prevention of ill health that 
are widely recognised: the high-risk approach, where people at high risk of disease or ill 
health are identified and targeted, and the whole population approach, in which 
population-wide changes to risk factors are made (Rose et al. 2008). In a consensus 
statement on diabetes prevention the IDF suggested that both high risk and whole 
population approaches should be taken for the prevention of type 2 diabetes (Alberti et 
al. 2007). Each strategy has its merits and limitations, but to date the majority of research 
on type 2 diabetes prevention has focused on prevention in high risk groups (Alberti et 
al. 2007). Furthermore, clinical guidance published by The National Institute for Health 
and Care Excellence (NICE) in the UK clearly states that people at high risk of type 2 
diabetes should be offered lifestyle interventions (NICE 2012). 
Several well-designed randomised controlled trials (RCTs) have investigated the 
effectiveness of lifestyle and pharmacological interventions in high risk groups and have 
shown that the onset of type 2 diabetes can be prevented or at least delayed (Albright and 
Gregg 2013). A systematic review and meta-analysis of RCTs reported that lifestyle 
interventions reduced incidence of type 2 diabetes by around half and were as effective 
as pharmacological interventions (Gillies et al. 2007).  
One of the largest RCTs of diabetes prevention to date is the Diabetes Prevention 
Program (DPP). This was a multicentre trial conducted in 3,234 adults with blood glucose 
levels that were elevated, but not diagnostic of type 2 diabetes, in the United States (DPP 
research group 2002). The DPP randomly assigned participants to receive an intensive 
lifestyle intervention or pharmacological intervention and compared these to a group 
receiving a placebo. The aim of the lifestyle intervention was to reduce body weight by 
at least 7% and for participants to engage in moderate intensity physical activity for at 
least 150 minutes a week. Delivery of the lifestyle intervention was flexible but involved 
16 face to face lessons over a 24-week period covering diet, exercise and behaviour 
modification followed by monthly individual and group sessions. The lifestyle 
intervention was found to reduce incidence of type 2 diabetes by 58% over an average 
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follow up period of 2.8 years and by 34% over a 10 year follow period. In comparison, 
pharmacological intervention reduced incidence by 31% over 2.8 years and 18% over 10 
years (DPP research group 2009). Analysis of a subset of 350 women with a self-reported 
history of GDM showed that lifestyle intervention reduced incidence of type 2 diabetes 
by 35% and pharmacological intervention by 40% over 10 years (DPP research group 
2015). 
Although the efficacy of lifestyle interventions for preventing type 2 diabetes is well 
established, the lifestyle interventions included in the review by Gillies et al. (2007) were 
very resource intensive leading to questions about the feasibility of translating these 
findings to settings like primary care. Translational research attempts to answer these 
types of questions through assessment of smaller scale research in real world settings 
where resources are limited (Garfield et al. 2003). A synthesis of translational research 
on lifestyle interventions for the prevention of type 2 diabetes conducted by Johnson et 
al. (2013) included 17 studies which were conducted in a range of settings and based on 
either the DPP or Finnish Diabetes Prevention Study protocols with modifications to 
increase feasibility and access for the specific setting under study. For example, the most 
common modification was to deliver the intervention over fewer sessions. All but one of 
these studies reported weight loss than was greater in the intervention group compared to 
the control group. The authors conclude that there is potential for less intensive 
interventions to have an impact on future progression to diabetes in high risk individuals.  
1.3 Impaired glucose regulation 
The group of people most commonly targeted by prevention programs such as the DPP 
are those with impaired glucose regulation (IGR). People with impaired fasting glucose 
(IFG) or impaired glucose tolerance (IGT), known collectively as IGR, have blood 
glucose levels that are higher than normal but do not meet the diagnostic criteria for type 
2 diabetes mellitus. Empirical estimates of prevalence of IGR vary widely but is generally 
accepted that around 15% of adults in developed countries have some type of IGR (WHO 
2006). People with IGR are at an increased risk of developing type 2 diabetes and at 
increased risk of all cause and cardiovascular mortality (Unwin et al. 2002; Evans et al. 
2015). Around 5 to 10% of people with IGR will develop type 2 diabetes annually but it 
is thought that in the longer term the majority will go on to develop type 2 diabetes (Tabak 
et al. 2012). As an intermediate stage between normal glucose tolerance and type 2 
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diabetes, it is not surprising that the same risk factors are associated with IGR as with 
type 2 diabetes (Nathan et al. 2007). 
IGT was first formally recognised in published diagnostic guidance for diabetes in 1979 
while IFG was not recognised until 1997 with the precise glucose levels used to diagnose 
IFG and IGT depending upon the specific guidance used (National Diabetes Data Group 
[NDDG] 1979; Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus 1997). In the most current guidance from the American Diabetes Association 
(ADA 2010) and the WHO (2006), IGT is defined as an elevated two-hour plasma 
glucose (2hPG) concentration after an oral glucose tolerance test (OGTT) of between 7.8 
and 11.1 mmol/l and a fasting plasma glucose (FPG) concentration of less than 7 mmol/l. 
The ADA define IFG as an FPG of between 5.6 and 6.9mmol/l and WHO define it as an 
FPG of between 6.1 to 6.9 mmol/l and (if measured) a 2hPG in the normal range (less 
than 7.8mmol/l).  
1.4 Gestational diabetes mellitus 
Women who have had gestational diabetes mellitus (GDM) are another group that have 
been the target of type 2 diabetes prevention interventions.  GDM is defined as glucose 
intolerance that is first diagnosed in pregnancy and which increases the risk of 
complications for both mother and child during pregnancy (Buckley et al. 2012). 
Although normal glucose regulation usually returns shortly after delivery, the 
consequences of GDM extend far beyond pregnancy with affected women having a 
seven-fold increased risk of type 2 diabetes compared to women who have not had GDM. 
Rates of type 2 diabetes after a diagnosis of GDM vary depending on the population and 
length of follow up but have been reported to be as high as 70% (Ferrara 2007; Kim et 
al. 2002). Women are thought to be at the greatest risk of developing type 2 diabetes in 
the first five years following a pregnancy with GDM, with incidence plateauing at around 
10 years (Kim et al. 2002).  
It is estimated that GDM affects around 7% of all pregnancies worldwide although 
prevalence is difficult to estimate because of a lack of accepted diagnostic criteria (ADA 
2003). There are several diagnostic criteria in use internationally which outline different 
recommendations on the screening of women for testing, how testing should be 
conducted, and the precise blood glucose levels that should be considered as a diagnostic 
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of GDM (Buckley et al. 2012). A further complication in assessing GDM prevalence 
comes from women with undiagnosed pre-gestational diabetes. Data from the National 
Health and Nutrition Examination Survey conducted between 1999 and 2002 in the US 
shows that around 1% (95% Confidence Interval 0.1-3.1%) of women aged 20 to 39 have 
undiagnosed diabetes (Cowie et al. 2006). Although the definition of GDM as glucose 
intolerance first diagnosed in pregnancy means that some women with undiagnosed pre-
gestational diabetes will be incorrectly diagnosed with GDM, this research suggests that 
the number of women in this category would be small.  
 In Scotland, the Scottish Intercollegiate Guidelines Network (SIGN 2014) guidance 
forms the basis of clinical diagnoses of GDM and is aligned with the International 
Association of Diabetes and Pregnancy Study Group recommendations (IADPSG 2010). 
The most recent SIGN guideline recommends that women be assessed for the presence 
of risk factors at their first antenatal visit and all women with risk factors have 
Haemoglobin A1c (HbA1c) or FPG measured at this time, followed by a 75g OGTT at 
24 weeks. Established risk factors for GDM include increased maternal age, obesity, 
ethnic origin and family history of diabetes (Bellamy et al. 2009). Women assessed as 
low risk are recommended to have an FPG at 24-28 weeks.  GDM is diagnosed according 
to the following thresholds: an FPG of 5.1 and over, or plasma glucose of 10mmol/l and 
higher 1 hour after a 75g OGTT, or 8.5mmol/l and above 2 hours after OGTT.  
1.5 Gaps in the literature 
The evidence discussed up to this point shows that type 2 diabetes is a growing public 
health concern and that there is a need for preventative interventions to reduce the 
personal and financial burden of this condition. A diagnosis of IGR and GDM offer an 
ideal opportunity for the prevention of type 2 diabetes. However, there are a number of 
gaps in the literature that need to be addressed in order for this opportunity to be 
successfully realised. The publications included in this thesis aim to address these gaps 
to inform the development of interventions to prevent type 2 diabetes.   
Epidemiology of impaired glucose regulation and gestational diabetes 
mellitus 
In order to plan interventions and health care provision it is important to have a clear 
understanding of the epidemiology of IGR and GDM. Estimates of both IGR and GDM 
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vary widely from study to study. For example, a study assessing IGR prevalence in 13 
population groups in nine European countries reported estimates of IGR that ranged from 
3.2% to 64.2% (DECODE Study Group 2003). This variation is likely to be due to several 
factors such as the distribution of age and sex in the sample, differences in the data 
collection methodology, and differences in the criteria used to classify IFG and IGT. In 
order to provide a clearer understanding of IGR prevalence and the factors affecting 
reported estimates, the first publication in this thesis reports a meta-analysis of 
observational studies assessing the prevalence or incidence of IGR in the general 
population of adults in developed countries in Europe. This is the first meta-analysis to 
bring together all the evidence relating to IGR prevalence in Europe and offers a valuable 
contribution to the literature by making sense of disparate findings.  
In a review of studies assessing prevalence of GDM in Europe the majority of studies 
reported prevalence estimates of GDM in pregnant women of between 2 and 6% (Buckley 
et al. 2012). Assessment of GDM prevalence is made difficult by a lack of universally 
accepted diagnostic criteria (Buckley et al., 2012). While the review by Buckley et al. 
(2012) provides a useful starting point for understanding GDM prevalence, it did not 
employ systematic review methods or conduct a meta-analysis.  The second publication 
in this thesis reports a systematic review and meta-analysis of GDM prevalence in 
developed countries in Europe. This is the first systematic review and meta-analysis to 
bring together evidence on GDM prevalence in Europe. 
Progression to type 2 diabetes 
In planning interventions and health care provision it is also important to understand the 
number of high-risk individuals that are currently in contact with health services, and the 
rate and time scale of progression to type 2 diabetes in these individuals. If the lifestyle 
interventions for prevention of type 2 diabetes are to be translated into settings such as 
primary care, it is important to understand the size of the potential population that could 
be targeted by such an intervention without conducting additional screening. In addition, 
assessing the rate and timescale of progression to type 2 diabetes would help in the 
planning of these interventions. The third publication in this thesis reports on incidence 
of IGR and progression to type 2 diabetes in the Tayside region of Scotland; this 
publication is the first to investigate incidence of IGR and progression to type 2 diabetes 
in the UK. The fourth publication included in this thesis outlines progression from GDM 
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to type 2 diabetes in the Tayside region of Scotland and is the first published study to 
investigate this in Scotland.  
Patient beliefs and perceptions 
While these studies provide a useful starting point for understanding the perceptions 
people with IGR, there is a clear need for further research in the UK. Having a clear 
understanding of patient beliefs and perceptions about IGR can help to ensure that 
interventions are appropriately tailored and target those beliefs that may be a barrier (or 
facilitator) to behaviour change.   
Lifestyle interventions have typically included women with GDM alongside other high-
risk groups, rather than specifically targeting them. The DPP included over 2000 women 
with GDM but found that women with a history of GDM showed poorer engagement in 
lifestyle change compared to women without a history of GDM (Ratner et al. 2008). In 
recent years there have been several studies examining lifestyle interventions specifically 
for women with prior GDM but many of these have experienced challenges with 
recruitment (Gilinsky et al. 2015). The challenges facing women with GDM in making 
lifestyle changes are potentially quite different to those facing other high-risk groups, 
such as people with IGR. It is therefore important that the beliefs of women about GDM 
and about making lifestyle changes are assessed to ensure that interventions are 
appropriately tailored to women with GDM and well received by them.  
A review of research assessing perceptions among women with GDM identified no 
research conducted in the UK (Parsons et al. 2014). Since this review was carried out 
there have been two studies conducted in in the UK and one in Ireland (Lie et al. 2013; 
McMillan et al. 2018; Tierney et al. 2015). Participants in these studies reported that they 
were aware of their future risk of type 2 diabetes but did not always act on this. Changes 
made during pregnancy were motivated by the benefits they would give to their unborn 
child, but these changes were often not maintained after pregnancy due to several barriers 
including tiredness and the demands of looking after a young baby.  
The Medical Research Council (MRC) guidance on developing complex interventions 
suggests that an appropriate theoretical basis should be identified at the earliest stages of 
intervention development (MRC, 2006).  It is argued that the use of theory in intervention 
design increases the likelihood that an intervention will be effective by ensuring that the 
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causal determinants of behaviour are understood and addressed (Michie et al. 2008). Of 
the studies included in the review by Parsons et al. (2014), only two were informed by 
behaviour change theory. These two studies were informed by the health belief model 
and compared beliefs about GDM in people born in Sweden with people living in Sweden 
who were born in the Middle East (Hjelm et al. 2005) and Africa (Hjelm et al. 2012). As 
discussed above, theory is important for understanding the causal determinants of 
behaviour and aids the development of effective interventions (Michie et al. 2008). There 
is therefore a need for further research exploring beliefs and perceptions about GDM in 
the UK context that is underpinned by behaviour change theory. The fifth publication 
included in this thesis aims to assess perceptions among women with previous GDM in 
the Scottish context using semi-structured interviews. The fifth publication will build 
upon the previous research by using behaviour change theory to inform the interviews 
and analysis. 
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Chapter two: Methods 
The publications included in this thesis used a combination of quantitative and qualitative 
methods. These two approaches make different fundamental assumptions about the 
nature of knowledge and involve different research methods. Quantitative research is 
systematic and concerned with classification of size and number (Pope and Mays 2008). 
The assumptions about knowledge that quantitative research is based upon originated 
from a branch of philosophy called Positivism. Positivism values objectivity and argues 
that only things that are measurable actually exist. It holds the belief that there is an 
objective truth that exists and that this truth can be discovered and measured. Quantitative 
studies usually have a research question that needs to be answered or a hypothesis that is 
accepted or rejected. Attempts are made in quantitative research to reduce bias and 
subjectivity in order to allow the findings of the research to be generalised (Ross 2012). 
Quantitative research typically uses probability sampling where a random sample of all 
potential participants is taken. In probability sampling each person in the population 
under study has an equal chance of being selected (Ross 2012). The aim of probability 
sampling is to gather a sample that is representative of the population under study 
allowing generalisations to be made about the findings beyond the sample (Tillé and 
Wilhelm 2016). 
In contrast, qualitative research attempts to understand people’s subjective experiences 
of the world and how they make sense of these experiences. It asks questions such as 
what, how and why in order to gain an in depth understanding of human behaviour 
(Malterud 2001). There are a range of approaches in qualitative research and these are 
often underpinned by diverse theoretical perspectives. The role of theory in qualitative 
research has been contentious, with some researchers arguing that qualitative research 
should be underpinned by a theoretical perspective and others suggesting that the choice 
of method is as much driven by pragmatic or technical considerations as by a theoretical 
stance (Brannen 2005; Malterud 2001). Methods used to collect data in qualitative 
research include observation, interviews, analysis of documents, and analysis of speech 
or behaviour from recorded sources. These methods typically produce large amounts of 
data and involve smaller samples than quantitative research (Moser and Korstjens 2018). 
Qualitative research typically uses non-probability sampling where samples are gathered 
in way that does not give everyone in the population an equal chance of being selected. 
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These samples may be selected because they are convenient, readily available or fit the 
purpose of the study rather than because they are representative of the population under 
study (Malterud 2001). These samples are not selected with the intention that findings 
will be generalisable to the wider population but to gain a deeper understanding of the 
topic under investigation (Pope and Mays 2008). 
Although qualitative and quantitative research, and their theoretical underpinnings, have 
traditionally been posed as opposites with researchers identifying with one or the other, 
there has been a shift towards researchers using approaches that are driven by the nature 
of the question being asked. The research conducted in this thesis is based upon a 
pragmatic approach. Pragmatism originated in the late 1800s in the work of American 
philosophers Charles Sanders Pierce, William James, John Dewey and George Herbert 
Mead, and rejects attempts to understand the nature of knowledge and its relationship to 
reality (Biesta 2010). In a pragmatic approach the value of knowledge is judged by the 
consequences of this knowledge in action.  Rather than ask if knowledge reflects reality, 
pragmatism asks if the knowledge serves our interests (Cornish and Gillespie 2008).  As 
such, the methods chosen in this thesis were selected for their appropriateness for 
answering the research questions posed by each publication. 
Publications one and two used systematic review and meta-analysis methods. In 
publications three and four, data linkage and analysis of routinely collected health care 
data were carried out.  Publication five used semi-structured interviews. In terms of the 
number of people investigated and the level of personal contact with these people, the 
methods used in publications one to four are at one extreme of the spectrum upon which 
quantitative and qualitative methods sit, and the methods used in publication five are at 
the other. However, all these methods are valid and can complement each other if applied 
to appropriate research questions.  
2.1 Systematic review and meta-analysis 
Systematic review is a method that aims to identify and synthesise all the existing 
research on a specific topic by conducting a comprehensive search according to a 
predetermined method. All existing research that is relevant to the topic or question is 
included regardless of the direction or magnitude of the results (Klassen et al. 1998). A 
rigorously conducted systematic review offers an exhaustive summary of existing 
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evidence, can identify areas where evidence is lacking, and can help to resolve 
inconsistencies or controversies in the literature. Systematic reviews of observational 
studies can also help to identify factors that are associated with the outcome of interest 
(Denison et al. 2013). Limitations of the systematic review method include the difficulty 
in identifying all potentially relevant publications and variability in the quality of 
included studies which can limit the utility of the review (Klassen et al. 1998).   
The data collected in a systematic review can be observational or experimental and can 
be synthesised either by narrative synthesis or meta-analysis. Meta-analysis is a statistical 
technique for combining data from a minimum of two independent studies to provide a 
single estimate of the outcome of interest (Denison et al. 2013). Where results are in a 
numerical form it is generally recommended to try to combine them using a meta-analysis 
although there are situations where a meta-analysis is not possible or recommended. For 
example, combining studies with different research designs or studies of poor 
methodological quality is not recommended (Lipsey and Wilson 2000). In these 
situations, a narrative synthesis is recommended where results are descriptively 
summarised and relationships within and between studies are analysed (Centre for 
Reviews and Dissemination [CRD] 2009).   
Given the large number of studies available that assess prevalence of IGR and GDM, and 
the inconsistencies in the findings of these studies, a systematic review was conducted as 
it offers a way of summarising and making sense of these disparate findings. Meta-
analysis allows a single estimate of IGR and GDM prevalence to be produced and for 
factors that influence this estimate to be explored.  
2.2 Linkage of routine data 
A broad range of data is routinely collected in health care settings. Examples of data 
collected by the NHS include hospital bed occupancy, cervical screening rates, provision 
of contraceptive services, prescription dispensing, laboratory and diagnosis data (Kane et 
al. 2000). There are a number of arguments for utilising routinely collected data in 
research. One of the key benefits of routine data is that it is often readily available at a 
relatively low cost meaning that researchers can avoid the time intensive and costly 
process of primary data collection (Powell et al. 2003). Routine data can also be more 
comprehensive than sampled data and includes information on large numbers of patients. 
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The fact that routine data can be used retrospectively means that data for longer time 
periods can be gathered more quickly than in primary data collection (Kane et al. 2000). 
Potential limitations of routine data include that it may not be up to date and may not be 
complete. Because routine data are collected with a different purpose from that of the 
research being carried out, there may be key variables of interest missing (Kane et al. 
2000). 
The limited range of variables sometimes available in routinely-collected data can be 
addressed through linkage of data. Linkage of routine data refers to the process of linking 
records from two sources in order to identify pairs of records that belong to the same 
individual (Bohensky et al. 2010). Linking data allows a range of variables from different 
databases to be accessed offering a more comprehensive data-set. Linkage can be carried 
out between two separate data sources or within one source of data to track multiple 
entries for one individual (Bohensky et al. 2010). There are two commonly used methods 
of data linkage: deterministic and probabilistic. Deterministic linkage is used where there 
are unique identifiers such as an NHS number that can be used to match completely with 
other datasets. Probabilistic linkage is used where a unique identifier is not available and 
involves matching of other variables that partially identify the individual such as age or 
sex (Bohensky et al. 2010).  
2.3 Semi-structured interviews 
The last two decades have witnessed a huge increase in the use of qualitative methods in 
health research. As discussed at the start of this chapter, qualitative research aims to 
answer questions such as what, how and why, whereas quantitative research is concerned 
with classification of size and number (Pope and Mays 2008). The ability of qualitative 
research to answer these types of questions is one of the key reasons for the decision to 
use this method in the context of the questions posed by publication five in this thesis. 
Semi-structured interviews are conducted using an interview guide that contains a set of 
open-ended questions from which the interviewer or interviewee may diverge in order to 
pursue something not covered in the guide in more detail (Arthur et al. 2014). The semi-
structured format was appropriate for publication five as it is structured enough to ensure 
that topics of interest are covered, such as theoretical concepts posed by behaviour change 
theories, while allowing interviewees the freedom to discuss any issues not covered by 
the interview guide and the theoretical frameworks (Moser and Korstjens 2018).  
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Once qualitative data have been collected there are several different ways in which they 
can be analysed. A framework approach was taken/planned for the organisation and 
analysis of the data collected for publication five (Spencer and Ritchie 2002). This 
approach was developed by the National Centre for Social Research in the UK and is 
increasingly being used in health care research (Ritchie et al 2014). Examples of 
applications of the framework approach in health settings include exploring experiences 
of Chronic Obstructive Pulmonary Disease, barriers to weight loss in children and factors 
influencing the use of information technology in the emergency department (Elkington 
et al. 2004; Murtagh et al 2006; Ayatollahi et al. 2010). The framework approach is 
relatively structured and allows pre-set objectives and reasoning to inform data collection 
while still allowing original contributions from participants (Gale et al. 2013). A 
framework approach is therefore appropriate for publication five given that it is informed 
by theory and previous research (Pope et al. 2000).  
Spencer and Ritchie (2002) describe five key stages in undertaking a framework approach 
to analysing qualitative data: familiarisation, identifying a thematic framework, indexing, 
charting, mapping and interpretation. The first stage involves the researcher familiarising 
themselves with the interview transcripts. Through careful listening to recordings, 
reading of interview transcripts, and study of field notes the researcher should gain an 
overview of the range and diversity of the data. During this stage of the analysis, the 
researcher lists key ideas and themes that arise from the data and records the range of 
responses and summarise what participants are describing (Spencer and Ritchie 2002; 
Smith and Firth 2001).  
The second stage of the framework approach involves developing an analytical 
framework. The researcher does this by returning to the notes made during familiarisation 
and attempts to identify key concepts that can be used to sort the data. The framework 
draws upon both a priori issues, those brought up in interviews via the topic guide, and 
those that emerge from the participants themselves. Development of the framework 
requires the researcher to make judgements about meaning, relevance and significance of 
issues and is an iterative process with refinements being made to the framework as it is 
applied to data (Spencer and Ritchie 2002).  
After development of the framework the next stage of this approach is indexing, where 
the framework is applied to each transcript in turn. Data are read and annotated using 
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numerical codes that link back to the framework. As in stage two, indexing requires the 
researcher to make judgements about the data regarding meaning, relevance and 
significance. The fourth stage of the framework approach is to called charting and 
involves removing data from the transcripts and summarising it in a matrix according to 
the theme that it refers to. The matrix headings and subheadings may come from the 
framework, research questions or from practical considerations about how best to present 
the data. Charting involves abstraction and synthesis rather than copying sections of the 
data verbatim (Spencer and Ritchie 2002). 
When all the data have been charted, the final stage of the framework approach is 
mapping and interpretation of the data set as a whole. During this stage, the researcher 
reviews and maps the range of things people are saying about a theme in order to propose 
key underpinning themes or concepts. Finally, the researcher looks for any linkage and 
patterns between these themes and tries to search for key factors or processes that can 
account or explain these patterns (Spencer and Ritchie 2002; Gale et al. 2013). 
Research using a framework approach can sit anywhere on the inductive-deductive 
continuum depending on the research question and aims of the study (Gale et al. 2013). 
Purely inductive approaches to research attempt to generate new knowledge and theories 
whereas deductive approaches test out existing theories and reasoning (Ross 2012). The 
approach taken in publication five was a combination of inductive and deductive 
approaches and was driven by the aims of the research. One of the aims of the semi-
structured interviews was to inform the development of lifestyle interventions to prevent 
type 2 diabetes. As discussed in chapter one, it has been argued intervention design 
should be informed by theory to ensure that the causal determinants of behaviour are 
understood and addressed (Michie et al. 2008). As there is extensive research to support 
various psychological theories of behaviour change for predicting and changing 
behaviour (Armitage and Conner 2001; Hagger and Orbell, 2003; Hagger et al. 2017), it 
was decided that the interviews would be informed by these pre-existing theories rather 
than develop new theory using an inductive approach such as Grounded Theory 
(Charmaz 2006). However, psychological theories of behaviour change have been 
criticised for failing to consider several important influences on behaviour such as 
emotional responses (Sniehotta et al. 2014). Considering these criticisms, it was decided 
that a combined inductive and deductive approach would be taken when labelling data 
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during the familiarisation stage of analysis to ensure that important issues arising from 
the data, as well as from theory, were identified.  
Two psychological models were selected to inform the analysis in publication five: the 
Theory of Planned Behaviour (TPB; Ajzen 1991) and the Self Regulation Model of 
Illness Behaviour (SRM; Leventhal et al. 1992). The SRM and TPB offer different 
approaches to understanding behaviour change for prevention of type 2 diabetes with the 
SRM focusing on patients’ beliefs about their health condition (i.e. IGR or GDM and 
type 2 diabetes) whereas the TPB is concerned with beliefs about the lifestyle behaviours.  
The TPB states that voluntary behaviours are largely predicted by our intentions 
regarding the behaviour. Intentions in turn are determined by our attitude towards the 
behaviour (our judgement of whether the behaviour is a good thing to do), subjective 
norms (our judgement of what important others think of the behaviour), and perceived 
behavioural control (PBC; our expectation of how successful we will be in carrying out 
the behaviour; Ajzen, 1991).  
The SRM proposes that people interpret information about a potential illness to create a 
‘lay’ view or representation of the illness.  The coping responses employed by an 
individual, for example, adhering to treatment regimens and attending appointments, are 
said to be related to the illness representations they hold and to their appraisal of how 
successful they perceive the chosen coping responses to be. Illness representations are 
proposed to be formed around six different themes: identity (label or diagnosis of illness), 
cause (factors believed to have caused the illness), timeline (expected duration of illness), 
consequences (expected effects of illness on physical, social and psychological well-
being), control/cure (extent to which illness can be controlled/cured) and illness 
coherence (how well the person understands their illness; Leventhal et al. 1992). 
There is no evidence to suggest which model was most appropriate in the context of the 
questions posed by publication five (Armitage and Conner 2001; Hagger et al. 2017). 
Both models have been successfully used to understand a wide range of health behaviours 
and health conditions (Armitage and Conner 2001; Hagger and Orbell, 2003; Hagger et 
al. 2017). For example, the TPB has been used to inform qualitative research exploring 
physical activity in parents of young children, walking as treatment for intermittent 
claudication and non-attendance at diabetes appointments (Hamilton and White 2010; 
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Galea Holmes et al. 2017; Lawson et al. 2005). Examples of applications of the SRM in 
qualitative research include to explore women’s experiences of myocardial infarction, 
multimorbidity in long term conditions and help seeking for depression (White et al. 
2007; Bower et al. 2012; Rani Elwy et al. 2011). There has also been considerable 
research assessing interventions that address the beliefs and perceptions outlined by both 
the TPB and SRM (Hardeman et al. 2010; McSharry et al. 2011; French et al. 2006). As 
one of the aims of publication five was to inform the development of an intervention, the 
research supporting the role of these models in intervention development is valuable to 
publication five.  
The SRM has been widely used in understanding self-management of diabetes (Harvey 
and Lawson 2009). Although the self-management behaviours needed for the control of 
GDM and diabetes are largely similar, the timeline of GDM is much shorter than diabetes 
with blood glucose levels returning to normal in most women with GDM postnatally. 
Since most women with GDM are not considered to have an illness in the postnatal period 
it may not be appropriate to only use a model of illness, such as the SRM, and as such 
the TPB was selected to provide a theoretical approach that was not limited to 
understanding responses to illness. Therefore, both the TPB and SRM were used to 
inform semi-structured interviews in this thesis with the aim that the SRM would provide 
an insight into patient’s perceptions about IGR, GDM and type 2 diabetes, and that the 
TPB would provide an understanding of behaviour change in women with GDM .  
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Chapter three: Prevalence of impaired glucose 
regulation in Europe (publication one) 
 
 
 
 
 
 
 
 
The content of the above publication is presented in this chapter followed by a section 
providing critical reflection on the methods of this paper. A PDF of the published 
manuscript can be found in appendix 3.  
A verbatim copy of publication one starts below. 
3.1 Abstract 
Background: Impaired glucose regulation (IGR) represents an opportunity to prevent 
type 2 diabetes. It is important to have a clear understanding of the prevalence of this 
condition in order to be able to plan interventions and health care provision. This paper 
presents a meta-analysis of literature assessing the prevalence of IGR in the general 
population of developed countries in Europe. 
Methods: Five electronic databases were systematically searched in March 2014 to 
identify English language articles with general population samples aged 18 and over from 
developed countries in Europe. Values for the measures of interest were combined using 
a random effects model and analysis of the effects of moderator variables was carried out.  
Results:  A total of 5594 abstracts were screened, with 46 studies included in the review. 
Overall prevalence of IGR was 22.3%. Mean prevalence of impaired glucose tolerance 
(IGT) was 11.4% (10.1-12.8) and did not differ by gender. Sample age, diagnostic criteria 
Eades, C.E., France, E.F. and Evans, J.M.M. (2016) Prevalence of impaired glucose 
regulation: A meta-analysis. European Journal of Public Health, 26 (4), pp. 699-706. 
This paper was published in European Journal of Public Health, a peer reviewed journal with 
an impact factor of 2.43, and has been cited four times. The journal publishes 
multidisciplinary research on international public health issues with a focus on the European 
Region and is ranked 28th out of 157 journals in the Public, Environmental & Occupational 
Health category of the social science citation index.  
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and country were found to have a significant univariate effect on prevalence of IGT but 
only diagnostic criteria remained significant in multivariate analysis. Mean prevalence of 
impaired fasting glucose (IFG) was significantly higher in men at 10.1% (7.9-12.7) 
compared to 5.9% in women (4-8.7). The only moderator variable with a significant 
effect on IFG prevalence was country.  
Conclusions: This meta-analysis shows a moderate prevalence of IGR in developed 
Europe with over one in five people meeting the criteria for either IGT, IFG, or both.  
3.2 Introduction 
People with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) have 
blood glucose levels that are higher than normal but do not meet the diagnostic criteria 
for type 2 diabetes. These two states, known collectively as impaired glucose regulation 
(IGR), confer an increased risk of developing type 2 diabetes (Unwin et al. 2002). IGT 
was first formally recognised in published diagnostic guidance for diabetes in 1979 
(NDDG, 1979) while IFG was not recognised until 1997 (Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 1997) with the precise glucose levels 
used to diagnose IFG and IGT depending upon the specific guidance used. In the most 
current guidance from the American Diabetes Association (ADA 2010) and the world 
health organisation (WHO 2006), IGT is defined as an elevated two hour plasma glucose 
(2hPG) concentration after an oral glucose tolerance test (OGTT) of between 7.8 and 11.1 
mmol/l and an fasting plasma glucose (FPG) concentration of less than 7 mmol/l. The 
ADA define IFG as an FPG of between 5.6 and 6.9mmol/l and WHO define it as an FPG 
of between 6.1 to 6.9 mmol/l and (if measured) a 2hPG in the normal range (less than 
7.8mmol/l). 
Although people with IGR are at an increased risk of type 2 diabetes, research has shown 
that by making lifestyle changes they can prevent or delay progression to type 2 diabetes 
(Unwin et al. 2002). With prevalence of type 2 diabetes increasing rapidly, a diagnosis 
of IGR represents an opportunity for intervention to reduce the burden of type 2 diabetes 
(Davies et al. 2004). It is important to have a full and clear understanding of the 
prevalence of this condition in order to be able to plan such interventions and health care 
provision. Estimates of IGR prevalence vary greatly from study to study. A study of IGR 
prevalence in 13 population groups in 9 European countries reported estimates of IGR 
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ranging from 3.2% to 64.2% (DECODE Study Group 2003). It is likely that this variation 
in reported rates is due to a number of factors such as distribution of age and sex in the 
sample, differences in the data collection methodology and in the criteria used to classify 
IFG and IGT. In order to provide a clearer understanding of IGR prevalence and the 
factors affecting reported estimates, we carried out a meta-analysis of observational 
studies assessing the prevalence or incidence of IGR in the general population of adults 
in developed countries in Europe. We determined an overall prevalence estimate for IGR 
and examined moderator variables that potentially influenced this estimate. 
3.3 Methods 
Literature search and study selection 
A meta-analysis of published studies reporting prevalence and incidence of IGR was 
undertaken in accordance with the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines for reviews (Stroup et al. 2000). All authors have 
previously conducted systematic reviews that have been published in peer reviewed 
journals. After consulting colleagues with expertise in meta-analysis and a librarian at the 
University of Stirling regarding the search strategy, a search was conducted in 
MEDLINE, EMBASE, CINAHL, Health Source and PsycInfo for articles published in 
English from January 1948 to March 2014. The following combination of search terms 
were used with each database: (prevalence or incidence) and (impaired glucose tolerance 
or impaired fasting glucose or prediabetes or pre-diabetes or impaired glucose 
regulation). Key authors and experts in the field were not contacted due to the time 
consuming nature of this process with no guarantee of obtaining relevant information.   
After removing duplicates, the title and abstract of each paper were screened by two 
authors (CEE and JMME or EFF) against the following inclusion criteria:  
Population: general population, men or women, aged 18 and over, living in a developed 
country in Europe (as defined by the Financial Times Stock Exchange). 
Outcome measure: prevalence of IFG and/or IGT diagnosed using FPG and/or 2hPG in 
a way that is consistent with WHO criteria published from 1980 to 2006 or National 
Diabetes Group/ADA criteria from 1979 to 2011. 
Study design: observational study, published in English.  
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All papers were screened by CEE; JMME and EFF each screened half of the papers. In 
cases of disagreement between authors about the inclusion of a paper, the full text of the 
paper was accessed and consensus was reached through discussion. The review was 
limited to developed countries in Europe because of the wide differences in prevalence 
of type 2 diabetes and impaired glucose regulation between developed and developing 
countries (Wild et al. 2004; Tabak et al. 2012). This removed one potential source of 
heterogeneity in the review and also ensured that it is relevant for informing care and 
development of interventions in the context of developed health care systems. Studies 
were defined as having a sample drawn from the general population if it was drawn from 
a source that covered the majority of the population, such as census, other population 
register or general practice register (in countries where registration at general practice is 
near to universal). If this information was not reported, studies were only included if the 
paper explicitly stated that the sample was drawn from a general population. Studies that 
selected people who were at high risk of IGR (due to family history of type 2 diabetes, or 
lifestyle and medical factors), or who were recruited from hospital clinics or workplaces, 
were excluded. The full text of papers were retrieved for studies that were considered 
relevant, but also for those that contained insufficient information to allow judgement of 
relevance. Reference lists of included articles were reviewed to identify any additional 
relevant articles. 
Data extraction and coding 
Data were extracted and summarised from potentially relevant studies by one author 
(CEE) using a standardised data extraction form based on the example provided by the 
centre for reviews and dissemination (CRD 2009). Confidence intervals were calculated 
where possible for studies that did not report these for prevalence figures. Where there 
were multiple papers published that were based upon the same sample, only the paper 
reporting the most complete and definitive results was included. However, more than one 
paper from the same sample was included in the review if each paper reported on a unique 
aspect of the findings.   
The following information was extracted from each included study: first author, journal 
name and year of publication, country of study population, study period, study sample 
type, study design, age range, response rate, sample size, gender distribution in the 
sample (100% male, 100% female or mixed) and diagnostic criteria for IGT and/or IFG. 
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The outcome measures extracted were number and proportion of sample with IGT and/or 
IFG, and number and proportion of sample with IGT and/or IFG by age and gender. The 
diagnostic criteria for IGT were split into four categories, with the widest criteria in 
Category 1 through to the narrowest in Category 4:  1) 2hPG 7.8-<11.1mmol/l (e.g. 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997); 2) 
FPG <8.0mmol/l and 2hPG 8.0-<11.0mmol/l (e.g. WHO 1980);  3) FPG<7.8mmol/l and 
2h 7.8-<11.1mmol/l (WHO 1985) 4) FPG <7.0mmol/l and 2hPG 7.8-<11.1mmol/l (e.g. 
WHO 2006). Similarly, diagnostic criteria for IFG were split into three categories, with 
the widest criteria in Category 1 through to the narrowest in Category 3: 1) FPG 5.6-
6.9mmol/l (e.g. Genuth et al. 2003); 2) FPG 6.1-6.9mmo/l (e.g. Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus 1997); 3) FPG 6.1-6.9 and 2hPG 
<7.8mmol/l (WHO 1999). 
Where studies reported multiple prevalence estimates according to different diagnostic 
criteria, only one prevalence estimate was included in the meta-analysis to avoid 
dependency effects. For both IGT and IFG, the prevalence estimate generated by the most 
definitive criteria was selected, i.e. defined using both fasting and 2-hour samples. 
Otherwise, the criteria that was most commonly used in the papers included in the review 
was selected so that the estimate would be most comparable to other studies in the review.  
For studies reporting multiple prevalence estimates by other factors, such as age or year, 
an average of the estimates was calculated and used in the analysis.    
Quality appraisal 
The quality of included studies was assessed using a checklist based upon the example 
published by the Joanna Briggs Institute (2014) which was designed for assessment of 
quality in systematic reviews of prevalence and incidence. Quality assessment was 
completed for all included papers by one author (CEE) and a list of all identified 
weaknesses was compiled.  The list was then discussed by all of the authors and the 
weaknesses were categorised as either major or minor. Major weaknesses were those that 
put the study at high risk of bias or made the risk of bias difficult to assess. They included 
not reporting participation rate, very low participation rate (<50%) or not reporting the 
source of the study sample (e.g. census, general practice register). Participation rates can 
be defined in many ways but for this review the participation rate (recoded during data 
extraction if necessary and possible) was the proportion of eligible people sampled who 
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completed testing for IGT or IFG. Minor weaknesses were those that were less likely to 
put the study at risk of bias, and included low participation rate (50-70%), not reporting 
differences between participants and non-participants, not reporting who carried out 
blood samples, not reporting the proportions of men and women in the sample, and not 
reporting the details of fasting duration or what happened to non-fasters.  
Included studies were then given a quality rating as follows: 
 1: Only minor weaknesses, excluding a low participation rate. 
 2: Only minor weaknesses, including a low participation rate. 
3:  One major weakness.   
Data analysis 
The meta-analysis was carried out using the Comprehensive Meta-Analysis software 
version 3.3.070 (Biostat, Englewood, NJ). For each study, the proportion of people with 
IGR was transformed into a logit event rate effect size and the standard error associated 
with this was calculated (Lipsey and Wilson 2000). The logits were retransformed to 
proportions after analysis to aid interpretation of the results. Combined effect sizes were 
calculated and analyses were carried out both including and excluding outlying logit 
event rates. No significant differences were found so outliers were retained in the 
analyses.  
Significance tests and moderator analysis were carried out using a random effects model. 
Fixed effects models make the assumption that the effect size observed in a study 
estimates the corresponding population effect with random error that comes only from 
the chance factors associated with subject level sampling error (Lipsey and Wilson 2000).  
In contrast, random effects models allow for the possibility that there are also random 
difference between studies that are not only due to sampling error but as a result of some 
other factor such as variations in procedures, measures or settings. The choice of the 
random effects model to combine studies in this meta-analysis was based upon literature 
on IGR prevalence which suggests that the variability in reported prevalence for IGR may 
be the result of the use of different methodologies and criteria (DECODE study group 
2003).  
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The homogeneity of studies was evaluated using the Q test where the null hypothesis 
states that variability of the effect sizes is the result of sampling error only. If the 
assumption of homogeneity is violated it is customary for sources of variation to be 
explored by studying moderator variables. Q and I2 statistics were also calculated to 
assess differences in combined effect sizes for sets of studies grouped according to 
moderator variables.  
Categorical moderator variables were analysed using an analysis of variance for meta-
analysis. Differences between subgroups of these variables were explored using a test of 
interaction. The between study homogeneity statistic (QB) reflects the amount of 
heterogeneity that can be attributed to the moderator variable. The within study 
homogeneity statistic indicates the degree of heterogeneity that remains in the category 
in question (QW) and the I
2 statistic shows the proportion of the variation that is due to 
heterogeneity rather than sampling error. For continuous variables, a simple weighted 
regression was used, where QR represents the proportion of variability associated with the 
regression model and QE indicates the variability unaccounted for by the model.  
3.4 Results 
Description of included studies 
Figure 1 shows a PRISMA flow diagram of studies identified by the search. The search 
identified 5,594 abstracts of which 148 were potentially relevant after title and abstract 
screening. The full text articles were retrieved and assessed against the inclusion criteria, 
resulting in 46 included studies reported in 53 papers (additional papers: Heine et al. 
1996; Mooy et al. 1995; Borch-Johnsen et al. 2004; Eliasson et al. 2002; Tuomilehto et 
al. 1991; Wikström et al. 2011; Forouhi et al. 2007). These 46 studies included a total of 
77,379 participants. The characteristics of the studies included in the review are presented 
in Table 2 (Appendix 2). Of the 46 studies included, 13 assessed prevalence of IGT 
(Andersson et al. 2013; Brohall et al. 2006; Castell et al. 1999; Chatuverdi et al. 1994; 
Cruickshank et al. 1991; Garancini et al. 1995; Hiltunen et al. 1994; Larsson et al. 1995; 
Mykkänen et al. 1990; Rajala et al. 1995; Tuomilehto et al. 1986; Unwin et al. 1997; 
Verrillo eta al. 1985), 11 assessed the prevalence of IFG (Almoosawi et al. 2014; Baena-
Diez et al. 2009; Bernal-Lopez et al. 2011; Bonaldi et al. 2011; Bourdel-Marchasson et 
al. 2007; Gasull et al. 2012; Gourdy et al. 2001; Mentoni et al. 2009; Panagiotakos et al. 
2007; Thomas et al. 2005; Valverde et al. 2006) and 22 reported the prevalence of both 
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IFG and IGT (Bennet et al. 2011; Bonora et al. 2004; Boronat et al. 2004; Cederberg et 
al. 2010; de Pablos-Velasco et al. 2001; de Vegt et al. 1998; Gardete-Correia et al. 2010; 
Glümer et al. 2003; Harris et al. 2000; Lilja et al. 2013; López et al. 2012; Meisinger et 
al. 2010; Qiao et al. 2003; Rathmann et al. 2003; Saaristo et al. 2008; Soriguer et al. 2008; 
Soriguer et al. 2012; Valdés et al. 2007; Webb et al. 2011; Wild et al. 2005; Williams et 
al. 1995; Ylihärsilä et al. 2005).  
 
Figure 1: Flow diagram showing study selection 
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In total, prevalence of IGT was reported in 35 different samples and IFG in 33 samples 
No studies were identified that assessed incidence of IGR. Of the 35 studies where IGT 
prevalence was reported, prevalence was reported separately for men and women in 19. 
For IFG, 25 out of 33 studies reported prevalence separately by sex. Studies were 
conducted across 11 of the 17 countries defined as developed European countries: Spain 
(n=11), UK (n=9), Finland (n=8), Sweden (n=5), Italy (n=4), France (n=3), Germany 
(n=2), Portugal (n=1), Denmark (n=1), the Netherlands (n=1) and Greece (n=1).   No 
additional papers were identified by manual searching of reference lists.  
Quality of studies 
The quality category assigned to each study is reported in Table 2 (See appendix 2). Six 
studies were identified that had two major weaknesses (Baule 2003; Tuescher et al. 2001; 
Drivsholm et al. 2001; Tamayo-Marco et al. 1997; Croxson and Burden 1998; Aujla et 
al. 2010): all six had not reported from where participants were selected, and also had 
either a low or unspecified participation rate.  These studies were excluded from the 
review as this particular combination of problems made it difficult to assess the risk of 
bias in the study. Another study was excluded from the review as the reported prevalence 
estimates, sample size and the number with IGT reported in the paper were inconsistent 
with each other (Papazoglou et al. 1995). The majority of included studies were classed 
as either the higher (n=15) or middle quality category (n=16) and therefore had only 
minor weaknesses. The remaining studies fell in to the lower quality category (n=16) and 
in addition to any minor weaknesses also had one major weakness. The most common 
major weaknesses found in the lower quality studies were a very low participation rate 
(n=5) followed by non-reporting of where participants were selected from (n=8) and non-
reporting of participation rate (n=2). Of the weaknesses categorised as minor by the 
authors of this meta-analysis, the most common problems were non-reporting of who 
carried out blood glucose measurements (n=32), non-reporting of checks on fasting status 
of participants (n=32); non-reporting of information on non-responders (n=26) and low 
participation rate (n=18). Less common minor problems were non-reporting of details 
about the duration of fasting prior to measuring blood glucose (n=8) and non-reporting 
of the sex split of the sample (n=6).  
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Analysis of outliers  
In total four outliers were identified, three for IGT (Hiltunen et al.1994; Tuomilehto et 
al. 1986; Unwin et al. 1997) and one for IFG (Bonora et al. 2004).  The three outliers for 
IGT all reported prevalence of over 28% and the outlier for IFG reported prevalence in 
females of 17.6%. Sample age would appear to be the most obvious explanation for the 
high prevalence estimates in these studies, with three having samples aged 60 and older 
(Hiltunen et al. 1994; Unwin et al. 1997; Bonora et al. 2004) and one with a sample aged 
55 (Tuomilehto et al. 1986).   
Mean prevalence of impaired glucose tolerance  
The mean prevalence of IGT overall was 11.4% (95% CI: 10.1-12.8). The mean 
prevalence of IGT in men was 12.9% (10-16.4), 13.2% in women (10.5-16.5) and 9.9% 
(8.3-11.7) in mixed samples. There was no significant difference in prevalence of IGT 
between men and women (Q(1)=0.02; p=0.089). The analysis of homogeneity in the data 
with regards to sex showed variability within the studies assessing prevalence in men 
(Q(19)=500.73; p<0.001), those with women (Q(19)=670.22; p<0.001) and those with 
mixed samples (Q(12)=293.58; p<0.001). 
Analysis of moderators for impaired glucose tolerance 
As there was no significant difference in prevalence of IGT by sex, the analysis of 
prevalence by moderator variables is presented in overall terms. Table 3 shows the 
individual effects of different categorical moderator variables with the unit of analysis in 
all cases being the study. The effect of the continuous variable year is presented 
separately below. Sample age, diagnostic criteria and country the study was conducted in 
were found to have a significant effect on prevalence of IGT whereas the quality category 
of the study and year of data collection did not.  
Sample age 
The highest prevalence was found in samples aged 66 and over (25.1%; 17.8-34.1) 
followed by samples aged 30 to 65 (11.8%; 9.8-14.2) and the lowest prevalence was in 
samples aged 18 and over (9.4%; 7.1-12.4).  
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Table 3: Mean prevalence of IGT by several moderator variables 
 
 
* p<0.05; k: number of studies; N: total sample size; QB: between study homogeneity statistic; QW: within study homogeneity statistic; I
2 
proportion of variability within categories due to heterogeneity rather than sampling error. 
Variable K N Prevalence 95% CI QB (df) QW (df) I2 (%) 
Age        
18 and over 8 15,048 9.4 7.1-12.4 19.15 (2)* 198.58 (7)* 96.5 
30-65 23 45,828 11.8 9.8-14.2  1077.06 (22)* 98 
66+ 4 2,941 25.1 17.8-34.1  72.97 (3)* 95.9 
Diagnostic Criteria          
1. 2hPG 7.8-<11.1mmol/l 2 2,951 7.4 5.7-9.6 19.9 (3)* 3.86 (1)* 74.1 
2. FPG <8.0mmol/l and 2hPG 8.0-<11.0mmol/l 8 10,047 19.7 13.9-27.2  361.41 (7)* 98.1 
3. FPG<7.8mmol/l and 2h 7.8-<11.1mmol/l 19 43,722 10.3 8.6-12.2  704.38 (18)* 97.4 
4. FPG <7.0mmol/l and 2hPG 7.8-<11.1mmol/l 2 3,678 13.9 7.6-24.2  49.83 (1)* 98 
Quality Category        
1 – Higher 13 21,651 12.8 10.3-15.7 0.59 (2) 338.8 (12)* 96.5 
2 12 25,686 11.5 9.3-14  370.82 (11)* 97 
3 – Lower 10 16,480 12.8 8-20  992.21 (9)* 99.1 
Country        
Denmark 1 6,784 12 11.2-12.8 43.46 (8)* 0.00 (0) 0.0 
Finland 8 12,007 19.9 14.8-26.2  348.05 (7)* 98 
Germany 2 3,006 10.4 3.9-24.7  72.45 (1)* 98.6 
Italy 3 3,870 6.9 5.4-8.7  7.9 (2)* 74.7 
Netherlands 1 2,378 10.3 9.1-11.6  0.00 (0) 0.0 
Portugal 1 5,167 12.6 11.7-13.5  0.00 (0) 0.0 
Spain 7 11,817 9.5 7.0-12.7  151.38 (6)* 96 
Sweden 5 9,849 14 8.1-23  329.68 (4)* 98.8 
UK 7 9,659 11.1 8.6-14.3  79.9 (6)* 92.5 
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Diagnostic criteria 
Analysis of the effect of the four diagnostic categories on IGT prevalence found the 
highest prevalence estimate in studies using the second widest diagnostic criteria (19.7%; 
13.9-27.2). Contrary to what would be expected, the lowest prevalence estimate of 7.4% 
(5.7-9.6) was found in studies using the widest category. However, this category 
contained only two studies so the results need to be interpreted with caution. The next 
lowest prevalence was found for studies using the second narrowest criteria (10.3%; 8.6-
12.2). The widest category had a mean prevalence of 13% (9.2-18.2), but again this 
category contained only two studies so results should be interpreted with caution.  
Country 
In the analysis by country, the highest prevalence was found in studies conducted in 
Finland (19.9%; 14.8-26.2) and the lowest in Italy (6.9%; 5.4-8.7).  
Year 
With regard to the year in which data collection was completed, the simple regression for 
meta-analysis revealed no relationship between this variable and prevalence rates for IGT 
(QR(1)=2.8, R
2=4%, p=0.0942). 
Multivariate analysis 
With the complexity of the univariate results and the fact that none of the moderator 
variables alone can explain a substantial part of the observed variability in prevalence of 
IGT, a weighted multiple regression was performed in order to explore which variables 
independently made the greatest contribution to the variability in prevalence of IGT. 
Variables that were significant in the univariate analyses (sample age, diagnostic criteria 
and country) were entered in to the model. These three variables accounted for 35% of 
total observed variability (QR(13)=39.88, p<0.001, see Table 4 for full results) but only 
diagnostic criteria remained statistically significant when the other two variables were 
held constant.  However, the residual model was also statistically significant 
(QE(17)=475.54; p<0.001, I
2=96.4%) meaning that there was still variability in the data 
that was not explained by the variables analysed.  
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Table 4: Weighted multiple regression for IGT prevalence 
  95% CI Q(B) (df) 
Age    
18 + - - 2.25 (2) 
30-65 0.25 -0.28- 1.01  
66+ 0.72 -0.29- 1.72  
Diagnostic Criteria    
1) 2hPG 7.8-<11.1mmol/l 0.49 -1.05-2.02 10.41 (3)* 
2) FPG <8.0mmol/l and 2hPG 8.0-<11.0mmol/l 0.72 -0.29-1.72  
3) FPG<7.8mmol/l and 2hPG 7.8-<11.1mmol/l 0.09 -0.94-1.12  
4) FPG <7.0mmol/l and 2hPG 7.8-<11.1mmol/ - -  
Country    
Denmark 0.81 -0.42-2.05 7.44 (8) 
Finland 0.96^ -0.04-1.96  
Germany 0.65 -0.43-1.74  
Italy  - -  
Netherlands 0.73 -0.88-2.34  
Portugal 1.12 -0.33-2.57  
Spain 0.53 -0.61-1.68  
Sweden 0.74 -0.25-1.74  
UK 0.38 -0.62-1.38  
* p<0.05; ^ marginally significant p=0.0588; p QB: between study homogeneity 
statistic;  
 
Mean prevalence of impaired fasting glucose 
The mean overall prevalence of IFG was 8.4% (7.1-9.9). The mean prevalence of IFG in 
males was 10.1% (7.9-12.7), 5.9% in females (4-8.7) and 8.1% (6.1-10.6) in mixed 
samples. The prevalence of IFG was significantly higher in men than women (Q(1)=5.28; 
p=0.022). The analysis of homogeneity in the data with regards to sex showed variability 
within the studies with men (Q(14)=495.35; p<0.001), those with women (Q(13)=747.51; 
p<0.001) and those with mixed samples (Q(17)=1179.74; p<0.001).  
Analysis of moderators for impaired fasting glucose 
As significant differences in IFG prevalence existed between men and women, analyses 
were conducted and presented separately by gender. Table 5 shows the individual effects 
of different categorical moderator variables. The effect of the continuous variable year is 
presented separately below. The country in which the study was conducted had a 
significant effect on prevalence for both men and women. Sample age, quality category, 
diagnostic criteria and year had no effect on prevalence in either men or women.  
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Table 5: Mean prevalence of IFG in men and women by several moderator variables 
 
Variable 
 
k 
 
N 
 
Prevalence 
 
95% CI 
 
QB (df) 
 
QW (df) 
 
I2 (%) 
 
Men 
Age        
18 and over  6 5,548 10 6.6-14.8 0.13 (2) 121.7 (5)* 95.9 
30-65  7 8,480 10.6 8.7-12.9  55.67 (6)* 89.2 
66+  
 
2 7,385 8.9 2-3.2  298.06 (1)* 
99.7 
Diagnostic Criteria        
1) FPG 5.6-6.9mmol/l 2 2,298 13 4.8-30.6 0.37(2) 56.13 (1)* 98.2 
2) FPG 6.1-6.9mmo/l  8 14,668 10.7 7.7-14.8   306.42 (7)* 97.7 
3) FPG 6.1-6.9 and 2hPG <7.8mmo/l  
 
4 3,999 9.7 6.4-14.3  52.87 (3)* 
94.3 
Quality Category        
1 – Higher  6 6,685 10.6 8.7-12.8 0.09 (2) 30.24 (5)* 83.5 
2  5 8,523 10.9 7.5-15.4  129.52 (4)* 96.9 
3 – Lower  
 
4 6,205 9.4 3.7-21.8  298.73 (3)* 
99 
Country         
Finland 2 2,320 11.6 8.6-15.3 136.74 (8)* 6.39 (1)* 84.4 
France  3 6,177 7.5 3.6-14.9  111.53 (2)* 98.2 
Germany  1 896 4.2 3.1-5.7  0.00 (0) 0.0 
Greece  1 1,514 20.5 18.5-22.6  0.00 (0) 0.0 
Italy  1 2,240 12.2 10.9-13.6  0.00 (0) 0.0 
Netherlands  1 2,378 12 10.8-13.4  0.00 (0) 0.0 
Spain  2 752 6.1 1.9-18.4  15.4 (1)* 93.5 
Sweden  1 359 10.6 7.8-14.2  0.00 (0) 0.0 
UK  3 4,777 14.4 11-18.8  14.64 (2)* 86.3 
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Variable 
 
 
k 
 
 
N 
 
 
Prevalence 
 
 
95% CI 
 
 
QB (df) 
 
 
QW (df) 
 
 
I2 (%) 
 
Women 
Age        
18 and over  6 6,685 6.5 4.4-9.7 0.96 (2) 91.2 (5)* 94.5 
30-65  6 6,169 5.2 3.9-6.8  31.32 (5)* 84 
66+  
 
2 9,287 7.3 1.1-35.9  477.71 (1)* 99.8 
Diagnostic Criteria         
1) FPG 5.6-6.9mmol/l  7 14,610 7.2 3.9-13 1.27 (2) 549.58 (6)* 98.9 
2) FPG 6.1-6.9mmo/l  2 2,846 6.5 1.8-20.8  62.61 (1)* 98.4 
3) FPG 6.1-6.9 and 2hPG <7.8mmo/l  
 
4 4,103 4.7 3.0-7.4  30.93 (3)* 90.3 
Quality Category        
1 – Higher  5 4,977 5.9 3.9-9.1 0.06 (2) 47.09 (4)* 91.5 
2  5 8,298 6.3 3.0-12.7  287.22 (4)* 98.6 
3 – Lower  
 
4 8,866 5.5 2.3-12.4  206.1 (3)* 98.5 
Country        
Finland  2 2,595 5.1 4.3-6 119.82 (7)* 0.12 (1) 0.0 
France  3 8,647 3.8 2.4-5.9  29.57 (2)* 93.2 
Germany  1 757 1.9 1.1-3.2  0.00 (0) 0.0 
Greece   1 1,528 12 10.5-13.7  0.00 (0) 0.0 
Italy  1 2,497 9.9 8.8-11.1  0.00 (0) 0.0 
Spain  2 967 4.7 1.9-11.3  9.46 (1)* 89.4 
Sweden  1 382 6.3 4.3-9.2  0.00 (0) 0.0 
UK 3 4,771 10.6 5.6-19.2  56.12 (2)* 96.4 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity statistic; QW: within study homogeneity statistic; I
2 
proportion of variability within categories due to heterogeneity rather than sampling error
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Country 
For both men and women prevalence was highest in Greece (men: 20.5%, 18.5-22.6; 
women 12%, 10.5-13.7) and lowest in Germany (men: 4.2%, 3.1-5.7; women: 1.9%, 1.1-
3.2). However, there was only one study conducted in each of these countries so results 
must be interpreted with caution.  
Year 
With regard to the year in which data collection was completed, the simple regression for 
meta-analysis revealed no relationship between this variable and prevalence rates for IFG 
in men (QR(1)=0.75, R
2=0%, p=0.385) or women (QR(1)=0.07, R
2=0%, p=0.785). 
Analysis of moderators for combined impaired glucose tolerance and 
impaired fasting glucose 
As there was no significant difference in prevalence of combined IGT/IFG by sex, the 
analysis of prevalence by moderator variables is presented in overall terms. Table 6 
shows the individual effects of different moderator variables with the unit of analysis in 
all cases being the study. All studies assessing combined IGT and IFG used the same 
diagnostic criteria so this moderator variable is not included in the analysis. Sample age 
and country in which the study was conducted were found to have a significant effect on 
prevalence of IGT whereas the quality category of the study did not.  
Sample age 
The highest prevalence was found in samples aged 18 and over (3.5%; 2.5-4.7) and the 
lowest prevalence was in samples aged 30 to 65 (1.9%; 1.5-2.5).  
Country  
In the analysis by country, the highest prevalence was found in studies conducted in Spain 
(3.4%; 2.5-4.7) and the lowest was in Germany (1.2%; 0.8-1.9). However, there was only 
one study conducted in Germany so results must be interpreted with caution. 
Year 
With regard to the year in which data collection was completed, the simple regression for 
meta-analysis revealed no relationship between this variable and prevalence rates for 
combined IGT and IFG (QR(1)=0.1, R
2=0%, p=0.751). 
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Table 6: Mean prevalence of combined IGT and IFG by several moderator variables 
Variable k N Prevalence 95% 
CI 
QB (df) QW (df) I2 
(%) 
Age        
18 and over  4 9,959 3.5 
2.5-
4.7 
7.94 (2)* 21.53 (3)* 86.1 
30-65  6 
14,60
5 
1.9 
1.5-
2.5 
 24.88 (5)* 79.9 
66+ 1 499 2.7 
1.6-
4.6 
 0.00 (0) 0.0 
 
Quality Category 
       
1 – Higher  2 6,077 3.2 1.7-6 1.63 (2) 12.5 (1)* 92 
2  3 5,908 1.8 1-3.4  21.95 (2)* 90.9 
3 – Lower  
6 
13,08
0 
2.6 
1.9-
3.6 
 42.26 (5)* 88.2 
 
Country 
       
Finland  
2 3,217 1.9 
1.1-
3.4 
15.12 
(5)* 
3.56 (1)* 71.9 
Germany  
1 1,653 1.2 
0.8-
1.9 
 0.00 (0) 0.0 
Italy  
1 919 2.1 
1.3-
3.3 
 0.00 (0) 0.0 
Portugal  1 5,167 2.4 2-2.9  0.00 (0) 0.0 
Spain  
4 7,882 3.4 
2.5-
4.7 
 19.79 (3)* 84.8 
UK 
2 6,225 2.4 
1.2-
4.5 
 14.2 (1)* 93 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity 
statistic; QW: within study homogeneity statistic; I
2 proportion of variability within 
categories due to heterogeneity rather than sampling error.  
 
Multivariate analysis 
A weighted multiple regression was performed in order to explore which variables made 
the greatest contribution to the variability in prevalence of combined IGT and IFG. 
Variables that were significant in the univariate analyses (sample age and country) were 
entered in to the model. These three variables accounted for 47% of total observed 
variability (QR(7)=14.92, p=0.037, see Table 7 for full results) but neither variable 
accounted for a significant amount of variance alone when the other variable was held 
constant.  However, the residual model was also statistically significant (QE(3)=15.46; 
p<0.001) meaning that there was still variability in the data that was not explained by the 
variables analysed. 
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Table 7: Weighted multiple regression for combined IGT and IFG prevalence  
  95% CI Q(B) (df) 
Age    
18 + 0.61 -0.08-1.3 4.47 (2) 
30-65 - - - 
66+ 
 
0.6 -0.39-1.59  
Country    
Finland 0.23 -0.71-1.17 5.97 (5) 
Germany - - - 
Italy 0.57 -0.42-1.56  
Portugal 0.1 -1.04-1.23  
Spain 0.62 -0.3-1.54  
UK 0.42 -0.13-1.5  
*p<0.05 
3.5 Discussion 
This meta-analysis of 77,379 participants in 46 studies reported mean prevalence 
estimates of 11.4% for IGT, 8.4% for IFG and 2.5% for combined IGT and IFG. This 
suggests that the overall prevalence of IGR could be as high as 22.3%. No differences 
were found for prevalence of IGT or combined IGT and IFG by gender, but IFG estimates 
were found to be significantly higher in men than women. An increase in prevalence of 
IGT was found with increasing sample age. Diagnostic criteria and country were also 
found to have an effect on IGT prevalence.  The only variables that had a significant 
effect on IFG prevalence was the country in which the study was conducted. There were 
no clear trends in either IGT or IFG prevalence over time. 
The study methods were systematic and robust. We used independent reviewers to screen 
all of the titles and abstracts identified by the search for inclusion in the review. All 
decisions on the inclusion of papers were discussed and agreed upon by all three authors. 
A thorough quality assessment was conducted for all studies considered for inclusion 
using a template designed for observational epidemiology studies and the majority of 
studies included were of high quality. The methodology had only minor limitations: only 
papers published in the English language were included, experts in the field were not 
contacted, grey literature was not identified and data extraction was only carried out by 
one author.  
The quality assessment ensured that the majority of studies included in the review had 
relatively good participation rates and recruited participants from sources that have 
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coverage of the majority of the population (e.g. census) using appropriate methods (e.g. 
random sample or whole population). This allows us to be reasonably confident that the 
included studies used samples that were representative of the general population. Indeed, 
quality category of the study was not found to have any significant effect on prevalence 
of IGR. Although participation rates were generally good for the majority of included 
studies, around one third of studies had participation rates that would be classified as 
average at between 50 and 70%, and one tenth of studies had very low participation rates 
of less than 50%. Non-reporting of various methodological details was a common 
problem which made it difficult to assess fully the quality of some studies.  However, the 
impact of this problem on the quality of the review was minimised by the decision to 
exclude any studies that had more than one weakness defined by the authors as major. 
Collating data on IGT and IFG prevalence was also made difficult by heterogeneity in 
approaches to sampling, methods used to collect blood samples and the criteria used to 
define IFG and IGT. This heterogeneity may have accounted for some of the 
inconsistencies in findings.  
It is generally accepted that around 15% of adults in developed countries have some type 
of IGR, even though empirical estimates of prevalence vary widely (DECODE study 
group 2003). This figure of 15% is based upon WHO criteria and comes from studies 
conducted in Europe, Asia and the United States, whereas our estimates are based on both 
WHO and recent ADA criteria which have a wider range of values for the diagnosis of 
IFG. Consistent with other research in Europe and the United States, we found that 
prevalence of IGR increased when wider criteria were used, although these findings were 
not statistically significant for IFG (Joanna Briggs Institute, 2014). It is possible that our 
inclusion of studies using the new ADA criteria may have inflated the IGR estimate. 
However, the impact is unlikely to be large as the majority of included studies are based 
upon older, narrower criteria for IGR. Given the differences between our review and the 
studies upon which the 15% estimate was based, these estimates therefore accord well 
with each other.  
The trends found in this review of higher prevalence of IFG in men compared to women, 
higher prevalence of IGT but not IFG with increasing age and the higher prevalence of 
IGT compared to IFG are all consistent with the findings of the DECODE study in Europe 
and the DECODA study in Asia that explored these factors in 10 and 13 different samples 
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respectively (DECODE Study Group 2003; Qiao et al. 2000; DECODA Study Group 
2003; DECODE Study Group 2002). However, we found no difference in IGT prevalence 
between men and women, whereas the DECODE and DECODA studies reported higher 
IGT prevalence in men compared to women; although it has been noted that these sex 
differences were only significant in specific age groups and were less robust than those 
found for IFG.  
With IGR existing on a continuum with type 2 diabetes and sharing the same risk factors, 
we would expect to see increases in IGR over time mirroring those seen for type 2 
diabetes (Nathan et al. 2007). One study included in this paper that assessed four different 
samples recruited in the same way at four time points did find significant increases in 
both IGT and IFG between 1990 and 2004 (Gardete-Correia et al. 2010). However, the 
various factors identified by this review that influence IGR prevalence, such as age, 
gender and diagnostic criteria, and the differences in methodologies found across 
included studies, may have masked any possible temporal trends.  
In summary, this is the first meta-analysis to bring together all the relevant evidence 
relating to IGR prevalence in Europe and to make sense of disparate findings. In the 
general population of developed Europe, around 1 in 5 people meet the criteria for either 
impaired glucose tolerance, impaired fasting glucose, or both. These figures provide a 
basis for the planning of interventions and health care provision for the prevention of type 
2 diabetes. We now recommend that similar meta-analyses be conducted in other 
populations for comparison, for example those from developing countries, and from 
North America and Asia.  
This is the end of the verbatim copy of the publication one. 
3.6 Critical reflection  
Critique of methods 
This systematic review and meta-analysis has a number of strengths including the fact 
that independent reviewers were used to screen all of the titles and abstracts identified by 
the search, decisions about inclusion were discussed and agreed upon by three authors, a 
thorough quality assessment was conducted for all studies and the majority of studies 
included were of high quality. However, the limited time and resources available for 
conducting this review meant that experts in the field were not contacted, grey literature 
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was not identified, only papers published in the English language were included, 
independent screening was split between two authors and data extraction was only carried 
out by one author. A further weakness of the study related to the approach taken to 
assessing study quality. These limitations will now be discussed in more depth.  
The purpose of a systematic review is to attempt to identify all of the relevant evidence 
that is available on a given topic. Not contacting experts in the field or identifying grey 
literature potentially limits the ability of this systematic review to do this. Including grey 
literature in systematic reviews can help to minimise the effects of publication bias (Paez 
2017). Publication bias is the tendency for significant positive results to be published, 
published earlier, published in English, and published in journals with higher impact 
factors than nonsignificant results (Sterne et al. 2001). Therefore, by not including grey 
literature the findings of this systematic review may be biased. However, the CRD (2009) 
guidance recognises that contacting experts in the field in order to identify unpublished 
literature is time consuming and offers no guarantee of obtaining relevant information. 
Hartling et al. (2017) reviewed 129 systematic reviews on three topics and found that 
although most reviews searched for unpublished studies, very few included these studies 
with unpublished studies representing less than 2% of included studies. In the majority 
of cases inclusion of unpublished studies had negligible or small impact on the results 
(Hartling et al. 2017).  On balance, in the present systematic review it was felt that time 
and resources could be better used in other areas of the review process.  
Excluding articles published in languages other than English may have also biased the 
findings of the review. Research has shown that studies with statistically significant 
results conducted in non-English speaking countries are more likely to be published in 
English language journals than those with non-significant findings, a phenomenon known 
as language bias (Egger et al. 1997). However, research investigating the impact of this 
bias on the findings of systematic reviews is conflicting. For example, a paper exploring 
the effects of limiting meta-analyses by language reported that estimates of intervention 
effectiveness did not differ according to whether the meta-analysis restricted studies by 
language (Moher et al. 2000). However, Moher et al. (2000) did find that language 
restricted meta-analyses had significantly lower precision than those that included papers 
in any language because the analyses were based on fewer data. In contrast to the Moher 
et al. (2000) study, Jüni et al (2002) found that non-English trials were more likely to 
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have significant results and higher effect sizes. A systematic review of empirical studies 
assessing the effect of English language restriction concluded that there was no evidence 
of a systematic bias from the use of language restriction in systematic reviews in 
conventional medicine (Morrison et al 2012).  Although these findings suggest that there 
is no evidence that restricting inclusion by language affects estimates, all of the research 
discussed looked at randomised controlled trials of effectiveness of interventions and 
therefore may not be generalizable to the present meta-analysis which included different 
study types.  
The CRD (2009) and Cochrane guidance (Sterne et al. 2011) recognise that it is not 
always possible to include papers in languages other than English due to lack of time, 
facilities and resources. The CRD (2009) guidance recommends that in this case, non-
English language papers should be identified, documented and noted as being excluded 
on the basis of language. In line with this recommendation, the authors of the present 
meta-analysis checked and recorded non-English articles during the screening process. 
English abstracts were available for all studies and from these abstracts a total of five 
non-English language articles were identified as potentially relevant. Four of the five 
papers reported IGT prevalence and one reported both IGT and IFG prevalence 
suggesting that the precision of the estimate for IGT may have been affected by the 
exclusion of non-English language articles. However, these five studies together included 
4,644 participants which represents only 6% of the total number of participants included 
in the meta-analysis suggesting they are unlikely to have had a large effect on either 
pooled estimates or the precision of these.  
Several well-established handbooks for conducting systematic reviews recommend that 
at least two authors independently screen the records identified by the search (Higgins 
and Deeks 2011; CRD 2009; Eden et al. 2011). In the present review, the independent 
screening was split between two authors due to these authors having limited time to spend 
on the review. This involved the first author screening all records and the second author 
independently screening half and the third author independently screening the remaining 
half. Having two independent reviewers screening papers, rather than one, may have 
increased the variability in the screening process which could have resulted in papers 
being missed. Conversely, it could be argued that having two independent reviewers 
could be advantageous if it reduces the risk of reviewers becoming fatigued and making 
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errors.  It would have been valuable to calculate agreement scores to assess if there were 
any differences in the way the two independent reviewers conducted screening compared 
to the first author. The CRD guidance on conducting systematic reviews states that 
reliability of the decision-making process is increased if all papers are independently 
assessed by more than one researcher. A study by Edwards et al. (2002) assessed the 
accuracy and reliability of reviewers when screening records for systematic reviews and 
found that a single researcher misses on average 8% of eligible papers whereas a pair of 
reviewers did not miss any. While the approach taken in this systematic review was not 
ideal, this research suggests that it was likely to have resulted in fewer missed eligible 
studies than if the first author had reviewed the papers alone.  
Data extraction is a process that requires subjective judgements to be made about how to 
record variables of interest. Having only one author carry out data extraction, as was the 
case in publication one, increases the risk of errors in a systematic review. Research has 
shown that data extraction by a single researcher results in around 53% more errors of 
inaccuracy (where reporting of a given item was incorrect) and around 7% more errors 
of omission (information for a variable was missing or incomplete) than when conducted 
independently by two researchers (Buscemi et al. 2006). However, only the finding of 
increased inaccuracy errors was statistically significant. Buscemi et al. (2006) also found 
significant differences in the time spent on a single paper when data extraction was 
carried out by two researchers. The time spent on a single data extraction was 36% less 
when there was only one researcher conducting data extraction compared to a single data 
extraction when there are two researchers involved in the process. The authors of this 
study conclude that the decision to employ single or double data extraction will depend 
upon the time and human resources available for the review.  
The CRD (2009) guidance suggests that when resources are limited a second author can 
check the data extraction forms for accuracy and completeness. This method is likely to 
result in more errors than having two researchers’ independently complete data extraction 
but takes less time. Data extraction forms were not checked for accuracy in publication 
one due to limited resources. On reflection, having a second author check accuracy would 
have been an option for reducing errors in the present meta-analysis without incurring 
excessive time costs. The research by Buscemi et al. (2006) suggests that the decision to 
not carry out double data extraction or checking of data extraction is likely to have 
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resulted in their being more errors of inaccuracy in the present meta-analysis. Error of 
inaccuracy relating to the extraction of prevalence figures and demographic variables 
could have affected the mean figures for prevalence reported in the study. However, given 
that there were a large number of studies included in the meta-analysis it is less likely 
that errors of inaccuracy would have had a big effect on mean prevalence figures. 
Although double data extraction can reduce errors, the research by Buscemi et al. (2006) 
shows that it does not eliminate them completely.  
The way that quality was assessed and reported in the published report of this systematic 
review and meta-analysis has potentially conflated issues with study quality, risk of bias 
or reporting quality. Studies with these different types of quality issues were combined 
together in to groups categorised as low medium or high quality and this category was 
reported for each study. A more appropriate approach would have been to report the 
specific quality issues for each study in the table describing the studies.  
Critique of analysis 
When used appropriately, there are several strengths of meta-analysis as a tool for 
summarising findings from a systematic review. A key strength of meta-analysis is that 
it allows the findings to be presented in a more sophisticated way than can be achieved 
by a qualitative summary or by counting the number of statistically significant results. 
Statistical significance is heavily influenced by sample size and as a result studies may 
report a meaningful effect that is not statistically significant because of small sample size 
and low power (Lipsey and Wilson 2000). By pooling the size and direction of effects 
across a range of studies, meta-analyses can have increased power to detect relationships 
and increased precision in estimates. It also offers the opportunity to answer questions 
that are not posed by individual studies and can also allow exploration of differences 
between studies and their findings that can be difficult to decipher in a narrative analysis 
(Deeks et al. 2011).  
Although meta-analysis can be a powerful tool, there are situations where is it not 
possible or advisable to use this method of analysis. A common criticism of meta-
analyses is that they sometimes attempt to ‘combine apples and oranges’: meaning that 
they combine studies with diverse methods and outcomes. It is argued that summary 
statistics produced by meta-analyses are meaningless if they aggregate diverse studies 
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(Deeks et al. 2011). Decisions around which studies should and should not be combined 
are subjective and require discussion among researchers. In the present meta-analysis, 
these issues were discussed early in the review process. As a result of these discussions 
the authors restricted the meta-analysis to include only studies assessing IGR using FPG 
or 2hPG and excluded those using HbA1c to ensure that studies were using comparable 
outcomes. This resulted in a set of studies in the present meta-analysis with a relatively 
narrowly defined outcome of interest. However, despite efforts to reduce heterogeneity 
in measurement of outcomes there were differences in sampling methods from study to 
study. Another potential weakness of meta-analysis arises when studies at high risk of 
bias are included. Meta-analyses that include studies with a high risk of bias produce 
results that are potentially seriously misleading as meta-analysis compounds any errors 
in included studies (Deeks et al. 2011). This risk was minimised in the present meta-
analysis by the exclusion of studies that were believed to be at high risk of bias. 
A final weakness of this paper, and of the other quantitative papers in this thesis, relates 
to the imprecise use of the term rate. The term rate refers to the frequency with which an 
event occurs in a population over a defined period of time (Webb and Bain 2011). There 
are several references to prevalence as a rate in the quantitative publications in this thesis 
which is incorrect as prevalence is a proportion and has no element of time.   
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Chapter four: Prevalence of gestational diabetes 
mellitus in Europe (publication two)  
 
 
 
 
 
 
 
 
The content of the above publication is presented in this chapter followed by a section 
providing critical reflection of the methods. A PDF of the published manuscript can be 
found in appendix 5. 
A verbatim copy of publication two starts below. 
4.1 Abstract 
Aims: Estimates of the prevalence of gestational diabetes mellitus (GDM) vary widely. 
It is important to have a clear understanding of the prevalence of this condition to be able 
to plan interventions and health care provision. This publication describes a meta-analysis 
of primary research data reporting the prevalence of GDM in the general pregnant 
population of developed countries in Europe. 
Methods: Four electronic databases were systematically searched in May 2016. English 
language articles reporting GDM prevalence using universal screening in general 
pregnant population samples from developed countries in Europe were included.  All 
papers identified by the search were screened by one author, and then half screened 
independently by a second author and half by a third author. Data were extracted by one 
author. Values for the measures of interest were combined using a random effects model 
and analysis of the effects of moderator variables was carried out.  
Eades, C.E., Cameron, D. and Evans, J.M.M. (2017) Prevalence of gestational 
diabetes mellitus in Europe: a meta-analysis. Diabetes Research and Clinical Practice, 
129, pp. 173-181.  
This paper was published in Diabetes Research and Clinical Practice, a peer reviewed journal 
with an impact factor of 3.64, and has been cited 27 times. It is an international journal that 
publishes research on diabetes and related areas aimed at health care providers and clinically 
orientated researchers and is the official journal of the International Diabetes Federation. 
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Results:  A total of 3258 abstracts were screened, with 40 studies included in the review. 
Overall prevalence of GDM was 5.4% (3.8-7.8). Maternal age, year of data collection, 
country, area of Europe, week of gestation at testing, and diagnostic criteria were found 
to have a significant univariate effect on GDM prevalence, and area, week of gestation at 
testing and year of data collection remained statistically significant in multivariate 
analysis. Quality category was significant in multivariate but not univariate analysis.  
Conclusions: This meta-analysis shows prevalence of GDM that is at the upper end of 
previous estimates in Europe.  
4.2 Introduction 
Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is first 
diagnosed in pregnancy and increases the risk of complications for both mother and baby 
during pregnancy (Buckley et al. 2012). It is estimated that GDM affects around 7% of 
all pregnancies worldwide although prevalence is difficult to estimate as rates vary from 
study to study because of a lack of accepted diagnostic criteria and differences in 
screening procedures (American Diabetes Association [ADA] 2003). Some earlier 
diagnostic criteria were based on the criteria used in non-pregnant individuals and in 
others thresholds were created based on the predictive value of future type 2 diabetes in 
the mother.  In recent years, there has been an increasing focus on diagnostic thresholds 
that predict the likelihood of adverse outcomes in pregnancy (HAPO; Hadar et al. 2009). 
Adverse outcomes include macrosomia, shoulder dystocia and birth injury, primary 
caesarean delivery, preeclampsia, preterm delivery and foetal and neonatal mortality 
(Yogev and Visser 2009).  
In addition to adverse outcomes during pregnancy and birth, the consequences of GDM 
extend beyond pregnancy with affected women having a seven fold increased risk of type 
2 diabetes compared to women who have not had GDM. Rates of type 2 diabetes after a 
diagnosis of GDM vary depending on the population and length of follow up, but have 
been reported to be as high as 70% (Ferrara 2007; Kim et al. 2002). Women are thought 
to be at the greatest risk of developing type 2 diabetes in the first five years following a 
pregnancy with GDM, with incidence of type 2 diabetes plateauing at around 10 years 
(Kim et al. 2002).  
 57 
 
Although women who have had GDM are at an increased risk of type 2 diabetes, research 
has shown that by making lifestyle changes they can prevent or delay progression to type 
2 diabetes (Unwin et al. 2002). With prevalence of type 2 diabetes increasing rapidly, a 
diagnosis of GDM represents an opportunity for intervention to reduce the burden of type 
2 diabetes (Davies et al. 2004). This is why it is so important to have a full and clear 
understanding of the prevalence of this condition in order to be able to plan such 
interventions and health care provision. We have therefore conducted a meta-analysis of 
observational primary research studies that have assessed the prevalence of GDM in the 
general population of pregnant women in developed countries in Europe, regardless of 
the specific diagnostic criteria used.  We have derived an overall prevalence estimate for 
GDM and examined moderator variables that potentially influenced this estimate. 
Although narrative reviews exist on this topic, this is the first systematic review and meta-
analysis to bring together and synthesise all the evidence.  
4.3 Material and methods 
Literature search and study selection 
A meta-analysis of primary research studies reporting prevalence of GDM was 
undertaken in accordance with the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines for reviews (Stroup et al. 2000). A search was 
conducted in MEDLINE, CINAHL, Health Source and PsycInfo for articles published 
before June 2016. The following combination of search terms were used with each 
database: (prevalence or incidence) and (gestational diabetes or diabetes in pregnancy or 
gestational diabetes mellitus). Reference lists and citations of included papers were 
checked to identify any other potentially relevant papers but key authors and experts in 
the field were not contacted due to the time consuming nature of this process with no 
guarantee of obtaining relevant information.   
After removing duplicates, the title and abstract of all papers were screened by one author 
(CE). Independent screening of records was split between the two other authors, with JE 
screening half and DC screening the other half. The full texts of papers were retrieved for 
studies that were considered relevant, but also for those that contained insufficient 
information to allow judgement of relevance. These were checked against the inclusion 
criteria by CE and independently by JE. Reference lists of included articles were 
reviewed to identify any additional relevant articles. In cases of disagreement between 
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authors about the inclusion of a paper, the full text of the paper was accessed and 
consensus was reached through discussion.  
Papers were screened against the following inclusion criteria:  
Population: general population of pregnant women, living in a developed country in 
Europe (as defined by the Financial Times Stock Exchange). 
Outcome measure: prevalence of GDM diagnosed using universal screening carried out 
in the second or third trimester, using either a glucose tolerance test (GTT) alone or two 
step screening with glucose challenge test (GCT) followed by a GTT.  
Study design: observational study, published in English.  
The review was limited to developed countries in Europe because of the wide differences 
in prevalence of type 2 diabetes and GDM between developed and developing countries 
(Ferrara 2007; Wild et al. 2004). This removed one potential source of heterogeneity in 
the review and also ensured its relevance for informing care and development of 
interventions in the context of developed health care systems. Studies were defined as 
having a sample drawn from the general population of pregnant women if it was drawn 
from a source that covered the majority of the population, such as population registers, 
general practice registers or registers of clinics for pregnant women (in countries where 
registration at general practices and clinics for pregnancy women is near to universal). If 
this information was not reported, studies were only included if the paper explicitly stated 
that the sample was drawn from a general population. Studies that selected people who 
were at high risk of GDM (due to family history of type 2 diabetes, or lifestyle and 
medical factors) were excluded. Studies were excluded if the majority of the sample were 
immigrants and did not originate from an included developed country. 
Data extraction and coding 
Data were extracted and summarised from potentially relevant studies by one author (CE) 
using a standardised data extraction form based on the example provided by the Centre 
for Reviews and Dissemination (CRD 2009). Confidence intervals were calculated where 
possible for studies that did not report these for prevalence figures. Where there were 
multiple papers published that were based upon the same sample, only the paper reporting 
the most complete and definitive results was included. However, more than one paper 
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from the same sample was included in the review if each paper reported on a unique 
aspect of the findings.   
The following information was extracted from each included study: first author, journal 
name and year of publication, country of study population, study period, study sample 
type, study design, age range, response rate, sample size, type of screening/testing carried 
out and diagnostic criteria for GDM. The outcome measures extracted were number and 
proportion of sample with GDM, and where reported the number and proportion of 
sample with GDM by different demographic factors such as age and Body Mass Index 
(BMI).  
Where individual studies reported multiple prevalence estimates according to different 
diagnostic criteria, only one prevalence estimate was included in the meta-analysis to 
avoid dependency effects. The prevalence estimate deriving from the criteria that were 
most commonly used in other papers in the review was the one selected for inclusion in 
the meta-analysis so that the estimate would be comparable to other studies in the review.  
For studies reporting multiple prevalence estimates by other factors, such as age or year, 
an average of the estimates was calculated and used in the analysis.    
Quality appraisal 
The quality of included studies was assessed using a checklist based upon the example 
published by the Joanna Briggs Institute (2014) which was designed for assessment of 
quality in systematic reviews of prevalence and incidence. Quality assessment was 
completed for all included papers by one author (CE) and a list of all identified 
weaknesses was compiled. The list was then discussed by all of the authors and the 
weaknesses were categorised as high, medium or low according to how likely they were 
to put the study at risk of bias. High risk weaknesses were those that put the study at high 
risk of bias or made the risk of bias difficult to assess, and included not reporting 
participation rate, very low participation rate (<50%) or not reporting the source of the 
study sample (e.g. census, general practice register). Participation rates can be defined in 
many ways but for this review the participation rate (recoded during data extraction if 
necessary and possible) was the proportion of eligible people sampled who completed 
testing for GDM. Medium risk weaknesses included low participation rate (50-70%), not 
reporting women’s gestation at testing and sample size of less than 300. Low risk 
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weaknesses included not reporting characteristics of the sample and not reporting 
differences between participants and non-participants.  
Included studies were then given a quality rating as follows: 
 1: Only low risk weaknesses 
 2: One medium or more than one low risk weakness. 
3:  One high risk or multiple medium risk weaknesses.   
Data analysis 
The meta-analysis was carried out using the Comprehensive Meta-Analysis software 
version 3.3.070 (Biostat, Englewood, NJ). For each study, the proportion of people with 
GDM was transformed into a logit event rate effect size and the standard error associated 
with this was calculated (Lipsey and Wilson 2000). The logits were retransformed to 
proportions after analysis to aid interpretation of the results. Combined effect sizes were 
calculated and analyses were carried out twice: both including and excluding outlying 
logit event rates. No significant differences were found between these analyses so outliers 
were retained in the analyses.  
Significance tests and moderator analysis were carried out using a random effects model. 
Fixed effects models make the assumption that the effect size observed in a study 
estimates the corresponding population effect with random error that comes only from 
the chance factors associated with subject level sampling error (Lipsey and Wilson 2000).  
In contrast, random effects models allow for the possibility that there are also random 
differences between studies that are not only due to sampling error but as a result of some 
other factor such as variation in procedures, measures or settings. The choice of the 
random effects model to combine studies in this meta-analysis was based upon literature 
on GDM prevalence which suggests that the variability in reported prevalence for GDM 
may be the result of the use of different methodologies and criteria (Ferrara 2007).  
The homogeneity of studies was evaluated using the Q test where the null hypothesis 
states that variability of the effect sizes is the result of sampling error only. If the 
assumption of homogeneity is violated it is customary for sources of variation to be 
explored by studying moderator variables. Q and I2 statistics were also calculated to 
 61 
 
assess differences in combined effect sizes for sets of studies grouped according to 
moderator variables.  
Categorical moderator variables were analysed using an analysis of variance for meta-
analysis. Differences between subgroups of these variables were explored using a test of 
interaction. The between study homogeneity statistic (QB) reflects the amount of 
heterogeneity that can be attributed to the moderator variable. The within study 
homogeneity statistic indicates the degree of heterogeneity that remains in the category 
in question (QW) and the I
2 statistic shows the proportion of the variation that is due to 
heterogeneity rather than sampling error. For continuous variables, a simple weighted 
regression was used, where QR represents the proportion of variability associated with the 
regression model and QE indicates the variability unaccounted for by the model.  
4.4 Results 
Description of included studies 
Figure 2 shows a PRISMA flow diagram of studies identified by the search. The search 
identified 3,258 abstracts of which 161 were potentially relevant after title and abstract 
screening. The full text articles were retrieved and assessed against the inclusion criteria, 
resulting in 40 included studies reported in 41 papers (Aberg et al. 2001; Alberico et al. 
2004; Anderberg et al. 2007; Avalos et al. 2013; Breschi et al. 1993; Bugallo et al. 2011; 
Cauza et al. 2005; Chevalier et al. 2011; Chico et al. 2005; Coolen and Verhaeghe 2010; 
Cordero and et al. 2015; Corrado et al. 2012; Cosson et al. 2006; Di Cianni et al. 2003; 
Duran, et al. 2014; Fadl et al. 2010; Fedele and Lapolla 1997; Griffin et al. 2000; Ignell 
et al. 2014; Janghorbani et al. 2006; Jimenez-Moleon et al. 2002; Lacaria et al. 2015; 
Lind and Anderson 1984; Lindqvist et al. 2014; Malmqvist et al. 2013; Meek et al. 2015; 
Miailhe et al. 2015; Orecchio et al. 2014; Ostlund and Hanson 2003; Perez-Ferre et al. 
2012; Pintausdi et al. 2013; Poyhonen-Alho et al. 2005; Ricart et al. 2005; Ruetschi et al. 
2016; Sommer et al. 2015; Vassilaki et al. 2015; Vignoles et al. 2011; Sacks et al. 2012; 
Murgia et al. 2008; O’Sullivan et al. 2011; Oriot et al. 2014). These 40 studies included 
a total of 1,778,399 participants. The characteristics of the studies included in the review 
are presented in Table 8 (Appendix 4). Studies were conducted across 11 of the 17 
countries defined as developed European countries: Italy (n=9), Sweden (n=7), Spain 
(n=7), France (n=4), UK (n=5), Ireland (n=2), Belgium (n=2), Greece (n=1), Finland 
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(n=1), Austria (n=1), and Switzerland (n=1). No additional papers were identified by 
manual searching of reference lists.   
 
Figure 2: Flow diagram showing study selection 
 
 
Around half of studies (n=22) used a single step screening strategy where all women were 
given a GTT, and the others used two-step screening, where all women were screened 
first with a GCT, then those with a positive GCT were given a GTT. Two studies used 
both one-step screening in one cohort, and two-step screening in a second separate cohort 
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of women (Duran et al. 2014; O’Sullivan et al. 2011). The most commonly used 
diagnostic criteria were Carpenter and Coustan (1982) which were used to diagnose 
GDM in 14 studies as part of two-step screening and one study using one-step screening. 
The International Association of Diabetes and Pregnancy Study Group criteria (IADPSG 
2010) were applied in a total of ten studies, of which nine used one-step screening and 
one used two-step screening. The National Diabetes Data Group (NDDG 1979) criteria 
were used in three studies using two-step screening and one study using one-step 
screening. A modification of the European Association for the Study of Diabetes (1988; 
EASD) criteria that diagnosed GDM on the basis of two hour values only without 
assessing fasting blood glucose was used in four studies all using one step screening. 
Only three studies reported that they tested for and excluded any women with 
undiagnosed pre-existing diabetes that was uncovered in the first trimester.  
Quality of studies 
The quality category assigned to each study is reported in Table 8 (Appendix 4). Three 
studies were identified that had two major weaknesses (Di Cianni et al. 1997; Mello et 
al. 1997; Vitoratos et al. 1997): in all three studies it was not clear if the study sample 
was a whole population of pregnant women and response rates were not reported. These 
studies were excluded from the review as this particular combination of problems made 
it difficult to assess the risk of bias in the study. The majority of included studies were 
classed as either the higher (n=23) or middle quality category (n=11) and therefore had 
only low or medium risk weaknesses. The remaining studies fell in to the lower quality 
category (n=6) and in addition to any low risk weaknesses also had weaknesses that put 
the study at higher risk of bias. These higher risk weaknesses included non-reporting of 
response rate (n=4), not reporting where women were recruited from (n=1) and very low 
participation rate (n=1). Of the weaknesses categorised as low or medium risk, the most 
common problems were non-reporting of sample characteristics (n=21), non-reporting of 
information on women who did not participate (n=17), low participation rate (n=5), and 
non-reporting of gestation at testing (n=2).  
Analysis of outliers  
One outlier was identified that reported prevalence of 35.5% (Duran et al. 2014). This 
figure was reported for a cohort of women with a median age of 32 and median pre-
pregnancy BMI of 22.8kg/m2 and who were diagnosed with GDM through universal 
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screening using IADSPG criteria. The majority of women were Caucasian (62%) and 
only 2% had previous GDM. These characteristics are largely similar to those of other 
studies giving no clear explanation for the high prevalence found in this study.   
Mean prevalence of gestational diabetes mellitus 
The mean prevalence of GDM overall was 5.4% (95% CI: 3.8-7.8). The mean prevalence 
in studies using one-step screening was 6.4% (3.8-10.4) and 4.7% (2.7-8.1) in studies 
using two-step screening. There was no significant difference in prevalence of GDM 
between studies using one-step and two-step screening (Q[1]=0.64; p=0.424). The 
analysis of homogeneity in the data with regards to type of screening showed variability 
within studies assessing prevalence using one-step screening (Q[19]=13019.04; p<0.001) 
and those using two-step screening (Q[21]=15517.54; p<0.001). 
Analysis of moderators for GDM 
As there was no significant difference in prevalence of GDM by screening type, the 
analysis of prevalence by moderator variables is presented in overall terms. Table 9 
shows the individual effects of different categorical moderator variables. Sample age, 
diagnostic criteria, country the study was conducted in, year that data collection started 
and week of gestation at testing, all had a significant effect on the prevalence of GDM, 
whereas the quality category of studies, mean BMI, ethnicity, and family history of 
diabetes in samples, did not have a significant effect. There were too few studies reporting 
parity data for this variable to be included in analyses.  
Sample age 
Prevalence was higher in samples with a mean age of 30.8 years and over (9.6%; 6.7-
13.7) compared to those with a mean age of 30.7 and under (4.3%; 2.3-8.0). 
Diagnostic criteria 
Analysis of the effect of diagnostic criteria on GDM prevalence found the highest 
prevalence estimate in studies using the IADPSG criteria (14.1%; 9-21.5; 2010), the 
second highest prevalence was found in studies using Carpenter and Coustan criteria 
(6.9%; 5.4-8.7; 1982). The second lowest prevalence estimate was in studies using the 
NDDG criteria (5.3%; 2.7-10; 1979) and the lowest estimate was for those that defined 
GDM using modified EASD criteria with two hour readings only (1.4%; 0.9-2.2; 1988).  
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Table 9: Mean prevalence of GDM by several moderator variables  
Variable k N Prevalence 95% 
CI 
QB [df] QW [df] I2 
[%] 
Mean age [years] 
30.7 and 
below 
9 122,648 4.3% 2.3-
8.0 
4.75 [1]* 
 
2312.38 [8]* 99.7 
30.8 and 
above 
9 43,327 9.6% 6.7-
13.7 
806.49 [8]* 99 
Diagnostic Criteria  
NDDG 4 11,927 5.3% 2.7-
10 
60.1[3]* 79.13 [3]* 96.2 
Carpenter 
Coustan 
15 47,502 6.9% 5.4-
8.7 
 621.28 [14]* 97.7 
EASD 2 hour 
only 
4 299,153 1.4% 0.9-
2.2 
 420.48 [3]* 99.3 
IADPSG 10 46,557 14.1% 8.9-
21.5 
 2275.49[9]* 99.6 
Quality Category 
1 – Higher 24 325,888 6.0% 4.1-
8.5 
3.0 [2] 7999.56 [21]* 99.7 
2 12 1,442,4833 3.9% 2.2-
7.1 
 6869.37 [11]* 99.8 
3 – Lower 6 13,895 7.6% 4.8-
12.0 
 366.60 [5]* 98.6 
Country        
Austria 1 2,421 8.6% 7.5-
9.8 
101.96 
[10]* 
0.00 [0] 0.0 
Belgium 3 2,497 9% 3.3-
22.2 
 133.24 [2]* 98.5 
Finland 1 532 2.8% 1.7-
4.6 
 0.00 [0] 0.0 
France 4 19,080 8% 4.1-
14.9 
 403.18 [3]* 99.26 
Greece 1 1,122 9.1% 7.5-
10.9 
 0.00 [0]  0.0 
Ireland 2 6,799 5.9% 1.3-
23.8 
 85.59 [1] * 9.8 
Italy 9 13,486 10% 7.6-
13 
 210.45 [8]* 96.2 
Spain 8 34,031 8.6% 5.1-
14.1 
 1259.12 [7]* 99.4 
Sweden 7 1,663,514 1.5% 1-2.3  3335.68 [6]* 99.8 
Switzerland 1 1042 4.8% 3.7-
6.3 
 0.00 [0]  0.0 
UK 
 
5 37,292 2.4% 0.8-
7.0 
 1519.62 [4] * 99.7 
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Variable k N Prevalence 95% 
CI 
QB [df] QW [df] I2 
[%] 
Area of Europe 
Northern 15 1,708,137 2.3% 1.3-
3.8 
24.32 [2] 
* 
14880.94[14]* 99.9 
Western 9 26,346 7.3% 4.6-
11.3 
 651.79 [8]* 98.8 
Southern 18 47,783 9.6% 7.3-
12.6 
 1530.48 [17] * 98.9 
Year data collection started 
1980-1989 2 2,824 0.9% 0.1-
10 
14.95 [3] 
* 
27.77 [1] * 96.4 
1990-1999 14 1,508,604 2.9% 1.9-
4.5 
 5500.94 [13] * 99.8 
2000-2009 13 233,199 6.9% 4.3-
10.8 
 5434.77 [12] * 99.8 
2010-2016 9 34,343 11.1% 5.7-
20.6 
 2187.66 [8] * 99.6 
% sample with family history of diabetes 
14% and 
below 
5 10,106 12% 5.2-
25.3 
0.971 [1] 804.53 [4] * 99.5 
15% and over 3 9,989 7.6% 4.9-
11.5 
 65.3 [2] * 96.9 
% sample Caucasian  
79% and 
below 
2 3,276 20.3% 5.4-
53.6 
2.73 [1] 265.93 [1] * 99.6 
80% and over 7 102,821 5.5% 2.4-
12.3 
 3040.83 [6] * 99.8 
Gestation at testing 
24-28 weeks 28 105,096 7.5% 5.9-
9.4 
104.85 
[3] * 
2841.69 [27] * 99.1 
28 weeks 6 381,273 1.9% 1.5-
2.5 
 449.79 [5] * 98.9 
28-32 weeks 1 3,616 1.7% 1.3-
2.2 
 0.00 [0] 0.0 
Multiple time 
points 
4 8,877 13.1% 6.5-
24.7 
 367.84 [3] * 99.2 
Mean BMI        
20-24.9 10 19,131 9.8% 5.5-
16.9 
0.39 [1] 1062.55 [7] * 99.3 
25-29.9 2 6,799 5.9% 1.3-
23.8 
 85.59 [1] * 98.8 
* p<0.05; k: number of studies; n: total sample size; QB: between study homogeneity 
statistic; QW: within study homogeneity statistic; I
2 proportion of variability within 
categories due to heterogeneity rather than sampling error. 
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Country 
In the analysis by country, the highest prevalence was found in studies conducted in Italy 
(10%; 7.6-13) and the lowest in Sweden (1.5%; 1-2.3). Countries were sorted into three 
groups according to location in Europe: Northern Europe, Western Europe, Southern 
Europe. Highest prevalence was found in countries in Southern Europe (9.6%; 7.3-12.6) 
and lowest in Northern Europe (2.3%; 1.3-3.8). 
Year 
Estimates of GDM prevalence increased every decade with the lowest in the 1980s 
[0.9%; 0.1-10] and the highest in the 2010s (11.1%; 5.7-20.6).  
Gestation at testing 
The highest prevalence estimate for GDM was found in studies that screened for GDM 
at multiple time points in the second and third trimester (13.1%; 6.5-24.7) followed by 
those studies that tested participants between 24 and 28 weeks of gestation (7.5%; 5.9-
9.4) . The lowest prevalence estimate was in a study that screened for GDM at 28 to 32 
weeks gestation (1.7%; 1.3-2.2). However, as this category only contained a single study 
this result must be interpreted with caution. The second lowest prevalence estimate was 
found in studies that screened only at 28 weeks of gestation (1.9%; 1.5-2.5). 
Multivariate analysis 
A weighted multiple regression was performed in order to explore which variables made 
the greatest contribution to the variability in prevalence of GDM. All variables explored 
in the univariate analysis were initially entered into the model except for sample age and 
mean BMI as there were too few studies reporting these variables for them to be included 
in the multivariate analysis. Correlations between different variables were explored and 
used to inform the selection of variables for the multiple regression. A moderate 
correlation was found between year of data collection and diagnostic criteria (r=0.478; 
p=0.010; n=28). The variable diagnostic criteria could not be included in the multiple 
regression because of collinearity with this and other variables.  
The final model included the following variables: quality category, type of screening (one 
or two step), gestation at testing, year data collection started and area of Europe. These 
variables accounted for 83% of total observed variability (QR[11]=125.6, p<0.001, see 
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Table 10 for full results). All three of the variables that were significant in univariate 
analyses (area, gestation at testing and year of data collection) remained statistically 
significant when the other variables were held constant. Quality category and type of 
screening were not significant in univariate analysis but were significant in the multiple 
regression. However, the residual model was also statistically significant 
(QE[23]=1134.95; p<0.001, I
2=98.0%) meaning that there was still variability in the data 
that was not explained by the variables analysed. 
 
Table 10 Weighted multiple regression for GDM prevalence 
  95% CI Q[B] [df] 
Quality Category    
1 – Higher - - 14.85 [2] * 
2 0.042 -0.35-0.44  
3 – Lower 0.97* 0.47-1.47  
Area of Europe    
North  - - 18.07 [2] * 
West 0.54* 0.02-1.06  
South 1.04* 0.54-1.53  
Year data collection started    
1980-1989 - - 29.03 [3] * 
1990-1999 1.85* 0.71-3.0  
2000-2009 2.37* 1.21-3.52  
2010-2016 2.74* 1.61-3.88  
Gestation at testing    
24-28 weeks 0.49 -0.54-1.52 9.58 [3]* 
28 weeks -0.15 -1.11-0.83  
28-32 weeks - -  
Multiple time points 1.03 -0.11-2.17  
Type of Screening    
One step - -  
Two step 
-0.41* -0.77—0.04 
 
* p<0.05; QB: between study homogeneity statistic 
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4.5 Discussion 
This meta-analysis of 1,770,63 participants in 40 studies reported mean prevalence of 
GDM of 5.4%. No differences were found in prevalence estimates of GDM according to 
the type of screening used (one-step or two-step), mean BMI, ethnicity and family 
history. An increase in prevalence was found with increasing sample age and year of data 
collection. Diagnostic criteria, country and week of gestation at testing were also found 
to have an effect on GDM prevalence. Nevertheless, given the changing migration 
patterns across Europe, this prevalence estimate may well change in the future. 
The study methods were systematic and robust. We used independent reviewers to screen 
all of the titles and abstracts identified by the search for inclusion in the review. All 
decisions on the inclusion of papers were discussed and agreed upon by all three authors. 
A thorough quality assessment was conducted for all studies considered for inclusion 
using a template designed for observational epidemiology studies and the majority of 
studies included were of high quality. The methodology had only minor limitations: only 
papers published in the English language were included, experts in the field were not 
contacted, grey literature was not identified and data extraction was only carried out by 
one author.  
The quality assessment ensured that the majority of studies included in the review had 
relatively good participation rates and recruited participants from sources with coverage 
of the majority of the pregnant population (e.g. clinic register) using appropriate methods 
(e.g. whole population). The majority of included studies had good participation rates. 
Only four studies had participation rates of 50 to 70% and only one study had a very low 
participation rate of less than 50%. This allows us to be reasonably confident that the 
included studies used samples that were representative of the general pregnant 
population. Quality category of the study was not found to have any significant effect on 
prevalence of GDM in univariate analysis but was significant in the multiple regression.  
Non-reporting of various methodological details was a common problem which made it 
difficult to assess fully the quality of some studies.  However, the impact of this problem 
on the quality of the review was minimised by the decision to exclude any studies that 
had more than one weakness defined by the authors as major. Collating data on GDM 
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prevalence was also made difficult by heterogeneity in approaches to sampling, methods 
used to collect blood samples and the criteria used to define GDM.  
The way GDM is defined makes it difficult to differentiate between pre-existing 
undiagnosed diabetes and GDM. The IADPSG guidelines suggest that all women or those 
at high risk have either fasting blood glucose, A1c or random blood glucose measured at 
the first prenatal visit and overt diabetes diagnosed if fasting blood glucose is 126mg/dl 
or higher or A1c 6.5% or higher (IADPSG 2010). Only three of the studies included in 
the present review reported that they tested for pre-existing undiagnosed diabetes in this 
way and excluded any women meeting the criteria. Of these three studies two reported 
the number of women thus identified and in both the prevalence was very low at 0.1% 
and 0.5%. Similarly, analysis of the national health and nutrition examination survey 
carried out between 1999 and 2010 in the United States showed that approximately 0.5% 
of women of non-pregnant women of reproductive age had undiagnosed diabetes 
(Razzaghiet al. 2015). Therefore, although estimates of GDM may be inflated by the 
potential inclusion of women with undiagnosed pre-existing diabetes, given the low 
prevalence of this it is unlikely that the effect on GDM estimates would be large.  
The ADA guidelines estimate that around 7% of pregnant women will be diagnosed with 
GDM (ADA 2003) and a review by of GDM prevalence in Europe reported rates of 
between 2 and 6% (Buckley et al. 2012). This estimate of 2-6% was based on studies 
using both risk-based and universal screening, whereas our estimate of 5% was based 
only upon studies using universal screening which identifies more women with GDM 
than risk-based screening (Anderberg et al. 2007; Ostlund and Hansen 2003).  
The specific diagnostic criteria was found to have a significant effect on prevalence 
estimates in this review, with the IADPSG (2010) criteria giving the highest estimates 
and a modified EASD (1988) and Carpenter Coustan (1982) giving the lowest estimates. 
In contrast, the review by Buckley et al. (2012) reported no consistent trend in prevalence 
according to diagnostic criteria. The IADPSG criteria were proposed on the basis of 
evidence from the HAPO study on the relationship between maternal hyperglycaemia 
and adverse outcomes. A number of associations, including the ADA, have adopted these 
recommendations while others have argued that they will increase prevalence without 
necessarily improving outcomes. A study by Duran et al. (2014) has since shown that 
while using the IADPSG criteria does increases GDM prevalence, it also results in 
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significant improvements in pregnancy outcomes. This study reported increases in 
prevalence of 3.5 times compared to Carpenter and Coustan criteria whereas we found 
rates according to IADPSG criteria to be around double Carpenter and Coustan.   
 The present review confirmed previous research showing that GDM prevalence 
increases with increasing maternal age and is higher in Southern and Western Europe 
compared to Northern Europe (Buckley et al. 2012). We did not find any effect for BMI, 
ethnicity or family history, but there were few studies that measured or reported these 
variables so there may have been insufficient power to detect any differences.  A strength 
of the present study is that pooling studies using meta-analysis allows trends to be 
identified when there are inconsistencies between individual studies.  
With GDM being closely linked to type 2 diabetes and sharing some risk factors, we 
would expect to see an increase in GDM over time (Buckley et al., 2012). Although we 
found significant increases in GDM prevalence over time, year of data collection was 
moderately correlated with diagnostic criteria. The IADPSG criteria were associated with 
the highest prevalence estimates for GDM but were also the criteria published most 
recently. It was not possible to enter diagnostic criteria in to the multivariate analysis 
which makes it difficult to assess how much of the increase in prevalence over time was 
related to the widening of diagnostic criteria and how much it reflected true increases in 
prevalence. Increases in screening over time also makes interpreting trend in prevalence 
difficult (Ferrara et al. 2004), although by including only studies using universal 
screening this source of heterogeneity was removed from this review.  
In summary, this is the first meta-analysis to bring together all the relevant evidence 
relating to GDM prevalence in Europe and to make sense of disparate findings. In the 
general population of developed Europe, around 1 in 20 pregnant women meet the criteria 
for GDM. These figures provide a basis for the planning of interventions and health care 
provision for the prevention of type 2 diabetes. We now recommend that similar meta-
analyses be conducted in other populations for comparison, for example those from 
developing countries, and from North America and Asia. 
This is the end of the verbatim copy of the publication two. 
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4.6 Critical reflection  
Critique of methods  
The methods of this systematic review and meta-analysis are the same as the systematic 
review and meta-analysis reported in chapter three so in depth discussion of the strengths 
and weaknesses will not be repeated here. In summary, strengths that this review shares 
with the one reported in chapter three include the fact that independent reviewers were 
used to screen all of the titles and abstracts identified by the search, decisions about 
inclusion were discussed and agreed upon by three authors, a thorough quality assessment 
was conducted for all studies and the majority of studies included were of high quality. 
As with the review in chapter three, the limited time and resources available for 
conducting this review meant that only papers published in the English language were 
included, experts in the field were not contacted, grey literature was not identified, 
independent double screening was split between two authors, and data extraction was 
only carried out by one author.  
Critique of analysis 
As above the general strengths and weaknesses of the analysis used in this paper are 
covered in chapter three and will not be repeated here. The search for this paper identified 
no studies published in languages other than English and therefore the critique regarding 
exclusion of non-English language papers in chapter three is not relevant here. However, 
there are some issues around the aggregation of studies with diverse methods and 
outcomes that are specific to GDM.  As discussed in relation to IGR in chapter three, 
there are variations in the way that GDM is screened and the specific criteria used to 
diagnose GDM. Decisions around which studies should and should not be combined were 
discussed by the authors at the start of the review process and as a result of these 
discussions the authors restricted the meta-analysis to studies that used universal 
screening as opposed to risk based screening to ensure that studies were comparable and 
the findings were generalizable to the general population of pregnant women. Despite 
efforts to ensure studies were as comparable as possible, there was heterogeneity in 
approaches to sampling, methods used to collect blood samples and the criteria used to 
define GDM. It is argued that summary statistics produced by meta-analyses are 
meaningless if they aggregate diverse studies (Higgins and Green 2011). However, by 
using the appropriate model for the meta-analysis, the effect of diversity in study methods 
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on summary statistics can be reduced. As discussed in the methods section of the paper, 
the random effects model used in the present study assumes that there is heterogeneity in 
study methods. A random effects model weights individual studies according to 
heterogeneity and produces more conservative summary statistics than the alternative 
fixed effects model, which does not make such assumptions about study heterogeneity 
(Haidich 2010).   A further weakness of paper two was that the search was conducted on 
one fewer platform than the systematic review in paper one as I no longer had access to 
EMBASE. 
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Chapter five: Incidence of impaired glucose regulation 
and progression to type 2 diabetes (publication three) 
 
 
 
 
 
 
 
 
The content of the above publication is presented in this chapter followed by a section 
providing a critical reflection of the methods. A PDF of the published manuscript can be 
found in appendix 6. Ethical approval for this study was obtained from the School of 
Nursing, Midwifery and Health Research Ethics Committee at the University of Stirling 
(see appendix 7 for a copy of the approval letter). The NHS Tayside Committee for 
Medical Research Ethics have granted approval for studies using routinely collected 
anonymised health data provided that the Standard Operating Procedures (SOPs) for the 
anonymisation and release of data are followed. The SOPs for the Health Informatics 
Centre (HIC), who provided the data, were closely followed during this study. A copy of 
the NHS Research and Development approval obtained for this study can be found in 
appendix 8.  
A verbatim copy of publication three starts below. 
5.1 Abstract 
This study assessed incidence of impaired glucose regulation (IGR) and progression to 
type 2 diabetes in adults in one region of Scotland using routinely collected health-care 
data. Incidence of IGR was 2,720 per 100,000 person years. Nine per cent of IGR patients 
progressed to type 2 diabetes in a mean time of 34 months. 
Eades, C.E., Leese, G.P. and Evans, J.M.M. (2014) Incidence of impaired glucose 
regulation and progression to type 2 diabetes mellitus in the Tayside region of 
Scotland. Diabetes Research and Clinical Practice, 104 (1), pp. e16-e19. 
This paper was published in Diabetes Research and Clinical Practice, a peer reviewed journal 
with an impact factor of 3.04, and has been cited four times. It is an international journal that 
publishes research on diabetes and related areas aimed at health care providers and clinically 
orientated researchers. 
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5.2 Introduction 
People with Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) have 
blood glucose levels that are higher than normal but do not meet the criteria for type 2 
diabetes. These two states of Impaired Glucose Regulation (IGR) confer an increased risk 
of developing type 2 diabetes (Unwin et al., 2002). Research has shown that progression 
from IGR to type 2 diabetes can be prevented through lifestyle changes meaning that a 
diagnosis of IGR could offer an ideal opportunity to deliver preventative interventions 
(Davies et al. 2004). In order to assess the feasibility of an intervention with IGR patients 
it is important to assess the rate of identification of IGR by health care providers and to 
characterise progression to type 2 diabetes. Recent research in the United States has 
reported prevalence rates of IGR in the general population as high as 35% (Kavre and 
Hayward 2010). There has been little research on this topic conducted in the United 
Kingdom. The present study assessed incidence of IGR and characterises progression 
from IGR to type 2 diabetes in adults in one region in Scotland using routinely collected 
health-care data.  
5.3 Methods 
Study design 
The study adopted an observational retrospective cohort design using anonymised patient 
data for the complete population of Tayside, Scotland, UK (approx. population 400,000).  
Data were provided by the Health Informatics Centre (HIC) at the University of Dundee, 
and the main data set used was SCI-DC which is a validated diabetes clinical information 
system (Morris et al. 1997).  
Population 
HIC provided patient demographic information (i.e. gender, date of birth, and deprivation 
from the Scottish Index of Multiple Deprivation [SIMD]; Scottish Executive 2010) and 
all instances of blood glucose testing in the population of Tayside from January 2003 to 
December 2008. This totalled 2,119,177 tests after excluding non-valid records (e.g. 
damaged samples). Patients were classified as having IGT or IFG if they had undergone 
two blood glucose tests on the same date (one coded in the records as a fasting test with 
the second test assumed to be carried out after an oral glucose tolerance test) that met the 
WHO (2006) criteria for IGT and IFG (IGT - first test < 7.0 mmol/l and second test 7.8-
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11.0 mmol/l; IFG - first test 6.1-6.9 mmol/l; second test <7.8 mmol/l). However, the 
majority of patients were found to have only taken a fasting test. Although the WHO 
criteria allow a single fasting test to be used to diagnose IFG, it also states that this 
classification is uncertain. In order to avoid loss of relevant data, patients with only one 
fasting glucose test of 6.0-6.9 mmol/L were classified as having undefined IGR (uIGR). 
Patients meeting any of the above criteria for IGR were included in the study if aged 18 
and over with no previous diagnosis of type 2 diabetes. Figure 3 illustrates selection of 
patients in the study. Patients with IGR were followed up for diagnosis of type 2 diabetes 
using the SCI-DC database which held complete data up to December 2011. Patients with 
type 2 diabetes are defined as those who are diagnosed with diabetes over the age of 35 
years, or younger patients for whom there is no immediate requirement for insulin. The 
precise glucose levels used to diagnose type 2 diabetes depend upon the criteria used at 
the time of diagnosis. 
Analysis 
Incidence rates of IGT, IFG and uIGR were calculated by dividing the number of new 
cases in one year by the population of Tayside aged over 18 in the same year. The 
relationship between potential risk factors and development of type 2 diabetes was 
assessed by univariate and multivariate Cox regression, from which hazard ratios (HRs) 
and 95% CIs were calculated. Age, gender, deprivation category and type of IGR were 
entered as independent variables, with diagnosis of type 2 diabetes as the dependent 
variable. Statistical analyses were carried out using SPSS for Windows version 19. 
Ethical approval was obtained from the School of Nursing, Midwifery and Health at the 
University of Stirling. The Tayside Committee for Medical Research Ethics have granted 
approval for studies using routinely collected, anonymised health data.  
5.4 Results 
Incidence of impaired glucose regulation 
In total 50,321 patients were identified who met the criteria for either IFG (n=2284), IGT 
(n=1996) or uIGR (n=46041) during the study period (2003 to 2008). Of the 50,321 
patients identified, 52.3% were female and the mean age at diagnosis was 62.8 
(S.D.=17.2). The total incidence across the study period was 2,720 per 100,000 person 
years.   
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Figure 3: The identification of participants with impaired glucose regulation from the 
biochemistry data supplied by the Health Informatics Centre.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All instances of blood glucose testing in population of 
Tayside, Scotland from November 2003 to 2008 
n = 2,132,085 records 
Non-valid samples removed n = 12,908 records (e.g. 
fluid glucose tests, samples damaged in transit)  
n=2,119,177 valid records 
 
Patients with two blood glucose tests 
conducted in one day were identified  
n = 1,593,730 records 
Identified patients with a 
test coded as fasting and a 
second test in the same 
day meeting WHO 
criteria for IGT 
n= 32,807 records 
Patients with only one fasting blood glucose 
test in one day meeting WHO criteria for IFG 
were classified as having undefined IGR  
n = 97,237 records 
Identified patients with a 
test coded as fasting and 
a second test in the same 
day meeting WHO 
criteria for IFG 
n=99,108 records 
n=28,738  n=95,485  
 
Excluded patients that 
were also in IGT or IFG 
group (n=14,058). 
n=83,179 records 
3,340 records 
meeting IGT 
criteria in 
1,996 patients 
 
3321 records 
meeting IFG 
criteria in 
2,284 patients 
77,536 instances 
meeting uIGR criteria in 
46,041 patients 
Excluded patients who 
had identical readings 
for both tests assumed 
to be data recording 
error. 
 
Excluded patients 
aged under 18. 
Excluded patients 
with previous 
diagnosis of T2D 
n=58 
n=244 n=689 
n=40 n=539 
n=5,104 
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No significant differences were found in incidence of all types of IGR by gender 
(t(10)=0.253, p=0.897) or deprivation category (F(4)=0.21, p=0.930). Incidence differed 
significantly by age category (F(3)=39.44, p<0.001) with a steady increase in incidence 
noted with increasing age. 
Progression to type 2 diabetes 
A total of 4,548 patients with IGR (9%) were diagnosed with type 2 diabetes during the 
study with a mean time of 34 months between IGR and type 2 diabetes diagnosis. Table 
11 shows that men with IGR were at a small but significantly increased risk of developing 
type 2 diabetes compared to women, as were more deprived patients compared to the 
least deprived. The risk of progression to type 2 diabetes increased with increasing age. 
Patients with IGT were found to be at a small but significantly increased risk of 
developing type 2 diabetes compared to those with IFG or uIGR.  These associations 
were evident in univariate and multivariate analyses. Mean time for progression from 
IGR to type 2 diabetes was largely similar in high risk groups of patients, as for all 
patients who developed type 2 diabetes in the study. 
5.5 Discussion 
To the best of our knowledge this study is the first to investigate the incidence of IGR 
and progression to type 2 diabetes in the UK. We found that a considerable number of 
people were diagnosed with IGR over the study period, of whom nearly 10% of 
developed type 2 diabetes within a relatively short time frame. However, a mean time of 
nearly three years between diagnosis of IGR and type 2 diabetes does provide sufficient 
opportunity for an intervention to be delivered and lifestyle changes to be made. Those 
people with IGR at the highest risk of developing type 2 diabetes are those with IGT and 
from a deprived background: as such, these patients should arguably be prioritised within 
prevention programmes. The use of routinely collected patient data means that the rates 
of IGR reported here may not be reflective of the true rates in the general population. 
However, this methodology gives the findings greater clinical relevance which is of the 
highest importance if interventions are to be developed for use in this setting. 
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Table 11: Hazard ratio of developing type 2 diabetes in patients with all type of IGR according to sex, age, deprivation category and type of IGR 
 
 
Sex 
Univariate Multivariate 
 
No. (%) 
progressing to type 
2 diabetes 
Mean time to 
progress  
(months) 
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value 
Women  2114 (8.2) 33.9 1.00  1.00  
Men 2408 (10.2) 34.4 1.26 (1.19-1.34) <0.001 1.1 (1.04-1.17) 0.002 
Age at diagnosis of 
IGR 
      
18-27 14 (1.2) 30.9 1.00  1.00  
28-37 62 (2.5) 14.2 2.16 (1.21-3.87) 0.009 2.14 (1.2-3.83) 0.010 
38-47 330 (8.0) 38.6 6.89 (4.03-11.75) <0.001 6.73 (3.94-11.49) <0.001 
48-57 794 (12.0) 35.5 10.6 (6.24-17.97) <0.001 10.21 (6.02-17.32) <0.001 
58-67 1320 (13.5) 35.2 12.01 (7.1-20.33) <0.001 11.62 (6.86-19.67) <0.001 
68-77 1289 (11.9) 33.4 10.26 (6.06-17.37) <0.001 9.96 (5.89-16.87) <0.001 
78-87 629 (6.2) 30.6 5.25 (3.09-8.92) <0.001 5.14 (3.02-8.72) <0.001 
88 plus 84 (2.0) 22.3 1.68 (0.95-2.95) 0.072 1.68 (0.96-2.95) 0.072 
Deprivation 
Category 
      
5 least deprived 752 (8.3) 35.1 1.00  1.00  
4 1315 (8.5) 34.8 1.2 (1.09-1.33) <0.001 1.18 (1.07-1.31) 0.001 
3 820 (9.4) 33.2 1.19 (1.08-1.32) 0.001 1.21 (1.01-1.34) <0.001 
2 775 (9.8) 34.8 1.14 (1.14-1.04) 0.008 1.15 (1.04-1.27) 0.006 
1most deprived 794 (9.9) 32.3 1.03 (0.94-1.12) 0.569 1.04 (0.95-1.13) 0.431 
Type of IGR        
IGT 247 (12.6) 28.5 1.00  1.00  
IFG 182 (8.1) 33.4 0.64 (0.53-0.78) <0.001 0.64 (0.53-0.78) <0.001 
uIGR 4093 (9.1) 34.5 0.73 (0.64-0.83) <0.001 0.73 (0.64-0.83) <0.001 
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This is the end of the verbatim copy of the publication three. 
5.6 Critical reflection 
Critique of methods  
This study has a number of strengths. The use of routinely collected health care data gives 
the findings greater clinical relevance which is of the highest importance if they are to be 
used to inform care delivery or the development of an intervention for this setting. Use 
of routinely collected health care data also allowed access to a large amount of data which 
could not have been collected using primary data collection methods with the resources 
available. The data for this study came from the Tayside Health Board in Scotland which 
has a population of around 400,000 people. Tayside Health Board is demographically 
similar to the wider population of Scotland with the same sex-ratio and similar median 
age and population density (National Record of Scotland 2017) and very similar 
incidence and prevalence of diabetes (Scottish Diabetes Survey 2017). The findings of 
the present study are therefore likely to be generalisable to the wider population of 
Scotland.  
The diagnoses of type 2 diabetes were made using a validated diabetes clinical 
information system SCI-DC that has been extensively used in health care research. SCI-
DC utilises a unique patient identifier that is assigned to every patient in Scotland upon 
registration at a general practitioner called the community health index (CHI) number to 
link electronic records on diabetes. The CHI consists of 10 digits, with the first six digits 
containing the patient’s date of birth. A centrally held, continuously updated record 
contains data on the patient’s address, postcode, general practitioner, death and date of 
death and this is linked to their CHI. The CHI is recorded and used as the patient identifier 
for the majority of primary and secondary healthcare activities in Scotland. SCI-DC links 
data from a number of independent sources to identify cases of diabetes. Deterministic 
linkage is used in SCI-DC where possible to identify cases of diabetes, with CHI the 
unique patient identifier. In cases where CHI has not been recorded, for example in 
prescription and ambulance service data, probabilistic linkage is used instead. 
The original SCI-DC database for Tayside (known as DARTS) was set up to allow all 
patients with diabetes to be identified in order to improve diabetes care (Morris et al. 
1997). At the time that DARTS was set up, registers only usually included people treated 
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with insulin making it difficult to identify people with type 2 diabetes. The registers that 
did exist were typically created by aggregating records held be general practices or by 
combining these general practice registers with those of hospital diabetes clinics. The 
DARTS study aimed to test the central linkage of electronic records relating to diabetes 
from multiple independent sources and hypothesised that linkage of electronic records 
would be more efficient and effective method of identifying people with diabetes than 
general practice lists. The study found that electronic record linkage was more sensitive 
at identifying people with diabetes with a sensitivity of 95% for electronic record linkage 
compared to 91% for GP lists (Morris et al. 1997).   
Although the electronic record linkage used in this study has been shown to have good 
sensitivity for identifying diabetes, there are limitations to this method. When data-sets 
are linked, a proportion of cases will match and a proportion will remain unmatched. In 
false negative errors in data linkage, records that correspond to the same person cannot 
be linked and in false positive errors records that do not correspond to the same person 
are incorrectly linked (Bohensky et al. 2010). Broader issues with data collected in 
routine health care practice can compound these issues. Standards of data collected in 
routine health practice are often not as high as those expected for research purposes and 
there can be inconsistent coding of data and missing or inaccurate data. Much health care 
data is still recorded manually and the transfer of these data to electronic forms introduces 
further risk of human errors (Kane et al. 2000). Indeed, the number of years of data 
available for analysis in this study was limited, partly because of issues with recording of 
data. Biochemistry data for this study were available from 1998 and complete up until 
2008. However, analysis of the data showed that only 3% of people in the study who met 
the criteria for IGR were diagnosed between 1998 and 2002 and the data included in the 
study was therefore limited to between 2003 and 2008. It is likely that the small number 
of patients identified in the earlier study years is a reflection of lower rates of testing but 
also poorer recording of IGR data. It is important that these limitations are recognised 
and that the results of this study are interpreted accordingly.  
A further weakness of this study is that it was not possible to determine the exact nature 
of the second test used to diagnose patients as having IFG or IGT. It is possible that the 
presence of a second blood glucose test in one day could represent something other than 
an oral glucose tolerance test (e.g. pre and post-operative blood glucose testing), thus 
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there may be patients in the sample who are falsely classified as having IGT or IFG. 
However, patients classified using two tests in one day make up only a minority of the 
sample so it is unlikely that the proportion of patients falsely identified as having IGT or 
IFG is high.  People were also classified on the basis of a fasting test alone and some of 
these patients might have been diagnosed with type 2 diabetes if a glucose tolerance test 
had been performed. However, this is unlikely to be a major confounder as those with 
uIGR actually had a lower rate of developing type 2 diabetes than those with IGT.  
Both the ADA (2011) and WHO (2011a) now recommend that HbA1c can be used in the 
diagnosis of IGR and research has shown that HbA1c and FPG/2hPG tests do not identify 
the same people as being at high risk of type 2 diabetes (Mann et al. 2010; Barry et al. 
2017). By only using FPG/2hPG to identify people with IGR and not HbA1c, publication 
three is likely to have missed a portion of the population who are at high risk of type 2 
diabetes.  
A further limitation associated with the use of routinely collected data in this study is that 
the rates of IGR reported may not be reflective of the true rates in the general population, 
as there may be some people with IGR who have not been detected by the health service. 
This study used the adult population of Tayside as the denominator in the calculation of 
incidence of IGR. The presence of people with undiagnosed IGR in the general 
population of Tayside means it is likely that this study has underestimated the incidence 
of IGR. An alternative to using the entire adult population of Tayside as the denominator 
would have been to use all people with instances of blood testing in Tayside. This option 
was considered during the analysis but because people who have a blood test are arguably 
more likely to be higher risk patients, it may have resulted in an overestimation of 
incidence and the decision was made to take the more cautious approach to calculating 
incidence. A weakness of the analysis in publication three was that a key assumption of 
the Cox’s hazard model was not assessed. The proportional hazards assumption requires 
that the ratio of hazards for individuals in the study remains constant over time. It was 
assumed in this study that the proportional hazards assumption was not violated but this 
could have been tested by creating a time dependent covariate and including this in the 
model. If this covariate was statistically significant then the proportional hazards 
assumption has been violated.          
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Ethical considerations 
As this study used anonymised secondary data, there were only very limited risks to those 
involved in the study. The main risk to patients was breach of confidentiality. However, 
this risk was very small as all data in this study were anonymised and did not contain any 
identifiable information about patients. Anonymisation was carried out by the provider 
of the data, HIC, prior to the data being passed on to the researcher. The unique patient 
identifier assigned to every patient in Scotland called the community health index (CHI) 
was anonymised by HIC into a project specific pseudo-CHI. Date of birth data were 
anonymised by changing the day of birth to the 1st and the month to the middle of the 
appropriate quarter year. For example, a patient born on the 24th of January 1975 would 
be anonymised to the 1st of February 1975. Postcode was restricted to district by removing 
the last three digits (Galloway 2010). The anonymised data were stored on a secure server 
provided by HIC and accessed remotely. This server meant that data did not need to be 
stored on the researcher’s own computer but instead were accessed and analysed on a 
restricted, secure IT environment. The researcher was unable to print, access the internet 
or export data while on the secure server thus reducing the risk of the data being accessed 
by anyone else. Data outputs (e.g. tables or statistical analyses) were reviewed by HIC 
prior to being released to the researcher and HIC Standard Operating Procedures were 
adhered to at all times when working with the data (HIC 2016). 
Informed consent was not sought from participants in this study as the National Research 
Ethics Service guidance states that it is not an ethical or legal requirement for research 
using anonymised health care data (HIC 2016). Informed consent is when someone 
agrees to take part in research on the basis of having full access to information about what 
participation involves, including the potential harms and benefits (Royal College of 
Nursing 2011). Informed consent is a central part of research ethics and is embedded in 
various ethical codes such as The Declaration of Helsinki (World Medical Association 
2001). The process of gaining informed consent ensures that people who participate in 
research understand fully what this will involve, and that they are not coerced into 
participating.  
Although informed consent was not required in the present study, not seeking consent 
clearly raises ethical issues. It is possible that the people whose data were used in the 
 84 
 
present study would be unaware and/or unhappy about the use of their data in this way.  
Hill et al. (2013) carried out a systematic review and qualitative study to explore public 
attitudes towards the secondary use of existing health care data. The systematic review 
reported that in the majority of studies, participants were not aware of how their medical 
data might be used for research and expressed a wish to be informed about how and by 
whom their data were being used.  Although not aware of these potential uses, participants 
in the majority of studies recognised the benefit that medical research could have for the 
general population and often discussed the balance between obtaining consent and the 
benefits of unrestricted research. Despite recognising these benefits, many participants 
felt that informed consent should always be sought for research using medical data. 
Similar findings were reported in the focus groups carried out by Hill et al. (2013). 
However, focus group participants became more accepting of the use of medical data 
without consent after being given information about research processes and biases. Focus 
group participants were also more accepting of research using their medical data 
undertaken by the NHS compared to research for financial gain, for example, by 
pharmaceutical companies. 
Given that the participants in the Hill et al. (2013) study agreed to participate in this study, 
it is likely that their views on the topic were more positive than those of the general 
population. The research by Hill et al. (2013) suggests that some participants in the 
present study may not have been aware or accepting of the use of their data for this 
research. However, data in the present study were up to ten years old which would have 
made seeking consent very challenging. In addition to the practical challenges, it is 
suggested that seeking informed consent can affect the validity of research by introducing 
selection bias. Selection bias is where there are systematic differences between people 
who agree to participate in research and those who do not. A systematic review by Kho 
et al. (2009) reported that there were significant differences between participants and non-
participants in prospective observational studies using medical data where informed 
consent was sought.   It can be argued that NHS medical data is a publicly funded resource 
that should be utilised where possible for public benefit and that the benefits of having 
access to medical data without the need to seek informed consent outweigh the ethical 
issues.  
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Chapter six: Progression from gestational diabetes to 
type 2 diabetes (publication four)  
 
 
 
 
 
 
 
 
The content of the above publication is presented in this chapter followed by a section 
providing a contextualising narrative. Ethical approval for this study was obtained from 
the School of Nursing, Midwifery and Health Research Ethics Committee at the 
University of Stirling (see appendix 7 for a copy of the approval letter). The NHS Tayside 
Committee for Medical Research Ethics have granted approval for studies using routinely 
collected anonymised health data provided that the Standard Operating Procedures 
(SOPs) for the anonymisation and release of data are followed. The SOPs for the Health 
Informatics Centre (HIC), who provided the data, were closely followed during this 
study. A copy of the NHS Research and Development approval obtained for this study 
can be found in appendix 8. A PDF of the published manuscript can be found in appendix 
9. 
A verbatim copy of publication four starts below. 
 
 
 
Eades, C., Styles, M., Leese, G.P., Cheyne, H. and Evans, J.M.M. (2015) Progression 
from gestational diabetes to type 2 diabetes in one region of Scotland: an observational 
follow up study. BMC Pregnancy and Childbirth, 15, 11. Available: 
https://doi.org/10.1186/s12884-015-0457-8 [Accessed 6 October 2018]. 
This paper was published in BMC Pregnancy and Childbirth, an open access peer reviewed 
journal that publishes on all aspects of pregnancy and childbirth with an impact factor of 2.18, 
and has been cited 9 times. 
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6.1 Abstract 
Background 
The aim of this study was to investigate long-term risk of type 2 diabetes following a 
diagnosis of gestational diabetes mellitus (GDM) and to identify factors that were 
associated with increased risk of type 2 diabetes.  
Methods 
An observational cohort design was used, following up all women diagnosed with GDM 
attending a Diabetes Antenatal Clinic in the Dundee and Angus region of Scotland 
between 1994 and 2004 for a subsequent diagnosis of type 2 diabetes, as recorded on 
SCI-DC (a comprehensive diabetes clinical information system).  
Results 
There were 164 women in the study who were followed up until 2012. One quarter 
developed type 2 diabetes after a pregnancy with GDM in a mean time period of around 
eight years. Factors associated with a higher risk of developing type 2 diabetes after GDM 
were increased weight during pregnancy, use of insulin during pregnancy, higher 
glycated haemoglobin (HbA1c) levels at diagnosis of GDM, and fasting blood glucose. 
Conclusions 
These findings suggest there is a viable time window to prevent progression from GDM 
to type 2 diabetes and highlights those women who are at the greatest risk and should 
therefore be prioritised for preventative intervention. 
6.2 Background 
Gestational Diabetes Mellitus (GDM) is defined as glucose intolerance that begins or is 
first detected during pregnancy. GDM can have health consequences for the mother and 
baby both in the short and longer term. Although normal glucose regulation usually 
returns shortly after delivery, women diagnosed with GDM have at least a seven fold 
increased risk of developing type 2 diabetes in the future (Bellamy et al. 2009). In Europe, 
GDM affects between 2-6% of pregnancies but research has shown that the incidence of 
GDM has been rising (Buckley et al. 2012; Ferrera 2007). 
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Type 2 diabetes is a growing public health concern associated with a number of serious 
health complications that reduce both the life-expectancy and quality of life of sufferers 
(Donnelly et al. 2000; Colagiuri et al. 2006). There is good evidence to suggest that 
lifestyle interventions targeted at those at high risk of type 2 diabetes, such as those with 
pre-diabetes, can prevent or at least delay the onset of type 2 diabetes (Gillies et al., 2007). 
A diagnosis of GDM therefore represents a window of opportunity for preventative 
intervention. However, there has been little research on interventions designed 
specifically for women with GDM, and none in the UK to our knowledge. In order to be 
able to assess the feasibility and practicality of a lifestyle intervention targeted at women 
with GDM, it is important to establish the nature of the progression from GDM to type 2 
diabetes in the UK context. A systematic review of studies assessing the association 
between GDM and type 2 diabetes did not report any research that had been conducted 
in the United Kingdom (Kim et al 2002). This study therefore characterises the 
progression of GDM to type 2 diabetes in the Dundee and Angus region of Scotland, UK.  
6.3 Methods 
Study design and population 
This observational study used historical routinely collected health-care data to follow up 
women diagnosed with GDM. Antenatal care is a universal service accessed by almost 
all pregnant women in Scotland. Women diagnosed with GDM during routine antenatal 
care in the Dundee and Angus region (approximate population 250,000) attend the 
Diabetes Antenatal Clinic at Ninewells Hospital in the city of Dundee. All women in 
Dundee and Angus were screened with a fasting blood glucose (FBG) or random blood 
glucose (RBG) at 28 weeks gestation. All patients with any abnormal result (RBG of 
>5.5mmol/l-1 two or more hours after food or >7.0mmo/l-1 within two hours of food; FBG 
>5.5mmol/l-1), any glycosuria and all high risk pregnancies underwent a 75g oral glucose 
tolerance test (OGTT). All women diagnosed with GDM who had attended this clinic 
between 1994 and 2004, and who had no previous diagnosis of type 1 diabetes or type 2 
diabetes were included in this study. Women diagnosed with GDM in the first trimester 
of pregnancy were excluded as these women were likely to have had undiagnosed 
pregestational diabetes (International Association of Diabetes and Pregnancy Study 
Group [IADPSG], 2010). GDM was diagnosed on the basis of clinical guidance in use at 
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the time of the study which suggested an FBG of greater than 5.5mmol/l-1or a blood 
glucose reading two hours (2h BG) after an OGTT of greater than 9mmol/l-1.  
Data were extracted from paper based case records held at Ninewells Hospital containing 
clinical and personal data for all women who had attended the diabetes antenatal clinic 
between 1994 and 2004. These records included the following forms: a booking form 
which was completed at the first visit to the clinic after a diagnosis of GDM; follow up 
forms for each further visit to the clinic and a postnatal form containing information from 
a postnatal check-up. The information extracted from these forms included the mother’s 
date of birth, family history of diabetes, history of GDM in a previous pregnancy, parity, 
birth weight of previous babies, week of gestation, OGTT fasting and 2 hour blood 
glucose levels at booking and postnatal (where recorded), mother’s weight, Hba1C and 
treatment during pregnancy. Week of gestation, mother’s weight and HbA1c were 
extracted from the booking, follow up and postnatal forms where recorded.  
Data extracted from the paper based records were anonymised and linked to SCI-DC, a 
validated diabetes clinical information system (Morris et al., 1997), by the Health 
Informatics Centre at the University of Dundee (HIC). Patients were followed up for a 
diagnosis of type 2 diabetes using the Scottish Care Information – Diabetes Collaboration 
(SCI-DC) system which holds complete information on patients diagnosed with type 2 
diabetes in Scotland up to March 2012. Women who died or migrated out of the health 
board during the follow up were not excluded from the study but the date of 
death/migration was used as their study end date in the analysis.   
Patients with type 2 diabetes are defined as those who are diagnosed with diabetes over 
the age of 35 years, or younger patients for whom there is no immediate requirement for 
insulin. World Health Organisation (WHO) criteria were used to diagnose type 2 diabetes 
but the precise glucose levels used depended upon the criteria in use at the time of 
diagnosis. The majority of women included in the study (97%) were diagnosed using the 
WHO criteria published in 1999 (WHO 1999) which defines type 2 diabetes on the basis 
of a fasting plasma venous sample of 7.0 mmol/l-1 or higher and a 2 hour post OGTT 
value of 11.1 mmol/l-1. The remainder were diagnosed using the WHO 1985 criteria 
(WHO 1985) which had a higher value for fasting venous plasma of 7.8 mmol/l-1 or 
higher but the same 2 hour value. The data were also linked to a portion of the ISD 
SMR02 dataset which provided demographic information not available from paper based 
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records such as deprivation category from the Scottish Index of Multiple Deprivation 
(SIMD; Scottish Executive 2010) and body mass index (BMI). The SIMD deprivation 
category is a postcode measure derived from multiple aspects of deprivation including 
employment, income, health, education, access to services, crime and housing.  
Analysis 
In survival analyses, women were followed up from the date of diagnosis of gestational 
diabetes.  Women who had more than one pregnancy during the study period were 
followed up from the earliest date of diagnosis of gestational diabetes. The relationships 
between potential risk factors and development of type 2 diabetes were assessed by 
univariate and multivariate Cox regression, from which hazard ratios (HRs) and 95% 
confidence intervals (CIs) were calculated. Deprivation category, age, history of GDM, 
family history of diabetes, use of insulin during pregnancy, average weekly weight gain 
and weight, trimester, glycated haemoglobin (HbA1c), FBG, 2h BG at diagnosis of GDM 
were entered as independent variables, with diagnosis of type 2 diabetes as the dependent 
variable. Statistical analyses were carried out using SPSS for Windows version 21. 
Ethical approval was obtained from the School of Nursing, Midwifery and Health at the 
University of Stirling. The Tayside Committee for Medical Research Ethics has granted 
approval for studies using routinely collected, anonymised health data and this study falls 
under this approval.  
6.4 Results 
Characteristics of population 
Data were extracted from the records for 285 women, of which 164 women met the 
criteria for GDM and had no previous diagnosis of type 1 diabetes or type 2 diabetes, and 
were therefore included in the study. Of the remainder 75 women had type 1 diabetes, 12 
had type 2 diabetes, 2 were diagnosed with GDM in the first trimester and 1 had maturity 
onset diabetes of the young. A further 21 women were classified as borderline GDM as 
their blood glucose results were high but did not meet the criteria for GDM. Ten women 
with GDM were excluded due to having missing data or a previous diagnosis of type 1 
diabetes or type 2 diabetes.  
At the time of diagnosis of GDM, women ranged in age from 16 to 43 with a mean age 
of 30. Table 12 shows further characteristics of the population. Women were more 
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commonly from areas of higher deprivation than lower deprivation. A positive family 
history of diabetes was noted for around a third of women and the majority were having 
their first or second child. BMI data were not recorded for the majority of women in this 
study.  
Table 12: Characteristics of the population 
Deprivation Category n (%) 
5 (Lowest Deprivation) 17 (10.4) 
4 39 (23.8) 
3 21 (12.8) 
2 35 (21.3) 
1 (Highest Deprivation) 44 (26.8) 
Data Missing 
 
8 (4.9) 
Previous Live Births n (%) 
0 57 (34.8) 
1 54 (32.9) 
2 28 (17) 
3 or more 19 (11.6) 
Data Missing 
 
6 (3.7) 
Mother’s weight (kg) n (%) 
Up to 76.8 46 (28) 
76.8-92.5 49 (29.9) 
Over 92.5 53 (32.3) 
Data Missing 16 (9.8) 
 
Progression to type 2 diabetes 
Forty one women (25%) developed type 2 diabetes during follow-up. The time between 
diagnosis of GDM and type 2 diabetes ranged from 4 months to nearly 16 years, with a 
mean time of 93 months (SD=48.2) or nearly 8 years. Of these women only 3 (7.3%) 
went on to develop type 2 diabetes in the two years after their diagnosis of GDM and a 
further 4 (9.8%) developed type 2 diabetes two to four years after their diagnosis of GDM. 
Figure 4 shows a relatively steady rate of type 2 diabetes incidence after diagnosis of 
GDM over the study period. Table 13 shows the results of both univariate and 
multivariate Cox survival analysis. Greater weight during pregnancy, insulin use during 
pregnancy, higher HbA1c levels and FBG were associated with highly elevated risks of 
progression to type 2 diabetes in univariate and multivariate analyses. Although 2hBG 
and were also associated with an increased risk univariately, this association was no 
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longer statistically significant after adjusting for other variables. While there were no 
statistically significant associations for increasing age, family history of type 2 diabetes 
or previous history of GDM, the hazard ratios were elevated. There was no evidence for 
an association with deprivation or average weekly weight gain.  
Figure 4: Cumulative incidence of type 2 diabetes after diagnosis of GDM 
 
6.5 Discussion 
To the best of our knowledge this study is the first to investigate progression from GDM 
to type 2 diabetes in the UK. We found that around a quarter of women diagnosed with 
GDM developed type 2 diabetes with a mean time window between the two diagnoses of 
8 years. The vast majority of women who did develop type 2 diabetes after GDM did so 
five years or more after their diagnosis of GDM. This time period presents a considerable 
window of opportunity to deliver an intervention and for women to make necessary 
changes to their diet and activity levels in order to reduce the risk of progression to type 
2 diabetes. Many people find making lifestyle changes difficult and women who have 
recently had a baby face additional problems. For example, a lack of time is often cited 
by women who have had GDM as a barrier to making lifestyle changes (Parsons et al. 
2014).  
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Table 13: Hazard ratio of developing type 2 diabetes in patients with GDM according to previous history of GDM, family history of diabetes, 
deprivation category; insulin use and average weekly weight gain during pregnancy; and weight, age, trimester, HbA1c, fasting and 2 hour blood 
glucose at diagnosis of GDM 
 
 
Univariate Multivariate 
No. (%) 
progressing to 
type 2 diabetes 
Mean time to 
progress  
(months) 
Hazard ratio (95% 
CI) 
p value Hazard ratio (95% CI) p value 
Whole sample (n=164) 
 
41 (25) 93 
Deprivation Category (no. in each group)  
5 least deprived (17) 2 (12) 21 1.00  1.00  
4 (39) 8 (21) 78 1.44 (0.31-6.76) 0.647 0.68 (0.12-3.95) 0.671 
3 (21)  6 (29) 94 1.86 (0.38-9.20) 0.448 0.71 (0.11-4.61) 0.717 
2 (35) 13 (37) 115 2.81 (0.63-12.45) 0.174 1.92 (0.37-10) 0.438 
1 most deprived (44) 11 (25) 82 1.76 (0.39-8.89) 0.461 0.76 (0.15-3.93) 0.742 
Data missing (8) 1 (13) 106 0.81 (0.07-8.89) 0.860 0.9 (0.07-11.96) 0.936 
Age (no.) 
25 and under (32) 6 (19) 99 1.00  1.00  
26 to 34 (84) 19 (23) 93 1.28 (0.51-3.19) 0.604 1.35(0.48-3.79) 0.570 
35 and over (48) 16 (33) 86 1.90 (0.74-4.87) 0.179 2.38 (0.82-6.95) 0.112 
Previous history of GDM (no.) 
Yes (11) 4 (36) 83 1.7 (0.61-4.77) 0.315 2.83 (0.62-12.87) 0.179 
No/Data missing (153) 37 (24) 91 1.00  1.00  
Family history of Diabetes (no.) 
Yes (59) 17 (29) 89 0.80 (0.43-1.49) 0.485 1.42 (0.64-3.15) 0.385 
No/Data missing (105) 24 (23) 93 1.00  1.00  
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                                                                                                               Univariate                                                                               Multivariate 
 
 
 
Weight (kg) 
No. (%) 
progressing to 
type 2 diabetes 
Mean time to 
progress  
(months) 
 
Hazard ratio (95% 
CI) 
p value Hazard ratio (95% CI) p value 
76.8 to 92.5kg (49) 15 (31) 88 5.19 (1.5-17.93) 0.009 4.98 (1.23-20.18) 0.024 
Over 92.5kg (53) 20 (38) 89 6.49 (1.93-21.86) 0.003 5.22 (1.38-19.73) 0.015 
Data missing (16) 3 (19) 150 3.05 (0.62-15.12) 0.172 3.5 (0.53-23.34) 0.196 
Trimester at diagnosis (no.) 
2nd trimester (16) 5 (31) 96 1.21 (0.47-3.07) 0.696 1.05 (0.32-3.45) 0.942 
3rd trimester (147) 36 (24) 90 1.00  1.00  
HbA1c in mmol/mol (no.) 
33.3 and under (19) 3 (16) 150 1.00  1.00  
33.3 to 42.1 (22) 5 (23) 82 1.42 (0.34-5.95) 0.630 1.59 (0.29-8.84) 0.597 
42.1 plus (18) 8 (44) 57 4.41 (1.17-16.69) 0.029 5.34 (0.98-29) 0.052 
Data missing (105) 25 (24) 98 1.66 (0.5-5.5) 0.407 1.9 (0.45-7.94) 0.381 
Fasting Blood Glucose in mmol/l (no.)  
Under 5.1 (52) 6 (12) 102 1.00  1.00  
5.1 to 7.0 (72) 20 (28) 93 2.62 (1.05-6.53) 0.038 1.66 (0.52-5.24) 0.392 
Over 7.0 (17) 6 (35) 60 6.87 (2.2-21.44) 0.001 3.94 (0.92-16.91) 0.065 
Data missing (23) 9 (39) 99 3.87 (1.38-10.89) 0.010 35.29 (2.18-570.68) 0.012 
2 hour post load blood glucose in mmol/l (no.)  
Under 8.5 (39) 7 (18) 83 1.00  1.00  
8.5-11.1 (67) 14 (21) 96 1.15 (0.46-2.85) 0.762 1.54 (0.54-4.38) 0.417 
Over 11.1 (36) 12 (33) 84 2.58 (1.01-6.56) 0.047 2.37 (0.76-7.4) 0.139 
Data missing (22) 8 (36) 99 2.13 (0.77-5.88) 0.144 0.1 (0.01-1.56) 0.101 
Used Insulin during pregnancy (no.) 
Yes (51) 20 (39) 88 2.82 (1.52-5.2) 0.001 2.81 (1.35-5.86) 0.006 
No (113) 21 (19) 94 1.00  1.00  
Average weekly weight gain (kg) 
0.3 and under (61) 16 (26) 82 1.00    
0.31 and above (64) 14 (22) 90 0.71 (0.35-1.47) 0.360 0.61 (0.2-1.45) 0.259 
Data Missing (39) 11 (28) 105 1.04 (0.49-2.25) 0.912 1.12 (0.43-2.93) 0.821 
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Our findings suggest that the window of opportunity may be large enough for the majority 
of women to allow an intervention to be delayed until the child is slightly older and less 
dependent. Such a delay may help to address some of the barriers to lifestyle change faced 
by women with GDM but this argument becomes complex if women are planning to have 
more children. This issue is further complicated by the fact some women have already 
made lifestyle changes during pregnancy in an attempt to manage their GDM. With these 
women it may be best to intervene sooner after pregnancy to ensure these changes are 
maintained. The timing of lifestyle interventions for women who have had GDM clearly 
needs further exploration with women, along with the optimal content and means of 
delivery, if interventions are to be successful.  
Women who were at highest risk of developing type 2 diabetes after GDM were heavier 
women, those with an HbA1c of over 42.1mg/dL, those who used insulin during their 
pregnancy and those with FBG of 7.0 mmol/l and over. These women should arguably 
be prioritised for intervention. These findings are largely consistent with previous 
research reported in a systematic review of studies assessing the incidence of type 2 
diabetes after a diagnosis of GDM (Kim et al. 2002).  
Higher FBG levels and HbA1c were associated with higher risk univariately, but this 
increased risk was only marginally significant in the multivariate analysis. However, we 
identified an increased risk of four fold for women who had an FBG of 7.0 and over five 
fold for women with an HbA1c of over 42.1mg/dL. Given the small sample size and wide 
confidence intervals in this study, these marginally significant risks cannot be discounted. 
It is difficult to compare our finding for FBG with previous research that has generally 
looked at FBG as a continuous variable; thus particular thresholds of FBG for increased 
risk of type 2 diabetes have been difficult to pinpoint. Studies that did use categories for 
FBG reported varying findings. One study found an 11 fold risk in women who had an 
FBG of 5.9 or over compared to those with lower FBG values (Steinhart et al. 1997). 
Two other studies reported that women who went on to develop type 2 diabetes had a 
mean FBG of closer to 8.0 (Catalano et al. 1991; Kjos et al. 1990).  
The systematic review of studies assessing the incidence of type 2 diabetes after a 
diagnosis of GDM (Kim et al. 2002) reported mixed findings for the association between 
BMI and future type 2 diabetes risk. There were insufficient data for BMI in the present 
study to include it in the survival analysis. However, weight was found to be significantly 
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associated with increased risk of type 2 diabetes in the multivariate analysis, with other 
factors such as trimester controlled for. Although weight is typically regarded as an 
unreliable measure of obesity and disease risk as it does not take into account height, our 
study does suggest that it may be a useful indicator of future risk of type 2 diabetes in 
women with GDM.  
We did not find statistically significant associations between increasing age, history of 
GDM in a previous pregnancy or family history of diabetes and future risk of type 2 
diabetes. Although the hazard ratio estimates were elevated, particularly for previous 
history of GDM, and therefore increased risks cannot be discounted, the sample size in 
our study was relatively small and confidence intervals were wide.  Previous research 
reports mixed results for these risk factors; therefore larger studies are required to verify 
the results.  
Despite being a small study, the diagnosis of GDM in our sample of 164 women was 
validated for each one and we are confident in the high quality of our data. Detailed 
information was collected from paper records using a pre-defined data collection tool. 
The subsequent type 2 diabetes diagnoses were made using a diabetes clinical 
information system that has been extensively used in health care research and is known 
to be accurate. However, with around 2,600 births per year in Dundee and Angus, it is 
clear that we did not identify all cases of GDM during the study period. We would have 
expected to identify between 500 and 600 women over the period of the study using a 
conservative rate of 2% of pregnancies affected by GDM. On the other hand, we know 
that the women that we did include definitely had GDM, even if they represent a sample 
only. Reasons for the low number of women identified with GDM might include the non-
universal screening of women for GDM, ‘lost’ paper-based records, women attending 
other diabetes antenatal clinics in the region or women treated solely in primary care or 
general antenatal clinics. It is also likely that a proportion of women who had GDM went 
undiagnosed due to lower awareness of the condition in the past. Another limitation of 
this study was the high level of missing data in the paper records for several of the 
variables of interest which limited our ability to investigate them in depth. Despite these 
limitations, this is the first study of its kind to be carried out in the UK.  The region in 
which the study was carried out is broadly representative of the total population of 
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Scotland and the results are more generalizable to the UK than similar studies in Europe 
and the United States.  
Conclusions 
In summary, this study clearly shows how a diagnosis of GDM can have an adverse 
impact on health that extends long after the pregnancy. This study highlights those 
women with GDM who are at the greatest risk of progressing from GDM to type 2 
diabetes and should therefore be prioritised for preventative intervention and suggests 
there is a viable time window to prevent progression from GDM to type 2 diabetes in the 
majority of women. While a diagnosis of GDM presents an ideal opportunity for an 
intervention to reduce the growing burden of type 2 diabetes, identifying the most 
effective way and optimal time to help women who are at a particularly busy period of 
their lives to engage in lifestyle change remains a challenge that needs further 
exploration. 
This is the end of the verbatim copy of publication four. 
6.6 Critical reflection  
The use of data linkage of routinely collected health care data in this study is associated 
with many of the same strengths and weaknesses that were discussed in relation to 
publication three and these will not be repeated here. In addition to these, there were 
weaknesses that related specifically to the methods used in this study. As discussed in the 
publication, data about women with GDM were extracted by hand by two researchers. 
Although a standard form was used by both researchers, there is the risk of human error 
in the transfer of paper records to electronic forms. On reflection, this risk could have 
been mitigated by having each researcher check a selection of the other researcher’s 
electronic against the paper records. Alternatively, each researcher could have 
independently carried out data collection for a proportion of the other researcher’s 
records. Comparison of data collection by each researcher would have allowed errors to 
be identified and helped to ensure consistency in the way data were coded. However, 
extraction of data from the paper records was very time consuming, taking two 
researchers six full days to complete. Having a proportion of records being checked by a 
second researcher would therefore not have been feasible with the resources available for 
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the study but this is something I will endeavour to incorporate in to future projects where 
appropriate.  
Other limitations associated with the use of paper based records included incomplete and 
missing data. A number of years of forms had been lost which narrowed down the range 
of data available for the study. The records were completed by NHS staff for clinical 
purposes and as a result data were not always complete; for example, data on BMI was 
not recorded for the majority of women in paper based records. Data from the SMR02 
dataset which was linked with data from the paper based records was also not complete 
for BMI but was nearly complete for SIMD. As discussed in the publication above, the 
incomplete and missing data in this study was one factor that was likely to have 
contributed to the fact that this study did not identify all women with GDM. Despite this, 
it provides a useful overview of the number of women who can be expected to be 
identified in routine health care practice in Scotland. Having an understanding of this is 
vital if interventions for women with GDM are to be embedded within routine health care 
without additional screening being conducted.  
In addition to these methodological weaknesses, there are aspects of the reporting in the 
published paper that could have been clearer or covered in more depth. For example, the 
paper does not state that the SIMD quintiles used in the analysis were based on Tayside 
cut-points, rather than Scottish cut points nor how this study population compares to the 
population of Tayside in terms of SIMD. The study population in paper four were more 
deprived compared to the whole population of Tayside which would be expected as 
research in Scotland has shown that higher deprivation according to SIMD is associated 
with increased risk of GDM (Collier et al. 2017). 
Ethical considerations 
The methods used in this study are associated with many of the same ethical issues that 
were discussed in relation to publication three and these will not be repeated here. Ethical 
issues that related specifically to the methods used in this study included the risk of breach 
of patient confidentiality as the data extracted on women with GDM contained 
identifiable information. However, several measures were taken to minimise this risk. 
Firstly, the patient records and extracted data were not removed from the department they 
were stored in at Ninewells Hospital. This reduced the risk that the records could be 
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misplaced or viewed by anyone other than the researchers or staff at the department who 
would normally have access to the information. Secondly, data were extracted onto an 
NHS encrypted computer and then encrypted before being sent to HIC. Encrypting the 
data in this way ensured that only the appropriate individuals at HIC were able to view 
the extracted data. Identifiable data was only handled for the minimum time possible and 
only necessary identifiable information was extracted (i.e. only the information required 
by HIC to link to other datasets). Caldicott principles were adhered to at all times when 
dealing with identifiable information (National Data Guardian 2016). HIC anonymised 
the extracted data and this anonymised dataset was used in analyses. The anonymised 
dataset was stored on a secure server controlled by HIC and accessed according to HIC 
Standard Operating Procedure (2016), as discussed in relation to the data in publication 
three.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
 
Chapter seven: Postnatal experiences, knowledge and 
perceptions of women with gestational diabetes 
(publication five) 
 
 
 
 
 
 
The content of the above publication is presented in this chapter followed by a section 
providing a critical reflection of the methods. A PDF of the published manuscript can be 
found in appendix 10. Ethical approval was obtained from both the East of Scotland 
Research Ethics Committee and the School of Nursing, Midwifery and Health at the 
University of Stirling (see appendices 11 and 12 for approval letters) and Research and 
Development approval was gained from NHS Forth Valley (see appendix 13 for approval 
letter). Informed consent was obtained from each participant to ensure participant 
understanding of the study and to allow an opportunity for participants to decline to take 
part in the research (see appendices 14 and 15 for consent for and information sheet 
respectively).  
A verbatim copy of publication five starts below.  
7.1 Abstract 
Aim 
Women with gestational diabetes mellitus (GDM) are at increased risk of type 2 diabetes. 
This study aimed to explore experiences, knowledge and perceptions of women with 
GDM to inform the design of interventions to prevent or delay type 2 diabetes. 
 
 
Eades, C., France, E. and Evans, J.M.M. (2018) Postnatal experiences, knowledge and 
perceptions of women with gestational diabetes. Diabetic Medicine, 35 (4), pp. 519-
529. 
This paper was published in Diabetic Medicine, a peer reviewed journal with an impact factor 
of 3.05. It is the official journal of the charity Diabetes UK and publishes a range of diabetes 
research of interest to both clinicians and researchers worldwide. 
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Methods 
Semi-structured interviews were carried out with 16 women with GDM who were 
recruited from a clinic in one Scottish health board. A framework approach was used to 
manage and analyse data according to themes informed by psychological theory (self 
regulation model and theory of planned behaviour). 
Results 
GDM is not seen as an important, or even real diagnosis among some women, and this 
perception may result from perceived minimal impact of GDM on their lives. Some 
women did experience a bigger emotional and practical impact. Knowledge and 
understanding of type 2 diabetes was poor in general and many women were unconcerned 
about their future risk. Lower concern appeared to be linked to lower perceived impact 
of GDM. Lifestyle changes discussed by women mostly related to diet and were 
motivated primarily by concern for their baby’s health. Many women did not maintain 
these changes postnatally, reporting significant barriers. 
Conclusions 
This study has suggested potential avenues to be explored in terms of content, timing and 
potential recipients of interventions.  Educational interventions postnatally could address 
illness perceptions in women with GDM and redress the situation where lack of aftercare 
downplays its seriousness. For lifestyle interventions, the child’s health could be used as 
a motivator within the context of later joint or family interventions.  
7.2 Introduction 
Women with gestational diabetes mellitus (GDM) are at a particularly increased risk of 
developing type 2 diabetes. GDM affects around 5% of pregnancies in Europe (Eades et 
al. 2016). In women with GDM, normal glucose regulation usually returns shortly after 
delivery, but these women have up to a seven-fold increased risk of type 2 diabetes 
compared to women who have not had GDM (Bellamy et al. 2009). Lifestyle 
interventions targeted at high risk individuals can prevent or delay the onset of type 2 
diabetes (Gillies et al. 2007). However, the evidence for interventions that specifically 
target women with prior GDM is not as compelling (Gilinsky et al. 2015) and many 
studies report difficulties in recruiting and retaining participants (Cheung et al. 2011). 
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The challenges facing women with GDM in making lifestyle changes are potentially quite 
different to those facing other high-risk patient groups (e.g. people with impaired glucose 
regulation). Learning about the experiences of women with GDM may help to identify 
whether and which common beliefs and perceptions might be a barrier (or facilitator) to 
behaviour change, and to help ensure that interventions are appropriately tailored to them. 
This is important because uptake and engagement with such interventions can be 
compromised if insufficient attention is paid to the values and concerns of the intended 
recipients.  
There has been relatively little research in the UK exploring the perceptions of women 
with GDM about this condition and their future risk of type 2 diabetes. Although there 
has been a meta-synthesis of 16 studies on this topic (Parsons et al. 2014), only one study 
is UK-based (Lie et al. 2013).  The studies have shown that some women have awareness 
of their increased type 2 diabetes risk, but lifestyle changes that are made during 
pregnancy are difficult to maintain in the longer-term (Lie et al. 2013). Clearer 
information is needed, and interventions required that are tailored to women as patients, 
but also as caregivers (Parsons et al. 2014).  
The Medical Research Council (MRC) guidance on developing complex interventions 
suggests that an appropriate theoretical basis should be identified at the earliest stages of 
intervention development (MRC 2006). It is argued that the use of theory in intervention 
design increases the likelihood that an intervention will be effective by ensuring that the 
causal determinants of behaviour are understood and addressed (Michie et al. 2008). The 
overall aim of this study was therefore to explore qualitatively the perceptions and 
experiences of women with GDM in Scotland surrounding their diagnosis, their future 
risk of type 2 diabetes and preventative lifestyle behaviour, and to identify implications 
for the development of potential interventions to reduce subsequent type 2 diabetes risk.   
7.3 Methods 
Theoretical framework 
This study was framed by a theoretical approach which combined both the Self 
Regulation Model (SRM; Leventhal et al. 1992) and the Theory of Planned Behaviour 
(TPB; Ajzen 1991). The SRM (Leventhal et al. 1992) focuses on patients’ beliefs about 
their health condition and proposes that people interpret information about a potential 
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illness to create a ‘lay’ view or representation of the illness.  The coping responses then 
employed (e.g. adhering to treatment regimens or attending appointments), are related to 
the illness representations the individual holds and to their appraisal of how successful 
they perceive chosen coping responses to be. These illness representations are formed 
around seven different themes: identity (label or diagnosis of illness); cause (factors 
believed to have caused the illness); timeline (expected duration of illness); consequences 
(expected effects of illness on physical, social and psychological well-being); 
control/cure (extent to which illness can be controlled/cured); emotional representations 
(emotional responses to an illness); and illness coherence (how well the person 
understands their illness).  
The TPB (Ajzen 1991) is concerned with beliefs about lifestyle behaviours and asserts 
that voluntary behaviours are largely predicted by our intentions regarding the behaviour. 
Intentions, in turn, are determined by our attitude towards the behaviour (our judgement 
of whether the behaviour is a good thing to do), subjective norms (our judgement of what 
important others think of the behaviour), and perceived behavioural control (our 
expectation of how successful we will be in carrying out the behaviour).  
These psychological models have been widely used to understand a wide range of health 
behaviours and because there was no clear evidence to suggest which approach might be 
most appropriate in the context of the questions posed by our study (Armitage and Conner 
2001; Hagger and Orbell 2003), both models were used to underpin our theoretical 
approach. 
Participants and recruitment 
Women were recruited from a diabetes antenatal clinic operating in a single Health Board 
in Scotland, UK. They were eligible if they were aged 18 years and over, spoke fluent 
English and had been diagnosed in their current pregnancy with GDM according to the 
Scottish Intercollegiate Guidelines Network guidance (SIGN 2014). Clinical staff 
identified 49 eligible women from hospital records, gave them information about the 
study at the clinic and then asked if they were willing for the researcher (CE) to receive 
their contact details; all women agreed. A convenience sampling approach was used 
(Coyne 1997). Interested women either gave their details directly to CE (if she was 
present) or details were given to CE via clinical staff. The women then received an 
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information sheet about the study and informed that they would potentially be contacted 
from 8 weeks after delivery. The plan was to conduct approximately 20 interviews, so 
not all women would be interviewed, and CE collected more names than necessary to 
allow for drop out. During a post-delivery telephone call, CE checked if the woman was 
still willing to participate, then scheduled an interview. She had therefore either met or 
spoken by telephone to every participant before data collection. The final sample size 
was determined by data saturation, whereby CE conducted interviews until it was felt that 
no new ideas were being offered by participants. 
7.4 Data collection  
Attempts were made to contact 31 of 49 women post-delivery; women were selected to 
achieve maximum variation in factors such as age, parity, ethnicity and BMI. Thirteen 
women could not be reached using the telephone number held by the researcher and two 
stated they no longer wished to take part. The remaining 16 women were interviewed 
between January 2015 and August 2017 (Table 14). All interviews were conducted within 
a year of the women’s due date; the majority (14) between 12 and 26 weeks afterwards. 
Interviews took place in participants’ homes and were carried out by CE (then a part-time 
PhD student and a registered health psychologist) with previous experience of qualitative 
fieldwork. The only other individuals present were the baby, or occasionally other 
children. Participants knew that CE was conducting the study as part of her research 
degree and that she was not a member of clinical staff but was simply interested in finding 
out their thoughts on the topic. They were also told that there were no right or wrong 
answers.  
The semi-structured format following an interview guide informed by underlying theory, 
ensured that the topics of interest were covered while allowing interviewees the freedom 
to discuss any issues not covered in the guide. The main topics covered were: experiences 
of diagnosis of GDM; feelings about GDM diagnosis; consequences of GDM; 
understanding of GDM and information given by healthcare staff; understanding of type 
2 diabetes and information given by healthcare staff. Only if it was clear that the 
participant was already aware of increased risk of type 2 diabetes, were the following 
topics also discussed: understanding of type 2 diabetes prevention; lifestyle changes for 
type 2 diabetes prevention; advantages and disadvantages of making lifestyle changes for 
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type 2 diabetes prevention; views on receiving support to make lifestyle changes after 
having GDM. 
Table 14: Characteristics of participants 
Age                                                             Number 
20-29 
30-39 
>40 
 
3 
11 
2 
Parity 
+1 
+2 
+3 
9 
5 
2 
Gestation at diagnosis of GDM 
1st trimester 
2nd trimester 
3rd trimester 
 
2 
5 
8 
SIMD Deprivation Category 
1 (most deprived) 
2 
3 
4 
5 (least deprived) 
 
2 
2 
5 
3 
4 
Ethnicity  
White  
Asian 
Black African 
 
12 
3 
1 
Key to Participants Quoted in text 
P1 age 39, not first child, white, middle deprivation 
P2 age 42, first child, white, low deprivation 
P3 age 39, not first child, white, high deprivation 
P4 age 22, first child, white, high deprivation 
P5 age 34, first child, not white, high deprivation 
P6 age 35, not first child, white, middle deprivation 
P7 age 35, not first child, white, low deprivation 
P8 age 28, first child, white, low deprivation 
P9 age 38, first child, not white, low deprivation 
P10 age 33, not first child, not white, middle 
deprivation 
P12 age 38, first child, white, low deprivation 
P13 age 45, first child, white, low deprivation 
P14 age 32, first child, white, middle deprivation 
P15 age 38, first child, not white, low deprivation 
P16 age 25, not first child, white, middle deprivation 
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Interviews were audio-recorded with the participant’s permission and transcribed 
verbatim by a professional transcription service (but not returned to the participants). 
Interviews lasted between 11 and 66 minutes, and field notes written up afterwards.  
Written informed consent was obtained from all participants and approval to conduct the 
study was obtained from a National Health Service (NHS) Research Ethics Committee. 
7.5 Data analysis  
Fieldwork and analysis were conducted in parallel rather than sequentially. The 
framework method (Spencer et al. 2014) was used to organise and analyse the data 
combined with coding in NVivo 11 qualitative data analysis software.  The framework 
method is relatively structured and allows pre-set objectives and reasoning to inform data 
collection whilst still allowing original contributions from participants. The approach 
involves researchers familiarising themselves with the interview transcripts, then re-
reading them and paraphrasing or labelling any passages they interpret as important. 
These labels can come from predefined theories or models or can be “open”, that is where 
anything that is relevant from any perspective is labelled. In this study the three authors 
independently reviewed three transcripts and identified and coded areas of interest using 
an open approach. This open approach was used for the first few transcripts to ensure that 
any concepts or themes deriving from the data (as well as from theory) were identified.  
The three authors then compared their open coding of the three transcripts and agreed 
that most of the codes could be organised under subthemes derived from the theoretical 
concepts of the SRM and the TPB. Subthemes were organised under topic themes 
including GDM, type 2 diabetes, diet, exercise and reactions to a proposed future GDM 
intervention. Subthemes included, for example, identity, cause, timeline, consequences, 
and control (for data about GDM and type 2 diabetes). Additional data-derived subthemes 
included, for example, education about GDM and risk perceptions related to type 2 
diabetes. The full list of themes and subthemes are shown in Table 15.  
CE then applied the analytical framework to the remaining transcripts and data were 
summarised using matrices (Gale et al. 2013).  Six separate matrices were created, one 
for each topic theme. Each column was labelled with a subtheme (except column one 
which contained a participant identifier and demographic data).  Each row represented 
one participant. In each cell of the matrix, relevant data were summarised and a 
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supporting quote given (a matrix excerpt is shown in Appendix 16). A further summary 
matrix was used to juxtapose each summary of the participants’ understanding, and 
perceived impacts, of GDM and type 2 diabetes. Abstraction and interpretation followed; 
the matrices were read repeatedly to identify common patterns and disconfirming cases 
using constant comparison. The findings are presented below as overarching key themes 
(as depicted in Figure 5).  
Table 15: Framework used to organise data 
Theme Subtheme (theory subtheme relates to) 
 
1. Background 1.1 Family history3 
1.2 Pregnancy experience3 
1.3 Previous GDM3 
1.4 Postnatal testing3 
2. Gestational Diabetes Mellitus 2.1 Identity (SRM1) 
2.2 Timeline (SRM) 
2.3 Cause (SRM) 
2.4 Consequences (SRM) 
2.5 Control (SRM) 
2.6 Emotional Representations (SRM) 
2.7 Illness Coherence (SRM) 
2.8 Education about gestational diabetes3 
3. Type 2 Diabetes  3.1 Identity (SRM) 
3.2 Timeline (SRM) 
3.3 Cause (SRM) 
3.4 Consequences (SRM) 
3.5 Control (SRM) 
3.6 Emotional Representations (SRM) 
3.7 Illness coherence (SRM) 
3.8 Risk perceptions3 
3.9 Prevention3 
4. Diet 4.1 Attitude (TPB2) 
4.2 Subjective Norm (TPB) 
4.3 Perceived Behavioural Control (TPB) 
4.4 Intention (TPB) 
4.5 Behaviour (TPB)  
5. Exercise 5.1 Attitude (TPB) 
5.2 Subjective Norm (TPB) 
5.3 Perceived Behavioural Control (TPB) 
5.4 Intention (TPB) 
5.5 Behaviour (TPB) 
6. Intervention 6.1 Acceptability3 
6.2 Ideas3 
1Directly taken from illness representations of the Self Regulation Model (SRM) 
2 Directly taken /mapped to concepts of the Theory of Planned Behaviour (TPB) 
3Data-derived subthemes 
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Figure 5: Which theoretical concepts informed the overarching themes 
 
 
7.6 Results 
The results are discussed under the following overarching themes (mapping to key 
themes two to six): understanding of GDM, impact of GDM, understanding of type 2 
diabetes and future risk, lifestyle change during and after pregnancy, prevention of type 
2 diabetes. Verbatim quotes from study participants are identified by participant number. 
Table 14 provides their characteristics.  
Understanding of gestational diabetes mellitus 
Most women felt they had a good understanding of GDM during their pregnancy. With 
the time that had elapsed since being diagnosed they struggled to recall specific 
information about the condition, but most held an overall impression that the information 
they were given by NHS staff was clear and at an appropriate level. Many praised the 
staff involved in their care.  
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"Erm, and they were very good, [the Health Board] were really, really good. I mean it 
was, it was about an hour and a half, two hours with the diabetic nurse and she went 
through everything of…and how to use the machine and everything as well." (P9) 
When women were less satisfied with the information that they were given, it was 
generally because this was too vague and not tailored to their specific circumstances, 
producing feelings of frustration.   
“Really to, obviously to eat healthily and exercise but I think the problem is it’s very 
vague as to what eating healthily is.” (P7) 
"Nobody actually sat down with me and tell me, here's the list of all the food. They gave 
me a couple of leaflets, erm, but you know, the leaflets is for, erm, you need to customise 
them based on the patient, what type of food they're used. Because if you're, if you keep 
telling them, oh don't take, don't have a takeaway, well, I don't have a takeaway, I've 
already been having healthy eating." (P15) 
Although most women explicitly stated that they felt they understood GDM, further 
discussion revealed areas of confusion or misconception. One was related to the diagnosis 
of GDM, with some women questioning whether they ever really had the condition. Some 
suspected that high blood glucose readings identified during diagnostic testing were 
caused solely by food they had eaten recently, and others felt that a diagnosis very late in 
pregnancy or one that was classed as borderline meant that the diagnosis was less relevant 
to them.  
“I actually had a big bar of chocolate the day before I went, so I was thinking I bet it’s 
just cause of that.” (P8) 
"most of what they were telling you wasn't going to really apply to me because I only had, 
erm, a couple of weeks to go before, erm, I reached my term time."  (P6) 
These women often rationalised that since they met the diagnostic criteria for GDM they 
must have had GDM, but still found themselves questioning the diagnosis. 
“So, in one sense you kind of think to yourself, maybe I didnae have it all, and it was 
just…well obviously I did because I had the fasting thing beforehand” (P1) 
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Although not explicitly stated by participants, this questioning of the diagnosis was 
possibly linked to their perception that GDM had little impact on their lives; many women 
who questioned their diagnosis did not experience any symptoms, found GDM easy to 
control through diet, and had blood glucose readings in the normal range during 
pregnancy and when tested postnatally.  
Other common misconceptions related to the causes of GDM. Although some women 
correctly identified being overweight, family history of type 2 diabetes and ethnicity as 
risk factors for developing GDM, eating sweet and sugary foods was more commonly 
understood to have been the cause of this condition.  
"I was a sugar person first, yeah, yeah, I liked sugar very much… I said to the person, 
maybe because I eat sugar too much." (P10). 
Impact of gestational diabetes mellitus 
Perceptions of how much GDM impacted upon participants’ lives varied. We identified 
three groups of women: women for whom the diagnosis had little emotional impact; those 
for whom the impact was related to concerns about the wellbeing of their unborn baby; 
and those for whom the negative emotional impact appeared to last beyond pregnancy. 
However, the three groups are not necessarily exhaustive or mutually exclusive; this is 
an emergent finding that needs to be verified. 
Women in the first group reported that they were not worried or concerned by the 
condition at all, with this lack of concern often related to the fact that the condition was 
relatively common and had little impact on their day to day life.  
"it was quite common, so…that sort of puts your mind at ease, it didn’t scare me or 
anything. So, it was okay. Knowing that lots of people get it and it was quite normal…" 
(P2) 
"but if you manage it quite well it’s nothing for you, it’s like a part of brushing teeth every 
day, it’s like that. You don’t even feel like bad that you’ve got that gestational diabetes; 
I never felt bad." (P5). 
These women explained that the only real consequence of their diagnosis was having to 
make changes to their diet, which were viewed as being easy to make, and simply 
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involving cutting out or cutting down sugary foods and drinks; the condition was 
something temporary that they could forget about after they gave birth.  
"No, it’s just like a, erm, like buying maternity clothes, and gestational diabetes is like 
that, and you just forget everything” (P5). 
A second group of women had a strong emotional response to being diagnosed with 
GDM. This was usually caused by worry and guilt that they might have put their unborn 
baby’s health at risk.  
"I did, I felt…I actually had a wee cry. I was like, oh, I just felt like I’d let myself down 
and…maybe I just pigged out [over ate] too much. Um, and just felt as if I’d let her 
down." (P8) 
Often this concern eased after the initial diagnosis as the women learned more about the 
condition and found that they were able to control and manage it. 
"Um, no, to be honest with you, when, when, when I kept checking my sugar levels and 
that, I just, kind of, thought, well, cannae be that much of a big thing because I’m, I’m 
not over and I’m not under." (P8) 
Less commonly, concern and emotion about being diagnosed with GDM did not lessen 
over time, and women in the third group reflected that they were still affected by their 
diagnosis now. These women had often had a much more difficult time in controlling the 
condition, requiring dietary control to be supplemented with insulin and medication 
(something which many women stated being reluctant to do). They reported it as time 
consuming, they found injecting unpleasant and they suffered side effects from the 
medication.  
"So, um, I ended up having to take insulin, which was horrible as well…because they're 
a needle again.  So then I'm testing myself three times a day and my insulin at night, oh, 
it was just horrible." (P16) 
Understanding of type 2 diabetes and future risk 
General understanding of type 2 diabetes was very poor. A lack of understanding around 
types of diabetes and the differences between them was widespread, with many women 
unable to name type 2 diabetes, and knowing little about it. Some women did identify 
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poor diet and overweight as risk factors for type 2 diabetes and knew that it is controlled 
through diet and/or medication; but very few mentioned the health consequences of type 
2 diabetes and those who did were very vague about these.  
"And obviously there’s other health stuff as well at the back of it" (P1) 
There were some misconceptions over the causes of type 2 diabetes and its severity. Some 
women who had older relatives with type 2 diabetes believed it was a consequence of 
older age; others downplayed its seriousness, especially when they held a preconception 
that type 2 diabetes had little impact.  
"So, it’s only type two so it’s...I suppose, it’s not as bad but” (P4) 
"Erm, but my partner’s mum she’s got type two diabetes and I know that she takes a 
tablet.  I’m sure it’s in the morning. And that does her throughout the day" (P4) 
Nearly all women recalled being told that they were at an increased risk of diabetes in the 
future as a result of having had GDM (although few understood the time frame), and that 
they could reduce their risk through changes to their diet and physical activity levels.  
“Maybe not this early and this quick after having them…but probably more than likely 
later on in life, like maybe when I'm 50, 60, they said that I’ll probably, I’ll probably be 
likely to have it, yeah." (P16) 
However, many women downplayed the risk for themselves, indicating that because they 
were not overweight or had no other health problems, or because they had a late diagnosis 
during pregnancy, this meant that their risk was lower than for other women.  
“I have to go every year now for blood tests because of it and I do think it's pretty 
pointless to be perfectly honest because I think if it hadn't been diagnosed, then they 
would never have been none the wiser. I don't think it's something that I need to worry 
about in the future to be honest.” (P6) 
"she has taken my three-day result, or something, and she took my blood as well on that 
day, and she counted. And she said ………..you’re not that much, er, risk of getting type 
2 diabetes. So I thought, okay, that’s fine." (P5). 
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The extent to which women felt concerned by their increased risk of type 2 diabetes 
varied, but overall concern was not high. Many women made no mention of being worried 
about their risk of type 2 diabetes and one group of women felt that any risk was far in 
the future. 
"it's not an immediate thing for me, I'm not that fussed about it just now."  (P9)  
However, one participant had a difficult time managing her GDM when pregnant and felt 
that it had quite a big impact on her day to day life, as did another participant who reported 
being concerned about her future risk of type 2 diabetes. This suggests that concern about 
future risk type 2 diabetes may be linked to more severe perceived or actual impact of 
GDM.  
"I really would hate to be…to get diabetes again. It’s horrible" (P3) 
Lifestyle change during and after pregnancy 
Lifestyle changes discussed in the interviews predominantly related to changes to diet 
rather than physical activity. Women commonly described cutting out sweet foods, fizzy 
drinks and other junk food in response to their GDM diagnosis, after initially having been 
‘eating for two’.   
"I say, for me it was just cutting back on eating cakes and chocolates, which is what I’d 
been having…being pregnant" (P7) 
The dietary changes that women made after a GDM diagnosis were most commonly 
motivated by their concern for the health of their unborn baby and also by a desire to 
avoid taking medication to manage their GDM.  
" just thought of the baby and…obviously I didn’t want her to be in any danger when she 
was, when I was having her or anything like that, any complications or anything like that, 
so it had to be done." (P8) 
"changed my diet just to, kind of, make sure that...because I didn’t...I really didn’t want 
to have any, kind of, medication whether it was tablet or, eh, like injection" (P4) 
A few women did manage to continue with these changes postnatally, and were currently 
attending commercial weight loss groups, but most had not managed to maintain the 
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changes. Once the above motivations had passed, looking after their own health 
postnatally was not a priority for some women, especially in the face of many new 
challenges. 
"No, but you, you just need to find some energy sometimes. And eating seems to be the 
right plan for that, but it never is.  You just, you know, the sleep deprivation, and, erm, 
the constant, kind of, needing to be someone else's...you don't really look after yourself 
so much." (P13) 
Changes to physical activity levels were less commonly discussed by participants in this 
study. Some women recalled being advised to increase their activity levels when they 
were diagnosed (although this advice was briefer and more peripheral to the education 
they received on diet), while others did not receive any such advice. There was therefore 
confusion over what was appropriate. 
“I mean exercise, like I said, do more exercise. Walking, jogging, it…what kind of, you 
know, what, what would prevent it? So no, they didn't really… It was just like do some 
more exercise and stuff, yeah.” (P9) 
Among those who did increase physical activity levels, walking, then swimming, were 
the activities most frequently mentioned. Some women who had previously been active 
managed to continue this activity during their pregnancy while others reported that they 
reduced or stopped this exercise during pregnancy. Barriers included having a bump and 
feeling heavily pregnant, pregnancy-related back and pelvic pain, the demands of having 
one or more children to look after, tiredness and poor weather.  
"where exactly am I meant to go and how am I meant to do this, when I can’t nip out to 
the gym, I can’t go and walk the dog, or I can’t nip out and see a friend ’cause she’s in 
bed" (P1) 
Prevention of type 2 diabetes 
The majority of women stated that they would be open to additional support to make 
lifestyle changes after giving birth. However, two women stated clearly that they would 
not be interested, while another felt that there was already support available. Among those 
women who welcomed the idea there was a feeling of being left on their own after the 
high level of care they had received when they had GDM. 
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“Um, yeah, I would have…probably…looking back on it now, um, I’d have maybe liked 
a wee bit more, like, sort of, closure on it, a wee bit more explanation” (P12) 
While some women were invited to attend postnatal testing to ensure that their blood 
sugar levels had returned to normal, others reported that they had to arrange this testing 
themselves. This lack of aftercare led some women to question how serious their 
increased risk of type 2 diabetes was. 
"But because there's nothing…no after care as such…then you know, it's not like a major 
thing." (P9) 
These women felt that a greater level of aftercare might help to increase their motivation 
to make lifestyle changes to reduce their type 2 diabetes risk. Some suggested that 
additional blood testing over the longer term would be beneficial. One woman who was 
awaiting the results of her postnatal testing described how going for this test had made 
her think more consciously about her lifestyle. 
"when I had the letter through for to say for to go, em, for to get tested, and then you start 
to think, aah, oh wait a wee minute…and then have I really been paying attention or have 
I not …I know this sounds terrible, but in one sense I’m hoping it comes back quite high 
to give myself sort of a kick in the bum, do you know what I mean." (P1) 
As previously discussed, some women felt a need for more specific information about 
making changes to their lifestyle and suggested that this could be tied in with going for 
postnatal blood testing. Other women felt that group support to make lifestyle changes 
that involved other mums would be most beneficial for them. 
“As much as I love my mum, not just your mum going…you’re doing well and you’ve lost 
a wee bit of weight, well done and it took me so long after I’d had babies and stuff, but 
girls that are going through it…that are exactly the same as you. And that’s been a really 
good support network…” (P2) 
Women who lived outside the main towns/cities in the health board also noted that there 
were fewer group activities available to them. 
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7.7 Discussion 
This study provides an understanding of women’s perceptions and experiences of GDM, 
of making lifestyle changes after a diagnosis of GDM and their risk perceptions about 
type 2 diabetes.  In general, most women in this Scottish study had a positive experience 
of health care after their GDM diagnosis, as reported elsewhere in the UK (Lie et al. 
2013), but in contrast to the findings from a synthesis of international qualitative studies 
(Parsons et al. 2014). However, women identified an explicit need for more specific 
dietary advice, and advice on physical activity, during pregnancy and in the postnatal 
period.  
While the transitory nature of GDM was emphasised by some women in this, and other 
studies (Parsons et al. 2014), the belief that GDM is not an important (or even real) 
diagnosis, has not previously been explored, and often occurred among women for whom 
the perceived impact of GDM was minimal. Similarly, while most women had some 
(often vague) awareness of their future type 2 diabetes risk (confirming previous studies 
Parsons et al. 2014; Lie et al. 2013), a lack of concern appeared to tie in again with a 
minimal perceived impact of GDM. This is an important group of women to identify and 
target for preventative intervention, so that they understand the importance of behaviour 
change even if their GDM diagnosis did not seem significant at the time.  
The perception among some women that GDM was an insignificant diagnosis without 
longer-term implications, was reinforced by the perceived lack of after care and follow-
up. If such follow-up were provided, this might act to counter the postnatal resolution of 
GDM ‘lulling women into complacency’ (Parsons et al. 2014). 
Many women did achieve dietary and/or exercise behaviour change during pregnancy, 
and this was often motivated primarily by concern for their baby’s health. This ties in 
with the worry and guilt that increased the emotional impact of GDM among some 
women. However, awareness of type 2 diabetes risk did not provide sufficient motivation 
to overcome barriers to lifestyle change postnatally (including tiredness, lack of energy 
and the demands of a new baby).  
The strengths of this study include the participation of women with a range of different 
demographic characteristics such as age, ethnicity, and deprivation. By using theoretical 
models to inform the design and analysis, we have highlighted a range of beliefs and 
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illness perceptions which impact upon lifestyle change both during and after pregnancy. 
The sample size was relatively small and all women were recruited from one health board; 
this may mean that the experiences of care that women reported may not be comparable 
to women in other geographical areas. It was also only possible to ask questions about 
women’s views surrounding type 2 diabetes once they had indicated that they were 
already aware of their increased type 2 diabetes risk. While this may have introduced a 
slight bias, it was a requirement stipulated for ethical reasons, in order that women were 
not distressed by their sudden realisation of longer-term and more serious consequences 
of GDM. While we ensured that a selection of transcripts were coded independently by 
all three authors and the framework was developed through discussion between them to 
allow for varied and richer interpretations of the data, it is still possible that this study 
was influenced by the researchers’ backgrounds and beliefs. Despite these limitations, 
our findings accord and build upon those from a previous UK study (Lie et al. 2013). 
Findings for this study have important implications for the development of potential 
interventions for women who have had GDM. Regarding educational interventions, given 
the perception of GDM as being short-lived, easily controlled and having few 
consequences, this study suggests that illness perceptions surrounding GDM (as defined 
in the SRM), particularly the ‘consequences’, need to be addressed; and would be 
appropriately aimed at women for whom the perceived impact of GDM was minimal. 
The ‘timeline’ and ‘consequences’ of type 2 diabetes are also poorly understood and 
could be tackled. Timing such an educational intervention soon after delivery, combined 
with longer-term follow-up and testing, would help to redress the situation where a 
current lack of aftercare downplays the seriousness of GDM and subsequent type 2 
diabetes risk. 
In terms of lifestyle interventions for behaviour change, it is clear that women feel the 
need for more specific dietary and physical activity advice. There are significant barriers 
to behaviour change with a young family (perceived behavioural control in the TPB). 
However, given that the health of their unborn baby facilitates behaviour change during 
pregnancy, it may be that an important later source of motivation could be their child’s 
health, which could be used to target behavioural attitudes and intentions within the 
context of a joint or family intervention. Although other studies have identified weaning 
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as a time of increased receptiveness to lifestyle change (Parsons et al. 2014), this logic 
could extend to other times during a child’s development.  
In summary, this qualitative research with women about their experiences of GDM, 
underpinned by psychological theory, has suggested potential avenues to be explored 
further in terms of content, timing and potential recipients of interventions to reduce the 
risk of type 2 diabetes in women who have had GDM.  
This is the end of the verbatim copy of publication five. 
7.8 Critical reflection 
The concepts of reliability and validity are central to the critical analysis of scientific 
research and are concerned with the credibility of research evidence (Lewis et al. 2014). 
Validity refers to the extent to which the findings accurately measure the phenomenon 
under study and reliability to the how replicable the findings of the study are, i.e. would 
the findings be consistent if the study was repeated? These concepts were developed in 
relation to quantitative research findings and their application to qualitative research has 
been the subject of much debate. It has been argued that differences in the philosophical 
underpinnings of quantitative and qualitative research, as discussed in chapter three, 
mean that reliability and validity have limited value in qualitative research (Noble and 
Smith 2015).  
Lincoln and Guba (1985) proposed the following four criteria for assessing the 
trustworthiness of qualitative research as an alternative to reliability and validity: 
credibility, transferability, dependability and confirmability. The concept of credibility is 
analogous to internal validity and considers how congruent the findings of the research 
are with reality. Transferability is similar to the concept of external validity and refers to 
the extent to which findings can be generalised to wider populations. Dependability in 
qualitative research is proposed in preference to the concept of reliability. Confirmability 
in qualitative research is comparable to the concept of objectivity in quantitative research 
and refers to the extent to which the findings of the study are affected by researcher bias 
(Shenton 2004). 
The lack of consensus on how to assess the quality of qualitative research can make it 
difficult for researchers to demonstrate the credibility of their findings and can lead to the 
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research being deemed as lacking rigour and transparency (Mays and Pope 1995). 
Regardless of the terminology or approach used, it is important that researchers attempt 
to address quality in qualitative research to avoid these potential criticisms. A number of 
strategies can be used to address the trustworthiness of qualitative research findings with 
some of the most commonly used being triangulation, respondent validation, peer 
scrutiny of research, clear exposition of methods and reflexivity (Mays and Pope, 1995; 
Noble and Smith 2015). Each of these strategies will be discussed below with reference 
to the present study’s strength and weaknesses. Finally, the ethical issues associated with 
this study will be considered. 
Triangulation 
Triangulation is where a researcher uses more than one method of data collection or 
source of data to answer a research question. Results from these different methods are 
compared with the aim of confirming or providing a more comprehensive understanding 
of the findings (Mays and Pope 2000). Barbour (2001) argues that although triangulation 
appears easily achievable, it is difficult to carry out correctly in practice. Data from 
qualitative and quantitative methods are in different forms making direct comparison 
difficult. Data from different qualitative methods, for example interviews and direct 
observation, can also be difficult to compare directly. Barbour (2001) suggest that 
although similar findings arising from triangulation provide reassurance, an absence of 
similar findings does not necessarily call in to question the validity or credibility of the 
finding. Mays and Pope (2000) suggest that rather being used as a measure of credibility, 
triangulation is better viewed as a way of ensuring that research is as comprehensive as 
possible. Triangulation was not carried as part of the present study but since this study 
was conducted I have been involved in a further study using the framework developed in 
the present study. This study applied the framework to forum posts mentioning 
gestational diabetes from websites for parents: mumsnet and netmums. The study is not 
yet complete but preliminary findings are consistent with publication five. Posts on the 
forums by women with gestational diabetes were largely related to concerns about the 
health of their baby, fears about delivery of a potentially large baby, and very rarely 
mentioning their future risk of type 2 diabetes (Evans 2018). Women posting on these 
forums generally do not post using their real names and so may arguably be less subject 
to social desirability bias than in a face to face interview with a researcher. The 
consistency of Evans (2018) findings with those in publication five therefore suggests 
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that women’s responses in publication five were not a result of social desirability bias 
(where participants give responses that they believe to be socially desirable; Paulhus 
1991) or demand characteristics (where participants responds in a way that they believe 
the researcher wishes them to; Orne 1962). 
Respondent validation 
Respondent validation is a technique that aims to increase the credibility of qualitative 
findings and involves the researcher checking interim research findings with the 
participants themselves. By using this technique, the researcher can establish whether the 
interpretations they have made are appropriate and supported by participants (Mays and 
Pope 2000). Although this approach has value in ensuring the credibility of research 
findings it has limitations and may not always be appropriate (Barbour 2001). The 
overview of findings produced by the researcher is designed for a wide audience and as 
such may not reflect an individual’s concerns or focus and lead to discrepancies (Mays 
and Pope 2000). Respondent validation also places demands upon the participant’s time. 
As participants in the present study had young babies it was felt that it would not be 
appropriate to place further demands on their time by asking them to review and comment 
on study findings.  
Peer scrutiny 
Although participants’ views on the research findings were not sought, peer scrutiny was 
incorporated at various points in the present study. Other researchers were involved in 
the analysis of the findings through the use of multiple coding of transcripts. Multiple 
coding of transcripts refers to the process by which researchers independently code 
transcripts and then compare the codes applied. Multiple coding was only carried out on 
a selection of transcripts, rather than the whole dataset, and we did not calculate the 
degree of concordance between researchers. However, Barbour (2001) argues against 
multiple coding of entire datasets due the cost and time implications of this and suggests 
that it is not the specific degree of concordance that is important, but rather the process 
of multiple coding itself that improves rigour. Having other researchers from different 
backgrounds carry out multiple coding was valuable in helping me to challenge the 
assumptions I made and offered different perspectives on the data. This was important in 
ensuring the credibility of the research and also in helping to reduce researcher bias.  
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In addition to multiple coding, I presented a summary of emerging codes/themes at an 
early stage of the analysis to clinicians involved in the care of women with GDM in the 
local health board (consultants and diabetes specialist nurses) and sought their views on 
my interpretations. Although I intended this study to be informed by psychological 
theory, having other researchers and clinicians from different backgrounds helped to 
ensure that I considered alternative explanations not offered by these theories. 
Exposition of methods and findings 
Clear description of methods and findings is an important strategy in addressing the 
quality of qualitative research and can assist readers in assessing the generalisability or 
transferability of the findings. The concept of generalisability is particularly problematic 
in qualitative research as samples are not gathered with the intention of the findings being 
generalised to other populations (Shenton 2004).  
There were a number of characteristics of the present study which may have affected the 
transferability of the findings. Firstly, the sample was small and recruited from only one 
health board in Scotland. Women who took part in the study were all attending a clinic 
for management of their GDM. It could therefore be argued that these women were more 
concerned about managing their condition than women who did not attend the clinic. 
However, clinical staff reported that non-attendance rates at this clinic were very low 
which suggests that the women we had access to were quite typical of all women in the 
health board diagnosed with GDM. Recruiting from only one health board may have 
limited the transferability of the findings as women in different health boards are likely 
to have had different experiences of having GDM, and of the care they received for this. 
However, clinicians used national guidance for treating and managing GDM.  
Despite the difficulties in generalising from qualitative research, Lincoln and Guba 
(1985) suggest that if researchers provide contextual information about a study and where 
it was conducted, then readers can make judgements themselves about the transferability 
to other contexts. In this study, the COREQ checklist (Tong et al. 2007) for reporting of 
qualitative interview findings was used when preparing the written report of the study. A 
completed copy of this checklist can be found for the present study in appendix 17. All 
relevant items in the COREQ checklist were reported in the published report of the 
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present study.  By providing this information, readers can make judgements about the 
transferability of the findings of publication five to their own context.  
Reflexivity 
Reflexivity be defined as the process of evaluating our own position and background as 
the researcher and the effect that this might have on our research (Berger 2015). 
Reflexivity is an important strategy for reducing the effects of researcher bias and 
strengthening the confirmability of the study. In addition to having multiple investigators 
involved in the research process, as discussed above, other steps that were taken to foster 
reflexivity in the present study included reporting my background and position in the 
published report of the research and keeping a reflective journal. As part of the field notes 
taken during the data collection and analysis I recorded my thoughts on how data 
collection was progressing, the decisions I made and the reasons for these decisions. In 
these notes I reflected on how my own values, beliefs and professional background as a 
Health Psychologist might influence the research process. 
In addition to professional background, other researcher characteristics that can influence 
the research process include sex, sexuality, age, race, personal experiences, political 
ideologies and immigration status among others (Berger 2015). Berger (2015) suggests 
that these factors can affect the research in three ways. Firstly, they can influence the 
access that the researcher has to the study field as people may be more willing to engage 
in research if they perceive the researcher to be like them or sympathetic to their situation. 
Secondly, the characteristics of the researcher can affect the information that a participant 
is willing to share with the researcher, and thirdly, they can influence the way that the 
researcher interprets what a participant is saying, the way they pose questions and how 
they analyse the findings. 
Of the factors discussed it would seem likely that sex of the researcher and personal 
experiences of pregnancy and gestational diabetes would be of most relevance in the 
present study. I was pregnant in the later stages of data collection for this study and during 
my pregnancy I underwent the same testing for gestational diabetes as women in this 
study. It is possible that these factors may have made women more willing to take part in 
the study and influenced the information they were willing to share with me. However, 
prior to me being visibly pregnant I found that most women didn’t ask me if I had 
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children, and in my field notes I recorded that women seemed comfortable talking to me 
about personal and sensitive aspects of their pregnancy both before and after my 
pregnancy. The proportion of women agreeing to be contacted after they gave birth was 
very high throughout the study and did not change over time. Similarly, the proportion of 
these women who were contactable and agreed to take part when followed up after giving 
birth remained stable over the course of the study. Therefore, it seems that my changing 
circumstances during the study period did not seem to affect my access to participants or 
the information they were willing to share with me. The fact that I was a woman of a 
similar age to most participants in this study may have been enough to make women feel 
comfortable sharing personal information with me, regardless of whether I had children 
or not.   
Berger (2015) suggests that there are both advantages and disadvantages to the researcher 
studying a topic they are not personally familiar with. Being unfamiliar with the topic can 
help to reduce the power imbalance between the researcher and the participant as the 
participant can take the role of the expert. At the beginning of all interviews I made it 
clear to participants that I was not an expert on the topic but was there to listen to their 
views and experiences. On the other hand, challenges of carrying out research on a topic 
that you do not have personal experience of include that researchers may not be able to 
fully comprehend what it is like to experience the situation being described by 
participants and may struggle to recognise some of the nuances in the language of the 
topic they are studying. This in turn can affect the researcher’s ability to form appropriate 
questions and follow these up with suitable probes. My reflections recorded in my field 
notes were consistent with this as I noted how being pregnant gave me a better 
understanding of the challenges of pregnancy and how it influences behaviour and 
emotions, which in turn helped me to empathise with women and explore this aspect in 
more detail. For example, having experienced testing for gestational diabetes I 
understood more about the practical difficulties of attending this test that some women 
discussed, and experienced some anxiety about the results of the test. I also appreciated 
some of the challenges of making lifestyle changes, particularly in relation to physical 
activity, when suffering common pregnancy complications like morning sickness and 
pelvic pain.  Furthermore, after my pregnancy I felt I had a clearer understanding of the 
clinical care that women received in pregnancy and the terminology associated with this. 
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However, prior to being pregnant I would ask women to clarify anything I didn’t 
understand and I think that this is unlikely to have had a large impact on the research.   
It is not possible to avoid researcher subjectivity entirely in qualitative research but by 
taking steps to encourage reflexivity throughout the research process I have a better 
understanding and awareness of how my own position as the researcher influences my 
research. Some authors argue that the unique position of the researcher can add value to 
qualitative research, and in the present study I feel that the changes in my position and 
circumstances had a positive influence on my engagement with participants and the data. 
Although some aspects of my background and position as the researcher were discussed 
in the published report of this paper, limited space meant it was not possible to do this in 
depth which might be considered a weakness of this paper. 
Ethical considerations 
Face to face interviews are associated with a number of potential risks to both the 
participants and the researcher. The main ethical issue in the present study related to the 
discussion of future risk of type 2 diabetes with participants and the possibility that 
patients would not be aware of their own increased risk. Interviews were conducted 
approximately eight weeks after birth meaning that women would have attended their six 
week postnatal check-up by the time interviews are conducted. I was informed by the 
clinical staff involved in the study that all women would be told about their increased risk 
of type 2 diabetes at this six week check-up. However, I also understood that some 
women did not attend this check-up and therefore may have been unaware of their 
increased risk. There was also the possibility that women who did attend may not fully 
take this information in or remember it. Every effort was made to ensure that women did 
not discover this information for the first time during the interview. I checked whether 
the participant had discussed type 2 diabetes with their health care provider or was aware 
about it from any other source. For any women who were not aware of the link between 
type 2 diabetes and GDM, the line of questioning around type 2 diabetes and preventative 
behaviours was not be followed up. Despite this risk I felt it was important to try to 
discuss perceptions of risk with patients where possible as theory and research both 
suggest perception of risk may influence on adoption of risk reducing lifestyle behaviours 
(Janz and Becker 1984). 
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Even in those women who were aware of their risk of type 2 diabetes, discussing this 
might have caused distress or worry in participants. Although none of the participants 
showed any signs of distress, if this had happened I had planned to check that they were 
willing to continue with the interview and reiterate that they could withdraw from the 
study at any time. After the interview all participants were offered information about 
resources where they can find out more about diabetes (e.g. Diabetes UK website) and to 
a telephone support line where they can discuss any worries they had (the Diabetes UK 
Care line which is a telephone service where patients can speak to trained counsellors). 
Another ethical issue for participants related to the approach taken to recruitment. There 
was a possibility that women could feel under pressure to agree to give me their contact 
details at the clinic. However, both myself and the clinical staff highlighted the voluntary 
nature of participation and explained that by giving contact details they were not agreeing 
to participate. They were also told that even if they did agree to participate, they were 
free to withdraw at any point from the study without any consequences to them or their 
health care. The women had a sufficient period (eight weeks) between receiving 
information about the study and being contacted by myself to fully take in the written 
information and think about their participation. 
Finally, conducting interviews in the patient’s home presented a risk to the researcher. 
Several steps were taken to reduce this potential risk. I carried a mobile phone and 
arranged to make contact via text message with an agreed contact at the University of 
Stirling, both prior to entering the participants home and again when the interview was 
completed. I also gave this contact a list of the dates and times of interviews and the 
address I was visiting for each interview. 
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Chapter eight: Discussion 
This chapter will begin by summarising the findings of this thesis and will then consider 
the importance of these findings and how they compare to other research in this field. 
The implications of the findings for the development of lifestyle interventions for people 
with IGR and women with GDM will then be discussed. Finally, recommendations 
arising from the thesis will be summarised. 
8.1 Summary of thesis and findings 
This thesis described prevalence estimates, rates of progression and patient perceptions 
in relation to IGR and GDM: two conditions that put people at a particularly increased 
risk of type 2 diabetes. The aim is for the body of work in this thesis to inform the 
development of interventions to prevent or delay progression to type 2 diabetes in these 
patient groups. 
Impaired glucose regulation 
Prevalence estimates of IGR in developed Europe were summarised and factors that 
influenced these estimates were identified by conducting a systematic review and meta-
analysis. The meta-analysis reported that more than one in five people in the general adult 
population of developed Europe met the criteria for either IGT, IFG or both. Mean 
prevalence of IGT in the general adult population overall was 11.4% and did not differ 
by gender. Mean prevalence of IFG in the general adult population overall was 8.4% and 
significantly higher in men at 10.1% compared to 5.9% in women. Sample age, diagnostic 
criteria and country were found to have a significant univariate effect on prevalence of 
IGT, but only diagnostic criteria remained significant in multivariate analysis. The only 
moderator variable with a significant effect on IFG prevalence was country. 
This thesis also reported incidence of IGR and progression to type 2 diabetes in the UK 
in an observational retrospective study using routinely collected health care data. Total 
incidence of IGR across the study period was 2,720 per 100,000 person years. No 
significant differences were found in incidence by gender or deprivation category, but 
incidence was found to increase with increasing age. During the study period 9% of 
patients with IGR were diagnosed with type 2 diabetes with a mean time of 34 months 
between IGR and type 2 diabetes diagnosis. At a significantly increased risk of 
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progression to type 2 diabetes were men, those living in an area of deprivation and older 
patients.  
Gestational diabetes mellitus 
Prevalence estimates of GDM in developed Europe were summarised and factors that 
influenced these estimates were identified by conducting a systematic review and meta-
analysis. This meta-analysis reported mean prevalence of GDM in the general population 
of pregnant women in developed Europe of 5.4%. Maternal age, year of data collection, 
country, area of Europe, week of gestation at testing, and diagnostic criteria were found 
to have a significant univariate effect on GDM prevalence with area, week of gestation 
at testing and year of data collection remaining statistically significant in multivariate 
analysis.  
An observational cohort study using routinely collected healthcare data was carried out 
in the UK to investigate long term risk of type 2 diabetes in women with GDM.  The 
study found that one quarter of women with GDM developed type 2 diabetes, with a mean 
time period of eight years between diagnosis of GDM and type 2 diabetes. Increased 
weight during pregnancy, use of insulin during pregnancy, higher HbA1c levels at 
diagnosis of GDM and fasting blood glucose were all associated with an increased risk 
of developing type 2 diabetes after GDM. 
Finally, semi-structured interviews were conducted to explore the experiences, 
knowledge and perceptions of women with GDM. Women who participated in the 
interviews did not view GDM as something important and perceived it to have minimal 
impact on their lives. Linked to this, knowledge and understanding of type 2 diabetes was 
poor and women were unconcerned about their future risk.  Changes women made to 
their lifestyle, largely to diet, were motivated by concern for their baby’s health and many 
women did not maintain these changes postnatally.  
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8.2 Importance of findings and comparison to existing research  
Impaired glucose regulation 
Publication one – meta-analysis of impaired glucose regulation 
prevalence 
This publication was the first systematic review and meta-analysis to summarise data on 
the prevalence of IGR in Europe. Previous research estimating IGR prevalence in Europe 
has produced widely varying estimates. For example, a study of IGR prevalence in 13 
populations across nine European countries reported prevalence estimates of IGR that 
ranged from 3.2% to 64.2% (DECODE study group 2003). By synthesising all the 
available research on this topic, publication one provides clarity on what underlies some 
of the variations in reported prevalence estimates of IGR.  
Differences in the diagnostic criteria used to identify IGR have been suggested as one 
possible reason for the disparity in prevalence estimates in published research. The 
specific values and types of tests used for diagnosing IGR have changed over time and 
differ in guidelines published by different organisations. This is particularly true for IFG 
with considerable differences in the types of test and cut off values recommended by the 
ADA (2010) and WHO (2006) guidelines. A study comparing these diagnostic criteria in 
Denmark found the lower diagnostic threshold used by the ADA guidelines resulted in 
IFG prevalence of 37.6% in the sample compared to prevalence of only 11.8% when 
WHO criteria were applied (Borch-Johnsen et al. 2004).  
Consistent with the findings of the Borch-Johnsen et al. (2004) study, the systematic 
review and meta-analysis in publication one found that diagnostic criteria had a 
significant effect on prevalence of IGT. Prevalence of IFG increased when wider criteria 
were used but these findings were not statistically significant. However, prevalence of 
IFG was analysed separately by sex meaning that there were only a small number of 
studies in some of the diagnostic criteria categories; the lack of statistical significance for 
diagnostic criteria as a moderator of IFG prevalence may therefore be a result of 
insufficient power in the analysis rather than indicating lack of an effect. The mean 
prevalence estimate of 22.3% for IGR in the general adult population reported by the 
meta-analysis is therefore largely consistent with the widely accepted figure of 15% 
(DECODE study group 2003) when the differences in the criteria these estimates are 
based upon are considered. 
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Further difficulties in understanding the research on IGR prevalence arise from 
inconsistent findings on the demographic factors that influence the distribution of IGR. 
Prior to the systematic review and meta-analysis conducted as part of this thesis, data 
from the DECODE study (2003) in 13 European populations was cited as the most robust 
evidence for differences in IGR prevalence according to age and sex (Unwin et al., 2002). 
The DECODE study reported that IFG is more common in men than women in all age 
groups and IGT is more common in women than men in those aged 30-39 and 70-79. Sex 
differences for IGT were not significant in other age groups. The DECODE study also 
found that prevalence of IGT increased across all age groups but that IFG plateaued in 
middle age and decreased in older men (Unwin et al., 2002).  Although patterns were 
identified in the DECODE study according to age and sex, it is important to note that 
there were differences in findings between the individual populations summarised in the 
publication and that prior to the DECODE study the impact of sex on IGR prevalence 
was unresolved (Unwin et al. 2002; DECODE Study Group 2003). The meta-analysis 
reported in publication one confirmed the trends reported by the DECODE study (2003) 
of higher prevalence of IFG in men compared with women, and higher prevalence of IGT 
but not IFG with increasing age. The less robust DECODE finding of higher IGT 
prevalence in women compared with men in some age groups was not confirmed in this 
systematic review and meta-analysis. By synthesising all the available literature on this 
topic using meta-analysis methods, publication one was able to assess the effects of 
several variables on IGR prevalence at the same time allowing stronger conclusions to be 
drawn about the importance of these variables in influencing IGR prevalence.  
By providing a clear understanding of how many people in the general population are 
likely to have IGR, and who is more likely to have it, interventions to prevent type 2 
diabetes can be planned and appropriately targeted. Publication one is therefore useful 
not only as a reference paper for researchers writing about this topic, but it also provides 
a basis for the planning of interventions and health care provision for the prevention of 
type 2 diabetes.  
Publication three – incidence of impaired glucose regulation and 
progression to type 2 diabetes 
The observational retrospective study carried out in publication three was the first study 
of IGR incidence and progression to type 2 diabetes in the UK. Using routinely collected 
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health care data allows for incidence to be assessed without the need for costly and time-
consuming repeated testing of a sample of people over a period of time although 
incidence based on health care data may not represent true incidence in the general 
population (Zimmet, Alberti, Magliano Bennett, 2016). Furthermore, using routinely 
collected health care data to estimate incidence of IGR offers an approximation of how 
many people with IGR are currently being identified by the health service. This is 
important for planning current and future health care delivery and for planning 
preventative efforts for people with IGR (Zimmet et al. 2016).  
Although recent NICE guidelines (2011) on the prevention of type 2 diabetes recommend 
that GPs and other primary health care health professionals use validated risk assessment 
tools to identify those who may be at high risk of developing type 2 diabetes, research 
has suggested that this type of screening is rarely carried out in practice (Noble et al. 
2011). The lack of a universal approach to identifying people at high risk of type 2 
diabetes in practice makes it particularly important to assess how many people with IGR 
are currently being identified by the health service in a region if interventions are to be 
developed for this setting. Publication three reported that a considerable number of 
patients were identified as having IGR during routine health care in the Tayside Health 
Board which suggests that it would be feasible to deliver interventions to people with 
IGR in the health care setting without the need to carry out additional screening.  
No studies assessing incidence of IGR were identified by the systematic review in 
publication one. Although incidence and prevalence are different concepts they are 
closely related meaning that the findings of the meta-analysis of prevalence and the 
observational study of incidence can be compared. The incidence rate of a disease can be 
defined as the frequency of new occurrences of a disease in a population at risk over a 
period of time (Webb and Bain 2011). In contrast prevalence is the proportion of people 
who have the disease at a specific point in time. Generally speaking, the prevalence of a 
disease is equal to the incidence rate multiplied by the average duration of the disease. 
This assumes a stable population where the number of people entering the population is 
equal to the number leaving the population (Webb and Bain 2011). As IGR does not have 
a very short duration we would expect prevalence of IGR to be higher than incidence 
which is consistent with the findings in the study of incidence in publication three and 
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meta-analysis of prevalence in publication one. As incidence and prevalence are closely 
related we would also expect them to be affected by the same demographic factors.  
The observational cohort study carried out in publication three reported some trends in 
IGR incidence that are consistent with the findings of the meta-analysis in publication 
one. In publication three, incidence of IGR was found to increase with age which is 
consistent with the meta-analysis but the sex differences in IGR reported in the meta-
analysis were not found in publication three for IGR incidence. It was not possible to 
analyse sex differences in incidence for IGT and IFG separately in publication three 
because only an FPG test was conducted or recorded for the majority of patients in this 
study. Although WHO (2006) guidelines state that it is possible for a single elevated FPG 
to be used to diagnose IFG it also states that this classification is uncertain because a 
diagnosis of IGT cannot be excluded and thus we were unable to separate cases of IGT 
and IFG with confidence. Given that sex differences in prevalence were only reported for 
IFG and not IGT in the meta-analysis it is not surprising that trends for sex were not 
found in publication three when IGT and IFG were analysed together.  
In addition to reporting the number of new cases of IGR identified through routine health 
care in the UK, publication three was also the first to report progression to type 2 diabetes 
in Scotland using routinely collected health care data. Understanding rates of progression 
to type 2 diabetes is important for planning the timescale for delivering interventions to 
prevent type 2 diabetes. Publication three reported that 9% of patients progressed to type 
2 diabetes in a mean time of 34 months over a five year study period. A meta-analysis by 
Morris et al. (2013) reported that the incidence rate of type 2 diabetes was 4.5% per year 
in people with IGT and 4.7% per year for IFG. Morris et al. (2013) reported that 
progression rates differed according to the criteria used to define IGR, but the progression 
rates reported above were based on WHO criteria (2006) as were the progression rate 
reported in publication three meaning that these figures should be comparable. Although 
these figures cannot be directly compared with those reported in publication three as they 
are expressed as a rate per year and are only for people with IFG, the incidence of type 2 
diabetes in publication three is lower than in the Morris et al. (2013) meta-analysis.  
The meta-analysis by Morris et al. (2013) summarised studies from across the world 
including Asia, Europe, North America, Africa and Australia. Trends in type 2 diabetes 
are known to vary in different regions of the world (WHO 2016). South East Asia and 
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Western Pacific Region, two areas included in the meta-analysis, have the largest number 
of people with type 2 diabetes and together account for approximately half of all type 2 
diabetes cases worldwide (WHO 2016). Although type 2 diabetes prevalence has risen 
globally, this rise in prevalence has been faster in low and middle-income countries 
compared to high income countries (WHO 2016).  These differences in type 2 diabetes 
trends across regions of the world may mean that the summary figures reported by the 
Morris et al. (2013) meta-analysis are not comparable to the incidence rates reported in 
publication three which were based on data from Scotland, a high income European 
country.  
Two studies conducted in the UK assessing incidence of type 2 diabetes in people with 
IGR were included in the Morris et al. (2013) meta-analysis (Wareham et al. 1999; 
Forouhi et al. 2007) and two further UK studies published after the Morris et al. (2013) 
review were identified (Gillett et al. 2012; Hong et al. 2016). The Wareham et al. (1999) 
study assessed incidence of type 2 diabetes in people with HbA1c levels that were raised 
but not high enough to be diagnostic of type 2 diabetes (Wareham et al. 1999). Although 
both the ADA (2011) and WHO (2011a) now recommend that HbA1c can be used in the 
diagnosis of IGR and type 2 diabetes, research has shown that HbA1c and FPG/2hPG 
tests do not identify the same people as being at high risk of type 2 diabetes (Mann et al. 
2010; Barry et al. 2017). Therefore, the findings of the Wareham et al. (1999) study are 
not comparable with those of publication three.  
The second UK study identified by the Morris et al. (2013) meta-analysis was a 
longitudinal study of a random sample of adults of European origin without type 2 
diabetes drawn from one general practice in England (Forouhi et al. 2007). In this study, 
around one quarter of the 257 participants were found to have IFG at baseline using the 
same diagnostic criteria as publication three (FPG of 6.1 to 6.9mmol/l). The rate of type 
2 diabetes incidence in people with IFG was 1.75% per year over the 10 year study period. 
Incidence of type 2 diabetes in people with IGR in publication three was 9% over a study 
period of five years with a mean time of around three years between diagnoses of IGR 
and type 2 diabetes. Again, the different units of measurement mean that these figures 
cannot be directly compared but the rate of progression to type 2 diabetes in publication 
three appears to be reasonably consistent with the rate reported by Forouhi et al. (2007).  
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The two studies published after the Morris et al. (2013) systematic review both used data 
from routinely collected electronic health records in the UK (Gillett et al 2012; Hong et 
al. 2016). The study by Gillett et al. (2012) identified people coded as having IGT or IFG 
between 2000 and 2005 in the General Practice Research Database: a longitudinal 
primary care database containing data that covers around 6% of the UK population. In 
total, 29.3% of the 9,096 people identified as having IGT or IFG in the Gillett et al. (2012) 
study developed type 2 diabetes over a median follow up of 2.9 years (minimum follow 
up 0.9 years, maximum 53.6 years) The proportion of people progressing to type 2 
diabetes in the Gillett et al. (2012) study was higher than in publication three where 9% 
of people with IGR developed type 2 diabetes in a mean time of 34 months. Although the 
mean and median follow up times for the two studies were similar, the maximum follow 
up period in publication three was much shorter at eight years compared to 53.6 years in 
the Gillett et al. (2012) study. The shorter follow up in publication three may partly 
explain the lower proportion of people with IGR who developed type 2 diabetes. The 
diagnoses of IGT and IFG in the Gillett et al. (2012) study were based on codes recorded 
in GP records, whereas publication three used blood glucose test results meaning that the 
findings of the two studies may not be directly comparable.  
The study by Hong et al. (2016) used the same diagnostic criteria for identifying IFG 
(FPG of 6.1 to 6.9mmol/l) as publication three, meaning that the findings are particularly 
comparable. Incidence of type 2 diabetes in the 49,041 people with IFG who received a 
subsequent FPG test after diagnosis was 5.86 per 100 person-years. The incidence of type 
2 diabetes in people with IGR in publication three was less than half of that in the Hong 
et al. study (2016) at 2.72 per 100 person-years. However, the Hong et al. study (2016) 
only included people with a subsequent FPG test after diagnosis of IFG whereas in 
publication three people were included if they had one blood test meeting the diagnostic 
criteria. By only including participants with one elevated FPG test publication three may 
have falsely identified some people as having IFG or IGT when they may in fact have 
had elevated blood glucose levels for other reasons, such as illness. The possible incorrect 
identification of IGR in some patients in publication three may have contributed to the 
lower incidence of type 2 diabetes. Furthermore, Hong et al. (2016) suggested that those 
patients who receive a subsequent FPG after diagnosis of IGR are likely to be those 
considered at highest risk by their health care providers and therefore more likely to 
develop type 2 diabetes.   
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Publication three also reported that of the people identified as having IGR, those who 
were older, with IGT, male and living in a more deprived area were at the greatest risk of 
progressing to type 2 diabetes. Consistent with this, the study by Forouhi et al. (2007) 
also found higher incidence of type 2 diabetes with increasing age. However, two meta-
analyses reported no difference in risk of progression to type 2 diabetes between IGT and 
IFG (Gerstein et al. 2007; Morris et al. 2013). Because the majority of instances of blood 
glucose results in publication three were from a single test fasting only, it was not possible 
to be certain of the classification of IFG and IGT. As these classifications are not certain 
the findings regarding IGT and risk of progression need to be interpreted with caution.   
Research exploring the influences of a person’s sex on the risk of progression to type 2 
diabetes has produced mixed findings. Consistent with publication three, Forouhi et al. 
(2007) reported higher incidence of type 2 diabetes in men with IFG than in women 
whereas other research reported no difference between sexes (Qiao et al. 2003; Hong et 
al. 2016). The meta-analysis by Gerstein et al. (2007) reported that there was insufficient 
data to allow the effect of sex on progression to type 2 diabetes to be explored.  No studies 
were identified that assessed the effect of deprivation on progression from IGR to type 2 
diabetes. The influence of sex and deprivation on incidence of type 2 diabetes in people 
with IGR are therefore areas that would benefit from further investigation. 
The findings of publication three are generally consistent with and build upon the small 
body of literature assessing progression from IGR to type 2 diabetes in the UK. 
Publication three provides an understanding of the incidence of type 2 diabetes and the 
timescale of this in patients identified as having IGR through routine health care delivery 
in Scotland. As such it provides important information for planning interventions and 
health care delivery with this group of patients in this region.  
Gestational diabetes mellitus 
Publication two – meta-analysis of gestational diabetes mellitus 
prevalence 
Although narrative literature reviews exist summarising GDM prevalence in Europe, this 
thesis reports the first systematic review and meta-analysis to bring together all the 
evidence on this topic. Estimating prevalence of GDM has been challenging as rates vary 
from study to study due to a lack of accepted diagnostic criteria. The ADA guidelines 
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(2003) estimate that around 7% of pregnant women will be diagnosed with GDM and a 
previous narrative review of GDM prevalence in Europe estimated rates of between 2 
and 6% (Buckley et al. 2012). The mean prevalence of GDM of 5.4% of pregnant women 
reported in the meta-analysis, although at the upper end of the estimates reported by 
Buckley et al. (2012), can be considered consistent with the Buckley et al. (2012) review 
given the differences in screening strategies used in included papers. A narrative review 
of GDM prevalence published at the same time as publication two, and including many 
of the same studies, reported median prevalence of 5.8% of pregnant women in Europe 
(Zhu and Zhang 2016). 
There has been no consensus in previous research on the factors that influence GDM 
prevalence. As outlined in the discussion section of publication two, the findings of the 
meta-analysis regarding increasing prevalence with increasing maternal age and higher 
prevalence in Southern and Western Europe compared to Northern Europe are consistent 
with previous research (Buckley et al. 2012). Research conducted since the publication 
of paper two has similarly reported an association between maternal age and prevalence 
of GDM (Collier et al. 2017; Lavery et al. 2016). Publication two did not find any effect 
on prevalence for the well-established risk factors BMI, ethnicity or family history (Ben-
Haroush et al. 2004). However, very few studies included in publication two reported on 
these factors, so it is likely that the meta-analysis had insufficient power to detect any 
effects of these risk factors on GDM prevalence. 
The significant effect of diagnostic criteria on GDM prevalence reported in publication 
two was not consistent with the findings of the Buckley et al. (2012) narrative review. 
Buckley et al. (2012) reported that no consistent effect of diagnostic criteria on GDM 
prevalence was present. However, a study in Ireland that directly compared diagnostic 
criteria for GDM in one sample of women supported the findings of publication two 
(O’Sullivan et al. 2011). One of the strengths of meta-analysis is that it allows the effects 
of several variables to be assessed at the same time making it easier to identify patterns 
when there are relationships between variables. It may be that the narrative review by 
Buckley et al. (2012) was unable to identify an effect of diagnostic criteria on prevalence 
among the effects of other related variables. 
As outlined in the discussion section of publication two, the significant increase found in 
prevalence over time is difficult to interpret because of increases in screening and changes 
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in diagnostic criteria in this time period. A retrospective study of over 3 million women 
with GDM in the US published after publication two reported temporal increases in GDM 
prevalence that were partly explained by BMI, race and maternal smoking but also clearly 
linked to changes in diagnostic criteria (Lavery et al. 2017) which supports the 
interpretation made in the discussion section of publication two. 
By synthesising all the available research on this topic using meta-analysis, publication 
two provides clarity on some of the variations in the literature and offers a clear 
understanding of how many pregnant women have GDM and the demographic 
characteristics of these women. This publication is therefore useful not only as a reference 
paper for researchers writing about this topic, but also provides a basis for the planning 
of interventions and health care provision for the prevention of type 2 diabetes in women 
with GDM.  
Publication four – progression from gestational diabetes mellitus to type 
2 diabetes 
Publication four was the first study in the UK to investigate progression from GDM to 
type 2 diabetes. The use of routinely collected health care data gives this study greater 
relevance to clinical practice and for informing the development of interventions based 
in health care settings. Publication four reported that around one quarter of women 
identified as having GDM in one health board in Scotland went on to develop type 2 
diabetes over an average time period of eight years. This rate of progression to type 2 
diabetes falls within the lower to middle end of the range of cumulative incidence figures 
reported in the Kim et al. (2002) systematic review of 2.6% to 70%. Kim et al. (2002) 
reported that incidence increased markedly in the first five years after delivery and 
plateaued after ten years which is broadly consistent with the average time period for 
progression to type 2 diabetes in publication four.   
A comparison of the risk factors for progression to type 2 diabetes identified in 
publication four with findings of other research has been covered in depth in the 
discussion section of the published paper and this discussion will not be repeated here. 
To summarise, publication four found that weight during pregnancy, use of insulin during 
pregnancy, higher HbA1c levels at diagnosis of GDM, and FBG conferred the greatest 
risk of progressing from GDM to type 2 diabetes. Age, history of GDM in a previous 
pregnancy, and family history of diabetes were not found to be associated with an 
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increased risk of type 2 diabetes. Previous research was generally consistent with 
publication four regarding the findings for FPG and weight but were mixed for the other 
risk factors.   
Since the publication of paper four a systematic review and meta-analysis has been 
carried out to quantify the risk of progression to type 2 diabetes in women who have had 
GDM (Rayanagoudar et al. 2016). This review included 39 studies (including publication 
four) with a total of 95,750 women with GDM. Consistent with publication four, this 
meta-analysis found an increased risk of developing type 2 diabetes in women with raised 
FPG, higher HbA1c, higher BMI and who used insulin during their pregnancy. In contrast 
to publication four, Rayanagoudar et al. (2016) found that advanced maternal age and 
family history of diabetes were risk factors for progressing to type 2 diabetes. However, 
hazard ratio estimates for these risk factors were raised in publication four and with a 
small sample size and wide confidence intervals it may be that the study lacked the power 
to detect effects for these variables.  
The findings of publication four are largely supported by other research and suggest that 
women with higher FPG levels who use insulin during their pregnancy are at the highest 
risk of developing type 2 diabetes and should arguably be prioritised for preventative 
intervention. This study also suggests that there is a viable window of opportunity to 
prevent progression from GDM to type 2 diabetes in most women who are identified and 
treated during routine health care practice in Scotland. 
Publication five – perceptions and experiences of women with gestational 
diabetes mellitus 
There has been little research conducted in the UK exploring the perceptions and 
experiences of women with GDM and publication five is the first, to our knowledge, to 
be underpinned by health psychology theory. This basis in psychological theory has 
highlighted a range of illness perceptions and beliefs that may be impacting upon lifestyle 
change and could be addressed in a preventative intervention. Lifestyle interventions 
targeting people at risk of type 2 diabetes have not been as successful in women with 
GDM as they have in other high-risk groups (e.g. those with IGR; Gilinsky et al. 2015). 
This is likely because the challenges facing women with GDM in making lifestyle 
changes are potentially quite different to those facing other high-risk groups. Seeking the 
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views of women who have had GDM themselves is therefore important in helping to 
ensure that interventions are well received.  
The findings of publication five are broadly consistent with those of a meta-synthesis of 
16 qualitative studies assessing perceptions among women with GDM (Parsons et al. 
2014) and with three further qualitative studies conducted in the UK and Ireland (Lie et 
al. 2013; McMillan et al. 2018; Tierney et al. 2015). With the exception of the McMillan 
et al. (2018) study, all of these studies were conducted before publication five. Themes 
summarised by these papers that are consistent with the present study include the 
emotional response to being diagnosed with GDM, loss of normal pregnancy, focus on 
the baby’s health, perceived temporary nature of GDM, mixed understanding of causes 
of GDM, awareness of future risk of type 2 diabetes, lack of differentiation between 
different types of diabetes, lack of specific dietary advice, non-maintenance of lifestyle 
changes postnatally, barriers to postnatal lifestyle change and the acceptability of 
postnatal support for lifestyle change.  
A finding of publication five that contradicted other research related to experiences of 
care during pregnancy. Studies included in the Parsons et al. (2014) review described 
women’s negative experiences of the care received for GDM which is not generally 
consistent with publication five or the Lie et al. (2013) and McMillan et al. (2018) studies. 
These differences could be explained by the health-care contexts in which the studies 
were carried out. Publication five, the Lie et al. (2013) and the McMillan et al. (2018) 
studies were conducted in the UK whereas the studies included in the Parsons et al. (2014) 
review were conducted in regions outside of the UK including the United States, Sweden, 
Canada, Australia and Tonga. Participants in publication five, Lie et al. (2013) and 
McMillan et al. (2018) studies are therefore likely to have been receiving broadly 
comparable care based upon similar clinical guidelines during their pregnancy. 
Although the transitory nature of GDM emphasised by some women in publication five 
was also reported in previous research (Parsons et al. 2014; Lie et al. 2013;), the belief 
that GDM is not an important, or even a real, diagnosis for some women is not one that 
has been reported in previous qualitative research. However, a survey of 100 women in 
the US found that 22% perceived that they had been misdiagnosed with GDM (Tang et 
al. 2016). This perception of misdiagnosis was more common among those who managed 
their GDM with diet alone. This supports the link made in publication five between the 
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lack of concern about GDM diagnosis and perception of GDM having a minimal impact 
on women’s lives. In the Tang et al. (2016) study, the most common reasons given for 
perceiving a misdiagnosis included having blood sugar levels after diagnosis that were 
normal despite minimal changes in diet, borderline test results, concern about the new 2h 
75g OGTT and the perception that women did not fit the typical profile of someone with 
gestational diabetes (not overweight and a healthy diet). With the exception of concern 
about the new diagnostic test, these are all reasons given by women in publication five 
who doubted their diagnosis.  
The findings of publication five are generally consistent with the small body of other 
research on this topic in the UK and present some novel findings that add to our 
understanding of perceptions of misdiagnosis of GDM. The paper builds upon this 
research by using an explicit theoretical basis which helps to identify specific beliefs and 
perceptions that can be tackled by future interventions. Seeking women’s views on 
preventative interventions also offers an idea of what type of intervention might be 
considered acceptable. 
8.3 Intervention development 
The publications in this thesis address several gaps in the literature which are important 
for the development of lifestyle interventions to prevent type 2 diabetes in people with 
IGR and GDM. This section of the chapter will firstly discuss the use of frameworks for 
intervention development. The implications of the findings of this thesis, and other 
research, for the development of interventions in people with IGR will then be considered 
using a framework for intervention development to structure the discussion. Finally, 
development of an intervention for women with GDM will be discussed, followed by a 
summary of recommendations arising from the thesis.  
Frameworks for intervention development 
Human behaviour is complex and influenced by a wide range of factors and consequently, 
interventions that aim to alter behaviour are often considered complex. Complex 
interventions are typically defined as those with several interacting components. The 
MRC (2006) identifies various additional dimensions that can also make an intervention 
complex, such as having a range of possible outcomes, having variability in the target 
population, allowing flexibility or tailoring of the intervention, targeting a number of 
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groups or organisations, and targeting multiple behaviours or difficult behaviours (MRC 
2006). Preventative interventions for people with IGR and for women who have had 
GDM show a number of these aspects and can therefore be considered complex.  
A number of frameworks have been proposed that aim to address some of this complexity 
including, among others, intervention mapping, PRECEDE-PROCEED model and the 
MRC framework for the design and evaluation of complex interventions (Bartholomew 
et al. 1998; Green and Kreuter 2005; MRC 2006). There is little evidence to suggest 
which of the many frameworks available is most appropriate for intervention 
development in the current context. The MRC guidance has been used in a variety of 
settings but is now over 10 years old with an updated version due to be published in 2019. 
A recent framework called 6SQuID (six steps for quality intervention development) 
published by Wight et al. (2016) will therefore be used to discuss development of 
interventions in the present context. This framework draws and builds on existing 
frameworks, including the MRC framework, and provides a six-step pragmatic guide to 
intervention development.  
The six steps in the 6SQuID framework for intervention development are as follows:  
1. Define and understand the problem and its causes.  
2. Clarify which causal or contextual factors are malleable and have greatest scope for 
change.  
3. Identify how to bring about change: the change mechanism.  
4. Identify how to deliver the change mechanism.  
5. Test and refine on small scale.  
6. Collect sufficient evidence of effectiveness to justify rigorous 
evaluation/implementation 
Each of these steps will be discussed in turn below with reference to the findings of this 
thesis and other research, first in relation to the development of an intervention for people 
with IGR and then for women with previous GDM.  
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Impaired glucose regulation intervention development 
The first step of the 6SQuID framework requires researchers to define and understand the 
problem in question and its causes. Publications one and three in this thesis have helped 
to address the first step of this framework by clarifying the incidence and prevalence of 
IGR, and by identifying who is at most risk of progressing from IGR to type 2 diabetes, 
and therefore most likely to benefit from intervention. Publication one shows that around 
one in five people in the general population in Europe have IGR. In publication three 
50,321 people with IGR were identified from routinely collected health care data over 
the five year study period. Although it was not possible to ascertain where diagnostic 
testing was conducted (i.e. primary or secondary care), these findings suggest that it may 
be feasible to deliver preventative intervention in health care settings without additional 
screening. Attempts to translate the success of randomised controlled trials of lifestyle 
interventions for prevention of type 2 diabetes to health care settings often face challenges 
including lack of resources, lack of practitioner time and practical difficulties with 
recruitment (Cardona-Morrell et al. 2010). Targeting interventions at those people who 
are already being identified by the health service as having IGR could help to overcome 
some of these challenges. The mean time for progressing from IGR to type 2 diabetes in 
publication three was 34 months suggesting that a timescale of up to three years after 
diagnosis would be appropriate for delivering an intervention in this group. 
Once the nature and extent of the problem has been defined, the 6SQuID framework 
suggests that the influences or causes of the problem are explored (Wight et al. 2016). 
The review of literature presented in the introduction of this thesis identified the factors 
that cause IGR which include genetics, ethnicity and lifestyle (Nathan et al. 2007). The 
second step of 6SQuID is to clarify which of the causal or contextual factors are malleable 
and have greatest scope for change. Of the causal factors identified for IGR, lifestyle is 
the factor which has clear scope for change and as such is an appropriate target for 
intervention.  
Publication three reported that of the people identified as having IGR, those with IGT, 
who were older, living in a more deprived area and male were at the greatest risk of 
progressing to type 2 diabetes. These findings suggest that these groups of people could 
arguably be targeted for lifestyle intervention. However, the evidence for IGT and sex as 
risk factors for progressing to type 2 diabetes is mixed suggesting further research is 
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needed before these groups are targeted. In publication three, people aged between 48 to 
67 were at around a ten-fold risk of progressing to type 2 diabetes. As older age is a risk 
for type 2 diabetes in those without IGR, there is a clear rationale for focusing 
interventions on people in this age range.  
The relationship between lower socioeconomic status and unhealthy lifestyle has been 
evidenced for a range of behaviours including physical activity and diet, two behaviours 
which are important in the prevention of type 2 diabetes in people with IGR (Pampel et 
al. 2010). Recent data from Scotland shows that the proportion of adults adhering to 
physical activity guidelines is highest in the least deprived areas and declines as 
deprivation increases (Scottish Government 2017a).  Similarly, people living in the most 
deprived areas of Scotland have a poorer quality of diet (Whybrow et al. 2017) and are 
consistently more likely to be obese than those in affluent areas (Scottish Government 
2017b). This socioeconomic gradient in health behaviour in Scotland may partly explain 
the increased risk of progressing to type 2 diabetes found in people from deprived areas 
with IGR in publication three. This evidence demonstrates that there is clear scope for an 
intervention to promote healthier lifestyles in people with IGR living in deprived areas. 
The third step of the framework moves from understanding the problem in question to 
identifying how to bring about change. This involves developing a programme theory 
which defines the mechanism of change and describes how this mechanism will bring 
about changes in the targeted behaviour. The authors of the framework argue that the best 
developed programme theories are based upon theories of behaviour change (Wight et al 
2016).   
Once the change mechanism has been identified, the fourth step of the framework is to 
identify how to this change mechanism will be delivered. In this step an implementation 
plan is developed with the involvement of stakeholders where possible. At this point the 
researcher should also anticipate any potential unintended effects of the intervention and 
consider how to minimise these (Wight et al. 2016). If older people with IGR from 
deprived areas are to be targeted for intervention there are unique challenges to delivering 
interventions in this group that need to be considered.  
Research on behaviour change interventions has frequently cited difficulties in recruiting 
and retaining people with low incomes (Carroll et al. 2011). Although there are 
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challenges in recruiting and retaining people with low incomes, a review of recruitment 
and retention in physical activity interventions reported strategies that have been 
successful with hard to reach groups, such as those with low incomes (Carroll et al. 2011). 
Successful recruitment strategies included using multiple advertising channels, 
partnering with respected community stakeholders and organisations, and having well-
trained study staff who are culturally matched to the population of interest. Strategies for 
successful retention of participants included obtaining multiple contact numbers, making 
multiple contacts with participants, providing incentives, having a positive and caring 
attitude to participants, demonstrating sensitivity and respect for participants’ situations, 
and being flexible regarding location and timing of study visits. Carroll et al. (2011) also 
highlighted the importance of using formative research to develop strategies for 
recruitment and retention in the specific context under study. Furthermore, the authors 
describe that successful studies typically made a significant effort to ensure interventions 
were appealing, tailored and as interactive as possible. The findings of this review suggest 
that with appropriate formative research and careful design, an intervention targeted at 
older people from deprived areas with IGR could be feasible. 
In addition to recruitment and retention difficulties, there are also concerns about the 
effectiveness of behaviour change interventions for low income groups (Bull et al. 2014). 
A meta-analysis of interventions for healthy eating, physical activity and smoking in low 
income groups published between 2006 and 2014 reported only small positive effects on 
these three behaviours. However, similar reviews of studies that did not target low income 
groups tended to report larger effect sizes (Bull et al. 2014). Although it is not possible 
to make a true comparison without studies that compare the same intervention between a 
group with low income and a group including people with higher incomes, these findings 
do suggest that behaviour change interventions may be less effective for low-income 
groups.  
Analysis of the variance within the physical activity studies included in the Bull et al. 
(2014) meta-analysis showed that there were larger effect sizes in studies that targeted 
only physical activity compared to those targeting multiple behaviours (Bull et al. 2014). 
Another meta-analysis on the same topic covering literature published between 1995 and 
2006 also reported that interventions with fewer behaviour change techniques tended to 
be more effective, although this finding was only marginally significant (Michie et al. 
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2009). These findings suggest that an intervention for people with IGR from deprived 
areas may be most effective if it targets only one behaviour and contains a small number 
of behaviour change techniques.  
The remaining two steps of 6SQuID are to test and refine the intervention on a small scale 
and to collect sufficient evidence of effectiveness to justify rigorous 
evaluation/implementation. The authors of the 6SQuID framework stress that 
intervention development is not a linear process and researchers will often return to 
earlier stages before reaching the final stage of development (Wight et al. 2016). Using a 
framework allows a systematic approach to be taken to intervention development and 
evaluation and allows effective components of the intervention to be identified. This is 
important for maximising the effectiveness of interventions and ensuring resources are 
not wasted (Wight et al. 2016). The findings of this thesis contribute to understanding of 
the early stages of this framework allowing future research to build on this and address 
these later stages of development.  
Gestational diabetes mellitus intervention development 
Publications two and four in this thesis have helped to address the first step of the 6SQuID 
framework for intervention development, which is to define and understand the problem 
and its causes, by clarifying the prevalence of GDM and identifying who is at most risk 
of progressing from GDM to type 2 diabetes, and therefore most likely to benefit from 
intervention (Wight et al. 2016). Publication two shows that 5.4% of the general 
population of pregnant women developed GDM in Europe. The findings of this 
publication give a clear understanding of the prevalence of GDM on which to base the 
planning of an intervention. Publication four found that one quarter of women with GDM 
in one area of Scotland developed type 2 diabetes after a mean time period of eight years. 
This study, alongside the systematic review by Kim et al. (2002) which found that 
incidence of type 2 diabetes was most rapid in the first five years after GDM and 
plateaued after ten years, suggests that an intervention for women who have had GDM 
should ideally be provided within five years after women deliver to allow time for 
lifestyle changes to be made. 
Publication four reported that increased weight during pregnancy, use of insulin during 
pregnancy, higher HbA1c levels at diagnosis of GDM and fasting blood glucose were all 
 144 
 
associated with an increased risk of developing type 2 diabetes after GDM. Of these 
factors, increased weight and FPG were most consistently supported by previous 
literature suggesting that women with these risk factors should be targeted for 
intervention. However, the practicalities of targeting women with these risk factors would 
need to be considered as the effort needed to identify these women may not prove to be 
time or cost effective. This is something that would need to be explored with stakeholders 
during the later stages of intervention development described below.  
The second stage of the 6SQuID framework is to clarify which causal factors are 
malleable and have greatest scope for change (Wight et al. 2016). Causal factors for GDM 
include increased maternal age, obesity, ethnicity and family history of diabetes (Bellamy 
et al. 2009). Of these factors, diet and physical activity behaviours associated with obesity 
are the causal factors that have the clearest scope for change and are therefore an 
appropriate target for intervention. A review of research examining health behaviours in 
women with previous GDM found that they are less likely to meet physical activity 
recommendations and less likely to have adequate intake of fruit and vegetables (Jones 
et al. 2009). The finding of the Jones et al. (2009) study and the difficulties reported by 
women in publication five in maintaining a healthy diet and physical activity levels 
suggest that there is scope to improve both physical activity levels and dietary behaviour 
in women with previous GDM.  
Women interviewed for publication five were generally open to receiving an intervention 
to address either diet or physical activity, but some women expressed a preference for 
support for changing one of these behaviours over the other. A review of postpartum 
lifestyle interventions to prevent type 2 diabetes in women with previous GDM found 
that effective interventions typically included changes to diet and physical activity (Guo 
et al. 2016).  These findings suggest that an intervention for women with previous GDM 
should target both diet and physical activity but with the option to tailor the intervention 
to address a single behaviour according to individual preference.  
The third stage of intervention development, according to the 6SQuID framework, is to 
identify how to bring about change. The authors of the framework argue that the best 
developed interventions are based on theories of behaviour change (Wight et al. 2016). 
The semi-structured interviews conducted in publication five were informed by 
psychological theory and are therefore particularly helpful for identifying the potential 
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mechanism of change in an intervention for women with previous GDM. The interviews 
identified several illness perceptions that could be addressed by an intervention, in 
particular those relating to identity and consequences of GDM and timeline and 
consequences of type 2 diabetes. Specifically, many women did not see GDM as an 
important, or in some cases a real diagnosis, because of the minimal impact that it had on 
their lives. Similarly, women were unconcerned about their future risk of type 2 diabetes.  
In some women the lack of follow up care reinforced their perception that GDM and type 
2 diabetes were not serious conditions. 
According to Leventhal’s SRM of illness (1992), women with GDM will interpret 
information about their diagnosis to build up an understanding of the condition formed 
around various illness perceptions (identity, cause, timeline, consequences, control/cure 
and coherence). The model proposes that the way women respond to their illness is 
influenced by both these perceptions and by their emotional response to the illness 
(Leventhal et al. 1992). Consistent with this model, women in the present study reported 
that they were motivated to make changes to their diet by concern for their baby’s health, 
but most did not maintain these changes after giving birth as they viewed their GDM as 
being resolved. By addressing identity and consequences of GDM and timeline and 
consequences of type 2 diabetes in an intervention, the aim is that women will view 
lifestyle change as an appropriate and successful coping strategy for preventing future 
type 2 diabetes. Furthermore, it is hoped that receiving additional aftercare in the form of 
a preventative intervention will indirectly alter perceptions about the seriousness of GDM 
and type 2 diabetes.  
Other findings in publication five that are important for intervention development are 
those regarding the barriers to lifestyle change in the postnatal period. Tiredness, lack of 
energy and the demands of looking after a new baby were highlighted as barriers to 
lifestyle change by women interviewed in publication five. The TPB proposes that 
someone’s perceived ability to perform a given behaviour (perceived behavioural 
control), such as physical activity or dietary changes, has both a direct influence on the 
behaviour and an indirect influence via intention (Ajzen 1992). The TPB predicts that 
even if women intend to maintain lifestyle changes after giving birth, a belief that they 
are not able to because of barriers such as lack of energy may prevent them from being 
successful. Addressing perceived behavioural control is particularly important in an 
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intervention for women with previous GDM as some women reported feeling concerned 
or fearful about their diagnosis of GDM or their future risk of type 2 diabetes. Research 
has shown that fear of a disease without a concurrent message to encourage the 
individual’s confidence in their ability to prevent the disease can result in lower 
motivation and defensive coping responses such as avoidance (Witte and Allen 2000).   
The findings of publication five show that although there were some commonalities in 
the perceptions and beliefs held by women with previous GDM, the variations found from 
individual to individual suggest that an intervention would need to be tailored according 
to the women’s specific beliefs and perceptions. In particular, it may be valuable to assess 
illness perceptions in relation to GDM and type 2 diabetes and perceived behavioural 
control for postnatal lifestyle change and tailor the intervention according to the specific 
beliefs and perceptions held by individual women.  
After identifying the mechanism of change, the next step in the 6SQuID framework is to 
identify how to deliver the change mechanism. The demands on women in the postpartum 
period reported in publication five and other research (Lie et al 2013; McMillan et al. 
2018), and issues with recruitment to previous postnatal preventative interventions in 
women with GDM (Gilinsky et al. 2015), highlight the importance of careful 
consideration of the optimal timing and method of delivery for an intervention in this 
group. It has been suggested that the optimum time for starting a preventative lifestyle 
intervention is soon after the diagnosis of GDM during pregnancy (Ferrara et al. 2011). 
Ferrara et al. (2011) argue that a diagnosis of GDM is a teachable moment and that an 
intervention started soon after this diagnosis can take advantage of the motivation women 
have to make lifestyle changes driven by concern for their baby’s health. However, the 
findings of publication five and other research in the UK show that women in the UK are 
largely satisfied with the support they receive after a diagnosis of GDM to help them 
make the necessary lifestyle changes, and that the motivation to make lifestyle changes 
in response to a diagnosis of GDM was not sufficient for change to be maintained 
postnatally (Lie et al 2013). Women in these studies did however highlight a lack of care 
and a sense of abandonment in the postnatal period, suggesting that in the UK context an 
intervention delivered in the postnatal period may be most appropriate.  
The findings of publication five and other qualitative research (Lie et al. 2013; Parsons 
et al. 2014) suggest that the early postnatal period may be too soon for a preventative 
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intervention because of the demands of looking after a new-born baby and recovery from 
childbirth. The study by Lie et al. (2013) suggested that women may be receptive to an 
intervention when their baby is around six months old and they have starting weaning as 
women report feeling conscious of their own and their baby’s eating habits at this time. 
Although this research points to the latter half of the first year postnatally as being an 
appropriate time to deliver an intervention, the acceptability of this timing would need to 
be explored as part of the assessment of the feasibility of an intervention. 
In addition to the timing of an intervention for women with previous GDM, the mode of 
delivery also needs to be considered. An intervention for this group of women needs to 
be delivered in a way that takes account of their family and work commitments. One 
possible approach to intervention delivery that might help to minimise some of these 
barriers would be to deliver an intervention during women’s existing health care 
appointments complemented with mobile health technology.  
Clinical guidance in Scotland and England recommends that women with GDM are tested 
for diabetes approximately six weeks postpartum and annually thereafter (SIGN 2014; 
NICE 2008). These appointments could offer an opportunity for delivering a preventative 
intervention to women with GDM. However, a retrospective study of 127 primary care 
practices in England found that postpartum testing was only performed in 18.5% of 
women within six months of delivery and annual rates of postpartum testing were only 
around 20% (McGovern et al. 2014). While there are no studies assessing uptake of 
postnatal testing for diabetes in Scotland, findings from the interviews conducted for 
publication five (findings related to postnatal testing were not discussed in the 
publication) suggest that postnatal testing in Scotland is also far from universal.  These 
findings suggest that at present alternative opportunities to deliver preventative 
interventions need to be explored. I am involved in a study due to commence in 2019 that 
will assess the feasibility of delivering preventative interventions to women with previous 
GDM during health visitor appointments or cervical screening appointments (Evans et al. 
2018).   
Mobile technology is an avenue for intervention delivery in health that is receiving 
increased attention with the worldwide spread of mobile technologies. Mobile health 
technology is defined by WHO as medical or public health practices supported by mobile 
devices such as mobile phones or other wireless devices (WHO 2011b). Mobile devices 
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have a range of functions that may be utilised in health interventions, including text and 
media messages, telephone, web access, multimedia playback, social media and other 
applications (Free et al. 2013). Mobile health interventions have been applied to health 
behaviour change (e.g. smoking cessation) and to improve disease management (e.g. 
management of diabetes; Free et al. 2013).  
Advantages of mobile health technology interventions is that they are typically low cost, 
can be tailored to individual patients and can be used to relay data directly to the 
researcher. The flexibility and convenience that mobile health technology offers may 
mean that this approach would be well suited to women with young babies (McMillan et 
al. 2016). There is some evidence to support the effectiveness of mobile technology in 
health behaviour change interventions (Afshin et al. 2016) and findings from semi-
structured interviews with 27 women recruited from one hospital in England suggest that 
women feel there is a role for technology in supporting lifestyle change postnatally. These 
findings together suggest that an intervention combining existing health appointments 
and mobile technology may be a suitable approach for a lifestyle intervention for women 
with previous GDM.  
As discussed in the section on intervention development for people with IGR, the final 
steps of the 6SQuID framework are to test and refine the intervention on a small scale 
and collect sufficient evidence of effectiveness to justify rigorous 
evaluation/implementation (Wight et al. 2016). The findings of this thesis contribute to 
understanding of the early stages of this framework and provide a basis for further 
research to explore the latter stages of the framework. The findings of the thesis provide 
clear suggestions for the content, timing and mode of delivery for interventions to prevent 
type 2 diabetes in women with previous GDM. Further research is needed to explore the 
feasibility and acceptability of these suggested avenues for intervention.  
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Appendix 2 
Supplementary file for publication 1 containing table 2. 
Table 2: Characteristics of included studies. 
First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
IGT 
Andersson 
Sweden 
2002-2005  
Stratified random 
sample of two areas 
drawn from census 
(Vara and Skövde; 
population approx. 
66,000). 
2502 Men: 
46.8 
Women
: 46.5 
30-75 48 WHO 1999 
(3) 
NR 7.1% (5.6-
8.5) 
9.6% (8-
11.2) 
NR 1 
Brohall 
Sweden 
2001-2004  
 
Whole population of 
women aged 64 in 
one region drawn 
from county register 
(Gothenburg; 
population 4856). 
2595 N/A 64 
only 
0 WHO 1999 
(3) 
N/A N/A 22% (20.4-
23.6) 
N/A 2 
 
Castell 
Spain 
1994-1995 
Stratified random 
sample of 41 towns 
drawn from census 
2214 NR 30-89 44.1 WHO 1985 
(2) 
Age and 
sex 
standard
ised 
11.6% 
Age 
standardise
d 11.2% 
(9.2 – 13.2) 
Age 
standardise
d 12% 
(10.2-13.8) 
Significa
nt 
increase 
with age 
in men 
2 
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Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 (population 
3,495,434) 
 
(10.3-
12.9) 
 and 
women 
Chatuverdi 
UK 
NR 
(published 
1994) 
 
Stratified random 
sample of patients 
from six GP 
surgeries in one area 
of a city drawn from  
GP lists (Brent, 
London) 
 
1166 NR 46-64 46.7 WHO 1985 
(52 or 4?) 
9.1% 
(6.8-
11.4) 
9.1% (5.8-
12.6) 
9.0% (5.8-
12.2) 
NR 2 
Cruickshan
k UK  
NR 
(published 
1991) 
 
Stratified random 
sample of two 
practices in one area 
of a city (North-West 
London) drawn from 
family practitioner 
committee 
population registries 
 
 
101 Men:  
62 (7) 
Women
: 60.3 
(7) 
45-74 48.5 WHO 1985 
(2 or 4?) 
18.8% 
(11.2-
26.4) 
Age 
adjusted 
prevalence: 
25% (12-
37) 
Age 
adjusted 
prevalence: 
14% (4-23) 
NR 1 
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Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Garancini 
Italy 
1990 
 
Random sample of 
three areas 
(Cremona, 
Casalbuttano and 
Vescovato; 
population 38634) 
drawn from those 
registered on 
regional list. 
1797 NR 45+ 43 WHO 1980 
(1) 
8.4% 
(7.1-9.7) 
7.7% (5.7-
9.7)  
8.9% (7-
10.8) 
Significa
nt 
increase 
with age 
in men 
and 
women 
2 
Hiltunen 
Finland 
1992 
 
Whole population 
aged 70 to 93 years 
in three areas 
(Kempele, Oulunsalo 
and Hailuoto; 
population 501) 
drawn from official 
population registries 
(residents legally 
required to register). 
379 Men: 
75.7 
(4.9) 
Women
:  76.8 
(5) 
70-93 37 WHO 1985 
(2) 
34% 
(29.3-
38.8) 
31.9% 
(24.2-39.6) 
35.3% 
(29.2-41.4) 
NR 1 
Larsson 
Sweden 
Whole population of 
women aged 55-57 
in one area (Malmö; 
population 2745). 
1843 NR 55-57 0 WHO 1985 
(2) 
N/A N/A 27.9% 
(25.9-30.0) 
NR 3 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
1986-1987 
and 1990-
1991 
 
Doesn’t report where 
names drawn from.  
 
Mykkänen 
Finland 
1986-1988 
 
Random sample of 
one area (Kuopio) 
drawn from 
population registry. 
 
1300 Men: 
68.9 
Women
: 69.1 
65-74 36.2 WHO 1985 
(4) 
18.6 
(16.5-
20.7) 
17.8% 
(14.4—
21.3)  
 
19.1% 
(16.4-21.7) 
NR 1 
Rajala 
Finland 
1992 
 
Whole population 
aged 55 in one area 
(Oulu; population 
1008). Doesn’t 
report where names 
drawn from. 
717 
 
N/A 55 
only 
43 WHO 1985 
(2) 
27% 
(24.2-
30.7) 
28.6% 
(23.5-33.6)   
26.7% 
(22.4-30.9) 
NR 3 
Tuomileho 
Finland 
1984 
 
Whole population of 
men aged 65-84 in 
two areas. Doesn’t 
report where names 
drawn from. 
763 72.6 65-84 100 WHO 1995 
(2) 
N/A 31.8% 
(28.4-35.3) 
N/A No 
significan
t increase 
found 
with age.  
3  
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Unwin 
UK 
1993-1994 
 
Systematic stratified 
sample in one region 
(Newcastle; 
population 6448) 
drawn from 
Newcastle family 
health services 
authority patient 
register. 
610 NR 25-64 49.6 WHO 1985 
(2) 
10.1 
(7.7-
12.4) 
12.8 
(10.1-
15.4) 
 12.5% 
(8.8-16.2) 
Age 
adjusted 
9.7% (6.4-
13.0)13.1% 
(9.3-16.8) 
 NR 2 
Verrillo  
Italy 
1981-1982 
 
Whole population 
aged over 18 in one 
area (Sanza; 
population 1362) 
drawn from registry 
office data.  
1154 NR 18-92 45.8 WHO 1980 
(1) 
6.4% (5-
7.8) 
4.9% (3.1-
6.8)  
7.7% (5.6-
9.8) 
Age 
adjusted: 
7.9% 
Significa
nt 
increase 
with age 
in men 
and 
women. 
 
1 
 
IFG 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Almoosawi 
UK 
2008 
 
Random cluster 
sample from the 
whole of UK drawn 
from postcode 
address file. Those 
who completed 3 or 
4 days of a diet diary 
were eligible to give 
a blood sample. 
 
633 NR 19+ 41 Fasting 6.1-
6.9mmol/l 
(2) 
8.7 (6.5-
10.9) 
 
10.5% (6.7-
14.2)  
7.5% (4.8-
10.1) 
Significa
nt 
increase 
in age for 
women 
but not 
men. 
 
3 
Baena-
Díez, 
Spain 
1995 and 
2000 
 
Stratified random 
sample of 33 towns 
in one area (Girona; 
population 303,903) 
drawn from census. 
 
4801 NR 25-74 48.5 Fasting 6.1-
6.9 mmol/l 
(2) 
10% NR NR NR 1 
Bernal-
Lopez 
 Spain 
2007 
Random sample of 
one health centre in 
Malaga (population 
29,818) drawn from 
health centre list.  
2144 42 
(15.2) 
18-80 49.9 ADA 2003 
(1) 
16.3%  
(14.7-
17.8) 
NR NR NR 2 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 
Bonaldi 
France 
2006-2007 
 
Stratified random 
sample of whole 
country drawn from 
phone lists.  
2012 NR  18-74 37 WHO 1999 
and ADA 
2003 (1+2) 
WHO 
1999: 
5.6% 
(4.3-7.4) 
ADA 
2003:  
15.5% 
(13.2-
18.1) 
WHO 
1999: 7.9% 
(5.7-10.9)  
ADA 2003: 
19.9% (16-
24.5)  
WHO 
1999: 3.4% 
(2.3-5.1) 
ADA 2003: 
11.2% (8.9-
13.8) 
No 
significan
t increase. 
3 
Bourdel-
Marchasso
n 
France 
1999-2001 
 
Whole population 
aged 65 and over in 
three areas 
(Bordeaux, Dijon, 
Montpellier; 
population 
1,134,321) drawn 
from electoral 
register. 
8564 74.2 
(5.5) 
 
65+ 39.3 WHO 1999 
(2) 
3.6% 
(3.3-4.1) 
4.2% (3.6-
4.9)  
2.8% (2.4-
3.3). 
NR 3 
Gasull 
Spain 
Random sample of 
one area (Catalonia; 
population 
886 45.1 
(15) 
18-74 42.9 WHO 2006 
(2) 
23% 
(20.0-
25.6) 
Subjects 
with IFG 
significantl
y more 
 NR 3 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
2002 
 
  
6,506,440) drawn 
from census.   
likely to be 
male than 
those 
without 
IFG. 
Gourdy 
France 
1995-1997 
 
Stratified random 
sample of three areas 
(Lille, Bas-Rhin, 
Haute-Garonne) 
drawn from electoral 
register.  
3248 NR 35-64 50.9 ADA 1997 
(2) 
Age 
adjusted: 
8.5% 
(7.6-9.4) 
12.3% 
(10.7-13.8) 
5.6% (4.5-
6.7) 
Significa
nt 
increase 
with age 
in men 
and 
women  
2 
 
Muntoni  
Italy 
2002-2005 
 
Stratified random 
sample of four areas 
(Ploaghe, Sorso, 
Sinnai, 
Maracalagonis; 
population 39,624) 
drawn from 
municipal records.  
4737 NR 20+ 47 WHO 1999 
(2) 
10.3% 
(9.4-
11.2) 
12.2% 
(12.1-12.4)  
 
9.9% ( 9.7-
10.1) 
NR 1 
 
Panagiotak
os Greece 
Random sample of 
one area (Attica). 
3042 NR 18-89 49.7 ADA 2006 
(1) 
16.2% 
(14.9-
17.5) 
20.5% 
(18.4-22.5)  
12% (10.4-
13.7) 
NR 3  
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
2001-2002 
 
Doesn’t report where 
names drawn from. 
Thomas  
UK 
1999-2001 
 
Random sample of 
patients from 24 
general practices 
across Britain drawn 
from general practice 
lists.  
7378 NR  60-79 50.6 WHO 1999 
(2) 
17.7 
(16.9-
18.6) 
17.9%  
(16.6-19.1) 
17.6% 
(16.4-18.9) 
NR 2 
 
Valverde 
Spain 
2006 
 
Stratified random 
sample of patients in 
the 12 health care 
centres in one region 
(Murcia; population 
901,920) drawn from 
health care centre 
lists.  
1570 47.4 
(17.7) 
20+ NR ADA 1997 
(2) 
4.9% 
(3.9-6.1) 
6.3% (4.6-
8.3)  
3.7% (2.5-
5.2) 
Significa
nt 
increases 
with age 
in both 
men and 
women 
2 
 
IGT and IFG 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Bennet 
Sweden 
2010 
Random sample of 
one area (Rosengård; 
approx. population 
22,000) drawn from 
census. 
 
79 NR 45-65 56 WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
10.1% 
(3.5-
16.8) 
IFG: 
15.2% 
(7.3-
23.1) 
NR NR NR 3 
Bonora  
Italy 
1990 
 
Random sample of 
one area (Bruneck; 
population 4793). 
Doesn’t report where 
names drawn from. 
 
 
 
 
919 NR 40-79 50.6 WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
5.7% 
(4.3-7.3) 
IFG: 
5.9% 
(4.5-7.5)  
IGT+IF
G: 2.1% 
(1.1-3.0) 
NR  NR NR 3 
Boronat 
Canary 
Stratified random 
sample of one area 
(Telde; population 
1030 48 
(11.9) 
30-82 43.5 WHO 1999 
(IGT not 
clear if 2 or 
4; IFG not 
IGT: 
10.4% 
Age 
adjusted 
Age 
adjusted 
NR 1 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Islands, 
Spain  
NR 
(published 
1998) 
 
42, 451) drawn from 
census. 
 
clear if 1 or 
3) 
(8.5-
12.3 
IFG: 
3.1%  
(2-4.2) 
 
IGT:11.4% 
(8.4-14.3)  
IFG: 3.3% 
(1.7-5.0)   
IGT: 9.6% 
(7.2-12.0 
IFG: 2.9% 
(1.6-4.3  
 
Cederberg 
Finland 
Baseline: 
1996-1998  
10 year 
follow up: 
2007-2008 
 
Whole population 
aged 61 to 63 in one 
area (Oulu; 
population 831). 
Doesn’t report where  
names drawn from. 
Baseline:49
9 
10 year 
follow up: 
384 
NR 61-63 40.3 WHO 1999 
for IGT (3) 
and IFG (3) 
Baseline 
IGT: 
18.7% 
(15.2-
22.1) 
IFG: 
7.2% 
(4.9-9.5)  
IGT+IF
G: 2.7% 
(1.2-4.0)  
Follow-
up 
Follow up 
IGT: 20.8% 
(14.7-27.0) 
IFG: 16.1% 
(12.5-19.8) 
Follow up 
IGT: 19.4% 
(14.6-24.2) 
IFG: 7% 
(4.5-9.6) 
NR 3 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
IGT: 
20% 
(16.2-
23.7)  
IFG: 
10.6% 
(7.6-
13.5)  
de Pablos-
Velasco 
Canary 
Islands, 
Spain  
NR 
(published 
2001) 
 
Stratified random 
sample of one town 
(Guia; population 
6355) drawn from 
municipal list.  
691 NR 30+ NR WHO 1985 
for IGT (2) 
and ADA 
1997 for 
IFG (2)  
IGT: 
17.1% 
(14.3-
19.9) 
IFG: 
8.8% 
(6.7-
10.9)  
 
IGT: 16.1% 
(11.9-20.2) 
IFG: 10.8% 
(7.3-14.3) 
 
IGT: 17.9% 
(14.1-21.7)  
IFG: 7.3% 
( 4.7-9.8) 
No 
significan
t 
increases 
in IFG 
with age 
for men 
or 
women. 
Significa
nt 
increase 
in IGT 
for men 
only 
between 
those 
1 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
aged 30-
39 (6.1%; 
-0.6-12.8) 
and those 
aged 80+ 
(19%; 
2.3-35.8) 
de Vegt 
plus Heine 
and Mooy 
Netherland
s  
1989-1992 
 
Random sample of 
one town (Hoorn, 
population 57,000) 
drawn from 
population register. 
2378 Men: 
61.2 
(7.3) 
Women
: 61.8 
(7.4) 
50-74 46 WHO 1985 
for IGT (4) 
and ADA 
1997 for 
IFG (2) 
IGT: 
10.3% 
(9.1-
11.5)  
IFG:  
12% 
(10.7-
13.3) 
 
IGT: 9.2 
(7.5-10.9)  
IGT: 11.2 
(9.6-12.8) 
IGT 
appears to 
increase 
with age 
for men 
and 
women 
but no 
CIs or 
significan
ce testing.  
1 
Gardete-
Correia 
Portugal 
2009 
Random sample of 
122 areas drawn 
from census.  
5167 NR 20-79 NR WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
12.6% 
(11.6-
13.6%) 
IFG: 
8.2% 
IGT: 12.1 
(10.7-13.5)  
IFG: 11.8 
(10.4-13.2) 
IGT: 13.2 
(12.0-14.4) 
IFG: 6.0 
(5.2-6.8) 
Significa
nt 
increases 
with age 
for IGT, 
1 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 (7.4-
9.0%) 
IGT + 
IFG: 
2.4% 
(1.9-2.9) 
IGT+IFG: 
2.9 (2.2-
3.6)  
 
IGT+IFG: 
2.1 (1.6-
2.6) 
IFG and 
IGT+IFG. 
 
Glümer 
plus 
Borch-
Johnsen 
Denmark 
1999-2001 
 
 
 
 
Stratified random 
sample of one area of 
a city (Copenhagen; 
population 13,016) 
drawn from civil 
registration system.  
6784 46 (7.9) 30-60 48.7 WHO 1999 
for IGT (3) 
and WHO 
1999 and 
ADA 2003 
(1+3) 
WHO 
1999  
IGT: 
12% 
(11.2-
12.8) 
IFG: 
11.8% 
(11.0-
12.6) 
ADA 
2003 
IFG: 
37.6% 
IGT: 30-35 
years 
9.9% 
IFG 
significantl
y higher in 
men  
IGT: 30-35 
years 
5.8% 
NR 2 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
(36.4-
38.8)  
Harris  
UK 
1994-1996 
 
Random sample of 
patients in 9 general 
practices in area of a 
city (Wandsworth, 
London) drawn from 
general practice lists. 
380 49.8 40-59 NR WHO 1999 
for IGT (3). 
ADA 1997 
and WHO 
1999 for 
IFG (2+3) 
WHO 
1999 
IGT: 
7.9% 
(5.2-
10.6) 
IFG: 
1.6% 
(0.3-2.8) 
ADA 
1997 
IFG: 
2.9% 
(1.2-4.6) 
NR NR NR 2 
Lilja plus 
Eliasson  
Sweden 
Stratified random 
sample of two areas 
drawn (Norbotten 
and Vaserbotten) 
2830 NR 25-64 48 WHO 2006 
for IGT (2) 
and IFG (2) 
1990 
IGT 
5.8% 
(4.2-7.4) 
1990 
IGT: 3.5% 
(1.1-6.0); 
1990 
IGT: 7.8% 
(5.0-10.7) 
NR 1 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
1990, 
1994, 2004 
and 2009 
 
from population 
registry.  
IFG 
7.2% 
(5.4-9) 
1994 
IGT 
7.5% 
(5.6-9.3) 
IFG 
5.6% (4-
7.3) 
2004 
IGT 
7.5% 
(5.6-9.5) 
IFG 
12.1% 
(9.7-
14.5) 
2009 
IGT 
12.4% 
IFG: 10.1% 
(7.0-13.2) 
1994 
IGT: 6.7% 
(4.3-9.2) 
IFG: 9.3% 
(6.2-12.4) 
2004 
IGT: 5.4% 
(2.9-7.9) 
IFG: 10.6% 
(7.6-13.6) 
2009 
IGT: 10.1% 
(7.2-12.9) 
IFG: 12.6% 
(9.1-16.2) 
IFG: 4.5% 
(2.2-6.7) 
1994 
IGT: 
8.2%(5.3-
11.1) 
IFG: 2.0% 
(0-4.4) 
2004 
IGT: 9.7% 
(6.6-12.8) 
IFG: 10.5% 
(8.2-12.8) 
2009 
IGT: 14.5% 
(11.2-17.9) 
IFG: 7.7% 
(5.0-10.4) 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
(9.7-
15.1) 
IFG 
10.3% 
(7.8-
12.8) 
López  
Spain 
2004 
 
Random cluster 
sample of one area 
(Galicia) drawn from 
public health service 
database. 
2848 41.4 
(15) 
18-85 46.4 ADA 2002  
for IGT (3) 
and IFG (3) 
IGT: 4% 
(3.3-4.7) 
IFG: 
12.9% 
(11.7-
14.1)  
IGT+IF
G: 4% 
(3.3-4.7)  
NR NR NR 3 
Meisinger  
Germany 
2006-2008 
Stratified random 
sample of one region 
(Augsburg; approx. 
population 600,000) 
drawn from 
population registries. 
1653 NR 35-59 54.2 WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
6.3% 
(5.1-7.4) 
IFG: 
2.9% 
(2.1-3.7) 
IGT: 6.4% 
(4.7-8.1). 
IFG: 4.2% 
(2.8-5.7)  
IGT: 6.3% 
(4.7-7.8) 
IFG: 1.9% 
(1.1-2.8)  
IFG, IGT 
and 
IGT+IFG 
increased 
with age. 
 
2 
 204 
 
First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 IGT+IF
G: 1.1% 
(0.6-
1.5). 
IGT+IFG: 
1.7% (0.8-
2.6) 
IGT+IFG: 
0.6% (0.1-
1.0) 
Qiao  
plus 
Tuomileht
o Finland 
1987 
 
Stratified random 
sample of three areas 
(North Karelia, 
Kuopio, Turku-
Loimaa) drawn from 
population register.  
2718 NR 45-64 46.9 WHO 1985 
and 1999  
for IGT 
(2+3) and 
WHO 1999 
for IFG (3) 
 
WHO 
1985 
IGT: 
4.3% 
(3.6-5.1) 
WHO 
1999  
IGT: 
12.4% 
(11.2-
13.6) 
IFG: 4% 
(3.3-4.7) 
IGT+IF
G: 1.5% 
(1.1-2.0) 
WHO 1985  
IGT 3% 
(2.0-3.9)  
 
WHO 1985  
IGT 5.5% 
(4.4-6.7) 
IGT 
appears to 
increase 
with age 
but no 
CIs or 
significan
ce testing.  
2 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Rathmann 
Germany 
1999-2001 
 
Stratified random 
sample of one region 
(Augsburg; approx. 
population 600,000) 
drawn from 
population registries.  
1353 NR  55-74 
 
NR WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
16.4% 
(13.8-
18.2) 
IFG: 7% 
(5.9-8.1) 
 
IGT: 16.8% 
(14.1-19.4) 
IFG: 9.8% 
(7.6-11.8)   
 
IGT: 16% 
(13.3-18.6) 
IFG: 4.5% 
( 3.0-6.0)  
 
Group 1  
IGT 
increased 
with age 
in both 
sexes 
(p<0.001)
.  IFG 
increase 
with age 
in women 
only 
(p<0.05). 
 
2 
Saaristo 
Plus 
Wikström 
Finland 
2004-2005 
 
Stratified random 
sample of three areas 
(Pikanmaa, South 
Ostrobothnia and 
Central Finland) 
drawn from 
population register.  
2824 59.8 
(8.5) 
45-74 48.2
% 
WHO 1999 
for IGT (3) 
and IFG (3) 
 
IGT: 
16.2% 
(14.9-
17.6) 
IFG: 
7.5(6.5-
8.5) 
IGT: 15.5% 
(13.5-17.6) 
IFG: 10% 
(8.2-11.8). 
IGT: 17% 
(15-19.1). 
IFG: 5.2% 
(3.9-6.5). 
IGT 
significan
tly 
increased 
in men 
and 
women 
with age. 
IFG 
significan
2 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 
 
 tly 
increased 
with age 
in men 
but not 
women. 
Soriguer, 
Goday  
Spain 
2009-2010 
 
 
 
Random cluster 
sample of whole 
country. Doesn’t 
report where names 
drawn from. 
3090 NR 18+ 41.6 WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
9.2% 
(8.2 – 
10.2) 
IFG: 
3.4% 
(2.9-4.0) 
IGT+IF
G: 2.2% 
(1.7-2.7) 
Prevalence 
of IGR 
significantl
y greater in 
men. 
 Prevalenc
e of IGR 
significan
tly 
increases 
with age.  
3 
Soriguer, 
Rojo-
Martínez 
Spain 
1997-1998 
Random sample of 
one town (Pizarra; 
population 6,600) 
drawn from census.  
910 38.9 
(13) 
18-65 NR WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
9.7% 
(7.8-
11.6)  
IFG: 
14.2% 
NR NR NR 1 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 (11.9-
16.4)  
IGT+IF
G: 4.5% 
(3.2-5.9) 
Valdés 
Spain 
1998-1999 
 
Random sample of 
people from in one 
area (Asturia). 
Doesn’t report where 
names drawn from. 
1034 NR 30-75 NR WHO 1999 
for IGT (3) 
and IFG (3) 
 
 
 
 
 
IGT: 
8.9% 
(7.2-
10.6)  
IFG: 
4.1% 
(2.9-5.3)  
IGT+IF
G: 3.5% 
(2.4-
4.6). 
NR NR NR 3 
Webb  
UK 
2005-2008 
Random sample of 
patients from 20 
general practices in 
one city (Leicester; 
population 149,311) 
4688 54.3 
(10.5) 
40-75 50.2 WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
9.1% 
(8.2-9.9)  
NR NR NR 3 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
 drawn from general 
practice list. 
 
IFG: 
2.7% 
(2.2-3.1)  
IGT+IF
G: 1.7% 
(1.4-2.1) 
 
Wild 
UK 
1988-1989 
 
Stratified random 
sample of patients 
from 11 general 
practices in one city 
(Edinburgh) drawn 
from general practice 
lists. 
 
 
 
1592 NR 55-74 51 WHO 1999 
for IGT (3) 
and IFG (3) 
IGT: 
8.1% 
(6.8-9.4) 
IFG: 
11.6% 
(10.0-
13.2) 
IGT+IF
G: 3.2% 
(2.3-4.1) 
IGT: 10.5% 
(8.3-12.6)  
IFG: 14% 
(11.6-16.5) 
IGT+IFG: 
4.2% (2.8-
5.6)  
IGT: 5.6% 
(3.9-7.2) 
IFG: 8.5% 
(6.5-10.5) 
IGT+IFG: 
2.4% (1.3-
3.5). 
NR 2 
Williams 
plus 
Forouhi  
Random sample of 
people aged 40-64 in 
one general practice 
in the city of Ely 
1122 NR 40-64 43 WHO 1985 
for IGT 
(unclear if 
2 or 4). 
IGT: 
16.7% 
IGT: 14.7 
(11.6-17.8)  
ADA 1997 
IGT: 17.4 
(14.5-20.3) 
NR 1 
 209 
 
First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
UK 
1990-1992 
 
(approx. population 
4922).  
ADA 1997 
and ADA 
2003 for 
IFG (1+2) 
(14.5-
18.8)  
ADA 
1997 
IFG: 
24.7% 
(22.1-
27.3)  
ADA 
2003 
IFG: 
36.1% 
(33.1-
39)  
IFG: 32.5% 
(28.2-36.9) 
ADA 2003 
IFG: 39.2% 
(34.5-43.5)   
  
ADA 1997 
IFG: 18.9% 
(15.7-22.0) 
ADA 2003 
IFG: 33.8% 
(30.0-37.6) 
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First 
Author, 
Country, 
Years data 
collected  
Sampling Method Sample 
Size  
Mean 
Age 
(SD) 
Age 
Range 
% 
Male 
Criteria 
Used 
(category) 
Prevalence (95% CI) Quality 
Score (1 
higher 
to 3 
lower 
quality) 
Overall Male Female By age 
Ylihärsilä 
Finland 
1992 
 
 
Stratified sample 
from three areas 
(North Karelia, 
Kuopio, Turku-
Loimaa) drawn from 
the population 
register 
2087 NR 45-64 45.8 WHO 1999 
for IGT (3). 
WHO 1999 
and ADA 
1997 for 
IFG (3+2) 
WHO 
1999 
IGT 
10% 
(8.7-
11.3) 
IFG 
8.8% 
(7.6-
10.0) 
ADA 
1997 
IFG 
13% 
(11.6-
14.5) 
WHO 1999 
IGT 10.8% 
(8.8-12.7) 
IFG 13.4% 
(11.2-15.5)  
ADA 1997 
IFG 18.6% 
(16.2-21.1)  
WHO 1999 
IGT 9.4% 
(7.7-11.1) 
IFG 4.9% 
(3.6-6.1) 
ADA 1997 
IFG 8.3% 
(6.7-9.9) 
IGT 
significan
tly 
increased 
with age  
No 
significan
t increase 
in IFG 
with age. 
1 
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PDF of published manuscript for publication 1. 
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Appendix 4 
Supplementary file for publication 2 containing table 8. 
 
Table 8: Characteristics of studies included in the review  
First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Åberg, 
Sweden, 
1995-1999 
Prospective 
study of all 
singleton 
pregnant 
women in one 
geographical 
area 
12,382 NR NR NR NR One step: 
75g OGTT  
27-28 GDM if 2 hour 
value of 
9mmol/l or 
more 
1.2% (1.0-
1.4) 
2 
Alberico, 
Italy, 1997-
2000 
Prospective 
study of all 
pregnant 
women at one 
clinic 
856 32.5 NR 61%  NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
6.6% (4.9-
8.2) 
3 
Anderberg, 
Sweden, 
1991-2003 
Retrospective 
of all pregnant 
women in one 
129,143 NR NR NR NR One step: 
75g OGTT 
28 GDM if 2 hour 
value of 
1.2 (1.2-
1.3) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
geographical 
area 
9mmol/l or 
more 
Avalos, 
Ireland, 
2007-2009 
Retrospective 
study of all 
pregnant 
women at five 
clinics 
5,500 32 
(5.3) 
26.9 
(5.1) 
NR 32% in 
1st or 2nd 
degree  
One step: 
75g OGTT 
24-28 OGTT 
interpreted 
according to 
IADPSG and 
WHO 2006 
IADPSG: 
12.4% 
(11.5-13.3) 
WHO 
2006: 9.4% 
(8.7-10.2) 
3 
Breschi, 
Italy, 1988-
1991 
Prospective 
study of all 
pregnant 
women at one 
clinic 
539 29.4 
(4.6) 
22.5 
(3.3) 
Mean: 
1.7 
34.2%  One step: 
100g 
OGTT 
Mean = 26 OGTT 
interpreted 
according to 
NDDG 
3.2% (1.7-
4.6) 
3 
Bugallo, 
Spain, 2004-
2006 
Retrospective 
study of all 
pregnant 
women at one 
hospital 
11,628 30 (6) NR NR NR Two step: 
those with 
positive 
50g GCT 
given 100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
6.4% (5.9-
6.9) 
1 
Cauza, 
Austria, 
1999-2001 
Prospective 
study of all 
pregnant 
women at one 
hospital 
2,421 NR NR NR NR One step: 
75g OGTT 
24-28 GDM if 1 hour 
value of 
8.9mmol/l or 
more 
8.6% (7.5-
9.7) 
3 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Chevalier, 
France, 
2002-2006 
Prospective 
study of all 
pregnant 
women at one 
hospital 
11,545 NR NR 46%  NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 
7.2mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
4.3% (3.9-
4.6) 
1 
Chico, Spain, 
1999-2001 
Retrospective 
study of all 
pregnant 
women at a set 
of clinics 
6,428 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
NDDG 
Carpenter and 
Coustan 
NDDG: 
6.5% (5.9-
7.1) 
Carpenter 
and 
Coustan:  
6.8% (6.1-
7.4) 
1 
Coolen, 
Belgium, 
2008 
Prospective 
study of all 
pregnant 
women 
attending one 
clinic 
317 30.6(0.
3) 
NR 33.9%  NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28  GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
3.2% (1.2-
5.1) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Carpenter and 
Coustan 
Cordero, 
Spain, NR 
Randomised 
controlled trial 
of pregnant 
women in one 
area.  
156 32.9 
(4.5) 
23.6 (4) 47.4%  14.1% 
1st 
degree 
and 32% 
2nd 
degree.  
Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
NDDG 
8.3% (4-
12.7) 
2 
Corrado, 
Italy, 1990 
Retrospective 
study of all 
singleton 
pregnant 
women seen 
by 6 
obstetricians 
738 NR NR NR NR One step: 
75g OGTT 
24-28 OGTT 
interpreted 
according to 
IADPSG 
11.9% (9.6-
14.3) 
1 
Cosson, 
France, 2002 
Prospective 
study of all 
singleton 
pregnant 
women at one 
hospital 
2,111 29.2 
(5.8) 
23.4 
(4.7) 
Mean 
2.08 
(SD 
1.37) 
12.8% One step: 
75g OGTT 
24-28 OGTT 
interpreted 
according if 
fasting value 
5.3mmol/l or 
more (French 
recommendatio
ns) and/or 2 
hour value of 
7.8 mmol/l or 
12.6% 
(11.1-14.0) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
more 
(according to 
WHO 1999). 
Di Cianni, 
Italy, 1995-
2001 
Retrospective 
study of all 
pregnant 
women at one 
clinic. 
3,950 31.1 
(4.7) 
22.5 
(3.7) 
56.1%  17.1% Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
8.4% (7.6-
9.3) 
1 
Duran, 
Spain, 2011-
2012 cohort 
1 
Prospective 
study of all 
pregnant 
women at one 
hospital 
1,750 32 Median 
22.7 
43.9% 8.4% Two step: 
those with 
positive 
50g GCT 
given 100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
10.6% (9.1-
12.0) 
1 
Duran, 
Spain, 2012-
2013 cohort 
2 
All pregnant 
women at one 
hospital 
1,526 32 Median 
22.8 
44.7%  9.4% One step: 
75g OGTT  
24-28 GDM 
diagnosed 
according to 
IADPSG 
35.5% 
(33.1-37.9) 
1 
 224 
 
First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Fadl, 
Sweden, 
1991-2003 
Retrospective 
study of all 
singleton 
pregnant 
women in 
Sweden  
1,260,29
7 
NR NR 42% NR Two step: 
those with 
positive 
RBG given 
75g OGTT 
NR RBG of 
8mmol/l or 
higher 
considered 
positive. GDM 
diagnosed on 
basis of 75g 
OGTT if 
fasting value 
6.1mmol/l 
and/or 2 hour 
value of 
9mmol/l or 
more.  
  
 
0.84% 
(0.82-0.86) 
1 
Fedele, Italy, 
1990-1991 
Prospective 
study of all 
women 
attending 
family 
planning 
clinics in one 
area 
490 NR NR NR NR Two step: 
those with 
positive 
50g GCT 
given 100g 
OGTT 
High risk 
women 10-
14, 24-28 
and 30-32. 
Others 24-
28. 
GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
10.8% (8.1-
13.6) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Griffin, 
Ireland, NR 
All women 
attending one 
hospital 
randomised to 
selective or 
universal 
screening 
1299 27.4 
(5.6) 
During 
pregnan
cy 28.2 
(4) 
39.3% NR Two step: 
those with 
positive 
50g GCT 
given 100g 
OGTT 
26-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
2.7% (1.8-
3.6) 
2 
Ignell, 
Sweden, 
2014 
Retrospective 
study of all 
singleton 
pregnant 
women in two 
areas.  
156,144 NR NR NR NR One step: 
75g OGTT 
28 GDM if 2 hour 
value of 
9mmol/l or 
more 
2.2% (2.1-
2.3) 
1 
Janghornbani
, UK, 1996-
1997 
Prospective 
study of all 
pregnant 
women 
screened in 
one area.  
3,933 NR NR NR NR Two step: 
those with 
positive 
RBG given 
75g OGTT 
24-28 RBG of 
6.5mmol/l or 
more positive. 
GDM 
diagnosed 
according to 
OGTT if 2 
hour reading of 
11mmol/l or 
more 
1.7% (1.3-
2.1) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Jiménez-
Moleón, 
Spain, 1995 
 
Retrospective 
study of all 
singleton 
pregnant 
women in one 
hospital. 
1,962 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
NDDG 
3.3% (2.5-
4.1) 
1 
Kayema-
Kay, UK, 
1996-1997 
Prospective 
study of all 
singleton 
women at one 
hospital 
1484 NR NR NR NR One step: 
75g OGTT 
24-28 GDM if 2 hour 
value of 9.0 
mmol/l or 
more 
1.2% (0.7-
1.8 
 
Lacaria, 
Italy, 2012-
2013 
Prospective 
study of all 
pregnant 
women in two 
areas. 
2497 33.5 
(5) 
22.8 (4) NR NR One step: 
75g OGTT 
24-28 OGTT 
interpreted 
according to 
IADPSG 
10.9% 1 
Lind, UK, 
1984 
Prospective 
study of all 
singleton 
pregnant 
women in one 
clinic. 
2,285 NR NR NR NR Two step: 
those with 
positive 
RBG given 
75g OGTT 
28-32 RBG greater 
than 4.3mmol/l 
to 6.4mmol/l 
(depending on 
time since 
meal) 
considered 
positive. GDM 
diagnosed on 
0.3% (0.1-
0.5) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
the basis of 
OGTT 2 hour 
value of 
8.0mmol/l and 
above.  
Lindqvist, 
Sweden, 
2011-2012 
Population 
study of all 
pregnant 
women in 
areas where 
universal 
screening 
offered 
20,822 30 25 NR NR One step: 
75g OGTT 
NR GDM if 2 hour 
value  over  
10mmol/l 
2.2% (2-
2.4) 
1 
Malmqvist, 
Sweden, 
1999-2005 
Retrospective 
study of all 
singleton 
pregnant 
women in one 
area 
81,110 30.4 
(5) 
NR 47.3%  NR One step: 
75g OGTT 
28 GDM if 2 hour 
value  over  
10mmol/l 
2% (1.9-
2.1) 
1 
Meek, UK, 
2004-2008 
Retrospective 
study of all 
singleton 
pregnant 
women  in one 
area 
25,543 30.7(9
5% CI 
30.6-
30.8) 
24.8 
(95% CI 
24.6-
24.8) 
38.7%  NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
26-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of 75g 
OGTT 
interpreted 
4.9% (4.6-
5.2) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
according to 
IADPSG 
Miailhe, 
France, 
2011-2012 
Prospective 
study of all 
singleton 
pregnant 
women in one 
area 
2,187 NR 36% 
with 
BMI 
>25 
41.7%  NR One step: 
75g OGTT 
24-28 GDM 
diagnosed 
according to 
IADPSG 
14% (12.7-
15.6) 
1 
Murgia, 
Italy,  NR 
Prospective 
study of 
pregnant 
women at one 
clinic 
1,103 31 (5) 22.5 
(3.8) 
NR 14.2% 
1st 
degree 
Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
16-18, 24-
26 and 30-
32 
GCT of 7.2 
mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
16-18: 
6.6% (5.2-
8.1 
24-26: 
5.8% (4.4-
7.2) 
30-32: 
9.9% (8.1-
11.6) 
Total: 22.4 
(19.9-24.9) 
1 
Orecchio, 
Switzerland, 
2004-2005 
Prospective 
study of all 
singleton 
pregnant 
women at one 
hospital 
1,042 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT 
24-28 GCT of 7.8 
mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
4.8% (3.5-
6.1) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Carpenter and 
Coustan 
Oriot, 
Belgium, 
2009-2011, 
cohort 1 
Retrospective 
study of all 
pregnant 
women at one 
hospital 
1424 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT. 
24-28 GCT of 
7.8mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
8.2% (6.8-
9.6) 
2 
Oriot, 
Belgium, 
2011-2012, 
cohort 2 
Retrospective 
study of all 
pregnant 
women at one 
hospital 
1206 NR NR NR NR One step: 
75g OGTT 
24-28 GDM 
diagnosed 
according to 
IADPSG 
22.9% 
(20.5-25.3) 
2 
Östlund, 
Sweden,  
1994-1996 
 
Prospective 
study of all 
pregnant 
women in one 
area 
3,616 27.9 
(4.8) 
23.8 
(4.1) 
46%  9.4% One step: 
75g OGTT 
28-32 
  
GDM 
diagnosed 
according to 
IADPSG 
1.7% (1.3-
2.1) 
1 
Pérez-Ferre, 
Spain, 2007-
2008 
Retrospective 
study of all 
pregnant 
1,311 NR NR NR NR Two step: 
those with 
positive 
GCT given 
24-28 GCT of 
7.8mmol/l or 
more positive. 
5.4% (4.5-
7) 
1 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
 women in one 
area 
100g 
OGTT. 
Carbohydra
te rich diet 
followed 3 
days prior 
to OGTT. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
Pintaudi, 
Italy, 2010-
2011 
Retrospective 
study of all 
pregnant 
women at one 
clinic 
1,015 NR NR NR NR One step: 
75g OGTT 
24-28 GDM 
diagnosed 
according to 
IADPSG 
11.1% 1 
Pöyhönen-
Alho, 
Finland, 
1996-1998 
 
Prospective 
study of 
pregnant 
women from 
one area 
532 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT. 
28 GCT of 
7.3mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
with fasting 
values of 
4.8mmol/l or 
more, 
10mmol/l or 
more  at 1 hour 
or 8.7mmol/l 
or more at 2 
hour. 
2.8% (1.4-
4.2) 
3 
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First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
Ricart, 
Spain, 2002 
Prospective 
study of all 
singleton 
pregnant 
women from 
16 hospitals 
9,270 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT. 
24-28 GCT of 7.8 
mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
NDDG 
8.8% (8.3-
9.4) 
1 
Rüetschi, 
Italy, 2010-
2012 
 
Retrospective 
study of all 
pregnant 
women in 
with OGTT 
data in 
laboratories in 
two areas 
2,298 31 NR NR NR One step: 
75g OGTT 
24-28 GDM 
diagnosed 
according to 
IADPSG 
10.9% (9.7-
12.3) 
1 
Sacks, UK, 
2000-2006,  
Prospective 
study of all 
pregnant 
women at two 
study centres 
1671 NR NR NR NR One step: 
75g OGTT 
24-32 GDM 
diagnosed 
according to 
IADPSG 
21.3% 
[20.1-22.6] 
3 
Vassilaki, 
Greece, 2007 
Prospective 
study of 
singleton 
pregnant 
women from 
1,122 NR NR NR NR One step: 
75g OGTT 
24-28 GDM 
diagnosed 
according to 
Carpenter and 
Coustan 
9.1% (7.4-
10.8) 
2 
 232 
 
First 
author, 
country, 
years data 
collected  
 
Sampling 
Method  
Sample 
Size  
Mean 
Age 
(SD) 
Mean 
BMI 
(SD) 
Parity 
(% 
nulli-
parous) 
Family 
History 
Screening 
Type 
Gestation 
at testing 
(weeks) 
Criteria Used 
(category) 
Overall 
prevalence 
(95% CI) 
 
Quality 
Score  
four clinics in 
one area 
Vignoles, 
France, 
2006-2007 
Retrospective 
study of all 
singleton 
pregnant 
women at one 
hospital 
3,237 NR NR NR NR Two step: 
those with 
positive 
GCT given 
100g 
OGTT. 
34-32 GCT of 7.2 
mmol/l or 
more positive. 
GDM 
diagnosed on 
basis of OGTT 
according to 
Carpenter and 
Coustan 
5.1% (4.4-
5.9) 
1 
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for publication 3. 
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NHS Tayside research and development approval letter for publication 3.  
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PDF of published manuscript for publication 5. 
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Appendix 11 
School of Nursing, Midwifery and Health Research Ethics Committee approval letter 
for publication 5. 
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NHS East of Scotland Research Ethics Committee approval letter for publication 5. 
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Appendix 13  
NHS Tayside research and development approval letter for publication 5. 
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Extension to NHS Forth Valley research and development letter of approval.
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Appendix 14 
Participant consent form for publication 5.  
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Appendix 15 
Participant information sheet for publication 5. 
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Appendix 16 
Illustrative excerpt from an analytical framework matrix for gestational diabetes mellitus topic theme. 
2. GDM 2.1 Identity 2.2 Timeline 2.3 Cause 2.4 Emotional Representations 2.5 Consequences 2.6 Control 2.7 Illness Coherence 2.8 GDM 
Education 
Theme Summary 
P1 
Age: 
late 
30s  
Baby 
age: 3 
months 
Parity: 
+2 
Dep: 
Middle 
(3) 
Felt very 
tired but 
questioned 
whether 
the high BG 
readings 
were down 
to eating a 
lot.  
"maybe I 
didnae 
have it all, 
and it was 
just…well 
obviously I 
did " 
Viewed as 
temporary.  
"I don’t 
need to 
remember 
that now 
because I’ve 
had 
her…and 
she tested 
fine" 
Caused by diet. 
" I’d already set 
myself down the 
road to the 
gestation 
diabetes…because 
I was stuffing 
Mars Bars in my 
mouth like you 
wouldnae believe 
[laugh] for to try 
and get a bit of 
energy about me" 
Saw diagnosis as a wake up call 
but not overly concerned. 
Mostly concerned about baby 
rather than herself.  
" it doesn’t really matter about 
me." 
Talked about the 
consequences  for 
her baby and for 
delivery.  
"you see these 
babies that just 
look so puffy 
and…not ill, 
because they 
don’t look ill, but 
just sort of…oh 
my god, what a 
shame, and I’ve 
done that to you, 
kind of thing. And 
then step two 
pops in and you 
think, how am I 
gonna to get that 
out? [Both laugh]. 
If it’s like a twelve 
pound baby 
because it’s all 
swollen or" 
Felt it was easy to 
control with diet.  
"they gave me the 
wee kit for to like, 
for to test the 
blood and things.  
And because you 
could see it was 
working, what you 
were doing" 
No data Didn't remember much 
but felt she it was fine at 
the time.  
"It was fine.  It wasnae 
like it was information 
overload or too technical 
or anything like that.  It 
was alright, it was 
alright." 
Questioned 
diagnosis and 
thought it was 
caused by her 
diet. Concerned 
for baby rather 
than herself. 
Doesn't seem to 
have had big 
impact on her 
life and found it 
easy to control. 
Viewed as 
temporary. 
 280 
 
P2 
Age: 
early 
40s 
Baby 
age: 3 
months 
Parity: 
+1 
Dep: 
Low (4) 
Had read 
about it 
books 
about 
pregnancy. 
Felt tired. 
"I felt that 
at night 
time I was 
getting 
really 
tired…and I 
knew that 
if I fell 
asleep 
early I 
wouldn’t 
sleep at 
night" 
N/D Caused by diet, 
particularly 
chocolate eaten 
to give her energy 
when she was 
tired.  
" I don’t normally 
eat chocolate and 
I think that might 
have 
triggered…the 
diabetes" 
Besides eating 
chocolate she felt 
she was very 
healthy and so 
was confused 
about why she 
got it and 
suggests it's just 
"one of those 
things".  
Not scared as saw it as 
something quite common.  
"it was quite common, so…that 
sort of puts your mind at ease, 
it didn’t scare me or anything. 
So, it was okay. Knowing that 
lots of people get it and it was 
quite normal, and the people 
at the hospital were really 
nice…and they spoke you 
through everything that 
happens…and it was fine." 
Mentioned the 
risk of getting 
GDM again in 
future.  
Found it easy to 
get under control 
through diet, 
particularly cutting 
out chocolate.  
" it was quite easy 
to get under 
control…it really 
was, just, as I said, 
cutting out the 
chocolate at night" 
No data Staff at hospital 
were nice and 
didn't make too 
big a thing about 
it. Felt she already 
knew a lot of what 
they were telling 
her about diet.   
"and then at the 
hospital they were 
really, really 
nice…and they 
didn’t make it a 
big thing…which 
you don’t need 
when you’re 
pregnant." 
Thought it was 
caused by diet. 
Found it easy to 
control and saw 
it as something 
quite common 
so wasn't 
concerned.  
P4 
Age: 
early 
20s 
Baby 
age: 6 
months 
Parity: 
+1 
Dep: 
High 
(1) 
Was thirsty 
and going 
to the 
toilet 
more.  
"Erm, I 
didn’t 
actually 
know that 
you could 
get 
diabetes 
when you 
were 
pregnant." 
Viewed as 
temporary. 
"So, it was 
only for so 
long and 
then they’re 
here." 
Caused by diet.  
"I had been really 
quite bad with my 
food to the extent 
it led me to get, 
eh, the 
gestational 
diabetes " 
Wasn't too bothered but 
partner was worried and 
upset.  
"Erm, and...but it didn’t really 
bother me because my wee 
sister’s got diabetes and so has 
my partner." 
"My partner was quite, 
erm...he was quite upset" 
Didn’t discuss 
apart from saying 
partner worried 
about the chance 
of the baby 
having diabetes.  
"he was saying he 
didn’t want him 
to have diabetes 
when he was 
born and things 
like that"  
Bloods were pretty 
normal through 
watching her diet.  
"I think, that was 
probably why my 
blood was always a 
lot better. Eh, and 
why it was never 
over just because I 
had changed from 
just eating sweeties 
and crisps and 
basically whatever 
I wanted to being a 
bit healthier in my 
diet again " 
Wasn't something she 
knew about before 
pregnancy.  
"Erm, I didn’t actually 
know that you could 
get diabetes when you 
were pregnant. Eh, I 
didn’t know that was a 
thing, erm, but it was 
fine" 
Felt it was 
explained well and 
wasn't too 
complicated.  
Thought it was 
caused by her 
diet. Not 
worried and 
managed to 
control through 
diet. Viewed as 
temporary. 
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Appendix 17 
Consolidated COREQ checklist completed for publication 5. 
Developed from: 
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research 
(COREQ): a 32-item checklist for interviews and focus groups. International Journal 
for Quality in Health Care. 2007. Volume 19, Number 6: pp. 349 – 357 
The section numbers refer to the section of the thesis that the information is reported in.  
 
No.  Item  
 
Guide questions/description Reported in 
Section No. 
Domain 1: Research 
team and reﬂexivity  
  
Personal Characteristics    
1. Inter viewer/facilitator Which author/s conducted the 
interview or focus group?  
8.4 
2. Credentials What were the researcher’s 
credentials? E.g. PhD, MD  
8.4 
3. Occupation What was their occupation at the time 
of the study?  
8.4 
4. Gender Was the researcher male or female?  8.3 
5. Experience and 
training 
What experience or training did the 
researcher have?  
8.4 
Relationship with 
participants  
  
6. Relationship 
established 
Was a relationship established prior to 
study commencement?  
8.3 
7. Participant knowledge 
of the interviewer  
What did the participants know about 
the researcher? e.g. personal goals, 
reasons for doing the research  
8.4 
8. Interviewer 
characteristics 
What characteristics were reported 
about the interviewer/facilitator? e.g. 
8.4 
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No.  Item  
 
Guide questions/description Reported in 
Section No. 
Bias, assumptions, reasons and 
interests in the research topic  
Domain 2: study design    
Theoretical framework    
9. Methodological 
orientation and Theory  
What methodological orientation was 
stated to underpin the study? e.g. 
grounded theory, discourse analysis, 
ethnography, phenomenology, content 
analysis  
8.5 
Participant selection    
10. Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball  
8.3 
11. Method of approach How were participants approached? 
e.g. face-to-face, telephone, mail, 
email  
8.3 
12. Sample size How many participants were in the 
study?  
8.4 
13. Non-participation How many people refused to 
participate or dropped out? Reasons?  
8.4 
Setting   
14. Setting of data 
collection 
Where was the data collected? e.g. 
home, clinic, workplace  
8.4 
15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
8.4 
16. Description of 
sample 
What are the important characteristics 
of the sample? e.g. demographic data, 
date  
Table 14 
Data collection    
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No.  Item  
 
Guide questions/description Reported in 
Section No. 
17. Interview guide Were questions, prompts, guides 
provided by the authors? Was it pilot 
tested?  
8.4 
18. Repeat interviews Were repeat inter views carried out? If 
yes, how many?  
N/A 
19. Audio/visual 
recording 
Did the research use audio or visual 
recording to collect the data?  
8.4 
20. Field notes Were ﬁeld notes made during and/or 
after the interview or focus group? 
8.4 
21. Duration What was the duration of the inter 
views or focus group?  
8.4 
22. Data saturation Was data saturation discussed?  8.3 
23. Transcripts returned Were transcripts returned to 
participants for comment and/or 
correction?  
N/A 
Domain 3: analysis and 
ﬁndings  
  
Data analysis    
24. Number of data 
coders 
How many data coders coded the data?  8.5 
25. Description of the 
coding tree 
Did authors provide a description of 
the coding tree?  
Table 15 
26. Derivation of themes Were themes identiﬁed in advance or 
derived from the data?  
8.5 
27. Software What software, if applicable, was used 
to manage the data?  
8.5 
28. Participant checking Did participants provide feedback on 
the ﬁndings?  
N/A 
Reporting    
29. Quotations presented Were participant quotations presented 
to illustrate the themes/ﬁndings? Was 
Yes – quotations 
from different 
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No.  Item  
 
Guide questions/description Reported in 
Section No. 
each quotation identiﬁed? e.g. 
participant number  
participants 
presented 
throughout 
results section 
with participant 
numbers. 
30. Data and ﬁndings 
consistent 
Was there consistency between the 
data presented and the ﬁndings?  
Attempted to 
make it clear 
throughout 
section 8.6 how 
data links with 
the findings. 
31. Clarity of major 
themes 
Were major themes clearly presented 
in the ﬁndings?  
Start of section 
8.6 and Figure 5. 
32. Clarity of minor 
themes 
Is there a description of diverse cases 
or discussion of minor themes?       
Yes – 
throughout 
results section 
 
